








The aim of the work presented in this thesis was to examine cell and antibody-
mediated immune mechanisms in heart muscle disease. The two conditions studied
were acute rejection of cardiac allografts as an example of cell-mediated immune
damage and alcoholic heart muscle disease as a potential example of antibody-mediated
disease.
In the first study experiments were performed on 94 endomyocardial biopsies
(EMB) from 73 patients to determine the relationship between the ability to grow
lymphocytes from EMB in culture and (i) grade of concurrent or future rejection, (ii)
the presence of endocardial lymphocytic infiltrates (ELI) and (iii) donor/recipient HLA
mismatches. These studies showed that outgrowth of lymphocytes was not closely
related to the degree of rejection, not influenced by the use of polyclonal activators in
the medium but it was affected by the presence of two HLA mismatches at the DR
locus. The presence of ELI was related to rejection but not to outgrowth of
lymphocytes. It was concluded that, contrary to predictions in the literature, the ability
to grow lymphocytes from EMB did not indicate presence of impending rejection.
In the second study experiments were performed to test the hypothesis that
alcoholic heart muscle disease may be caused by autoantibodies to acetaldehyde-
modified myocardial proteins. Sera from 61 subjects were tested by Western analysis
for antibodies against acetaldehyde treated human myocardial proteins. No such
antibodies were detected in 11 healthy control subjects or 28 patients with non-alcoholic
heart diseases. In contrast, 4 out of 14 patients with alcoholic heart disease (28%) had
detectable antibodies, suggesting a role for these antibodies in alcohol-induced heart
muscle disease.
To isolate potential antigenic myocardial proteins from small samples of
myocardium a novel technique was developed for rapidly electroeluting proteins
separated on a polyacrylamide gel. This system was validated by electroeluting
endothelin receptors from human myocardium.
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1. General Introduction
The aim of the work of this thesis was to examine the role of autoimmune
mechanisms in non-ischaemic cardiac disease. Two forms of cardiac disease were
selected for study: acute rejection of cardiac transplant allografts and alcoholic heart
muscle disease.
The detection of acute rejection relies upon histological examination of
endomyocardial biopsies (EMB), particularly during the early post-transplant period.
Histologically, EMB are graded using a system based upon the degree of cellular
infiltration and amount of myocyte damage detected. Unfortunately, no histological or
other features predict those patients who will subsequently develop rejection and so
EMB are performed routinely. When acute rejection is detected patients are normally
treated with intensive courses of additional immunosuppressive drugs.
Several groups have cultured the cells infiltrating EMB by means of in-vitro
culture systems employing interleukin-2 supplemented media. These studies have
shown a correlation between the ability to culture activated T-lymphocytes from EMB
and histological evidence of acute rejection. It has also been claimed that growth of
lymphocytes from biopsies without histological evidence of rejection predicts
subsequent episodes of rejection. These studies did not take account of the use of
different supplements to culture media, the effect of the presence of endocardial
lymphocytic infiltrates or the role of HLA mis-matches in influencing culture results.
In addition to the histological features characteristic of rejection, endocardial
lymphocytic infiltrates (ELI) have been observed. These are mixed infiltrates,
predominantly of T lymphocytes, together with macrophages. They may be associated
with histological evidence ofmyocyte damage but are thought to be distinct from acute
rejection. From their anatomical location in the area of the sub-endocardium, it is
possible that lymphocytes from such foci could preferentially grow from EMB.
The study of EMB was therefore set up with the following aims:
I ) to determine the effect of medium supplements on the ability to grow
lymphocytes from EMB.
2) to examine the relationship between lymphocyte growth in vitro and
histological acute rejection together with its predictive value for subsequent
episodes of rejection.
3 ) to determine whether the presence of ELI has any influence on the ability to
grow lymphocytes from EMB.
4 ) to determine if in vitro outgrowth of lymphocytes is related to the number of
HLA antigen mismatches between graft recipient and donor.
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Alcoholic cardiomyopathy was selected for study because alcohol has many
effects on the heart, both directly and through it's major metabolite, acetaldehyde.
Patients with alcoholic liver disease have abnormalities of humoral immune function
such as increased levels of immunoglobulin A and autoantibodies to acetaldehyde
adducts of liver proteins. Studies using immunofluorescence have demonstrated
immunoglobulin binding to the heart in patients with both idiopathic dilated
cardiomyopathy and alcoholic heart muscle disease. There are therefore grounds to
believe that alcohol, or a metabolite, may play a part in causing humorally mediated
autoimmune organ damage after prolonged alcohol abuse. Accordingly the hypothesis
tested in this part of the thesis, using Western immunoblotting, was that patients with
alcoholic heart muscle disease have circulating antibodies to acetaldehyde-modified
cardiac proteins as a result of chronic alcohol ingestion.
In order to isolate the proteins detected by Western blotting for further analysis
it was necessary to develop a method for electroeluting proteins from a polyacrylamide
gel whilst maintaining electrophoretic separation. In addition, studies of T cell
responses to fractionated human myocardium might allow the development of culture
supplements to improve the proliferation of cells cultured from EMB. A device to allow
such experiments was designed, constructed and tested using endothelin receptors,
which are known to be expressed in human myocardium.
This thesis is therefore presented in three sections. The first deals with the
lymphocyte culture technique, the second with immunoblotting and alcoholic







The first human heart transplant was performed in 1967 (Barnard, 1967). The
growth of heart transplantation since then has been such that the sixth report of the
Registry of the International Society for Heart Transplantation, which included data
from nearly all heart and heart-lung transplants, numbered orthotopic heart transplants
at 9,139 as of March 1989 (Heck, 1989). As the main indications for transplantation
were cardiomyopathy and ischaemic heart disease, this procedure is the only realistic
chance of long term survival, since, even with optimal medical therapy for end stage
cardiac failure, the one year mortality was around 39% (Consensus Trial Study Group,
1987). By 1988, nearly 2,500 heart transplantations were being performed annually.
From these data, the five-year survival for patients on triple therapy (cyclosporin,
azathioprine and steroids) was 81.9% and the ten year survival 73.3%.
Most cardiac transplants have been orthotopic, where the recipients diseased
heart is removed leaving the great vessels and posterior atrial walls, to which the donor
organ is connected. A much smaller number of heterotopic transplants, in which the
donor organ is anastomosed to the great vessels and the native organ is left in situ, have
been performed (including the original operation in 1967). The technical aspects of the
surgical procedures involved will not be discussed further here.
The availability of cardiac allografts has been limited and it is only recently that
cardiac transplantation has expanded beyond the two centres, Harefield and Papworth
Hospitals, where the current UK program began in 1979. The UK transplant program
was not activated in earnest until two key developments occurred. Firstly, the
emergence of improved immunosuppressive regimes (including the use of cyclosporin
A) and secondly, a safe and effective method for taking endomyocardial biopsy
samples from the right ventricle transvenously (Caves, 1973). By 1985 these two
centres had performed 186 transplants in 179 recipients (Pomerance, 1985).
The survival of cardiac allografts is particularly crucial since, as opposed to
renal transplants where graft failure can be treated with dialysis, graft failure will mean
death unless re-transplantation is possible. The three major hazards to survival of
cardiac allografts are rejection, infection and coronary occlusive disease (Sharpies,
1991). There is an inevitable connection between these hazards since the risk of
rejection is reduced by using immunosuppression which in turn puts patients at risk of
opportunistic infections. There is thus a balance of risk whereby sufficient
immunosuppression is used to avoid rejection but not so much as to make infection
highly likely. Coronary occlusive disease is perceived as a form of chronic rejection
and hence it too may be related to immunosuppression protocols.
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In order to detect rejection and tailor immunosuppressive treatment
appropriately endomyocardial biopsy (EMB) is performed routinely and frequently in
the early post-transplant period; with biopsies being performed less frequently as
patients survive beyond the early high-risk period for rejection (Pomerance, 1985).
There is no other reliable means of detecting potentially fatal rejection events. Thus a
great deal of reliance is placed on the histological interpretation of the morphological
changes observed in serial EMB.
2.1. The Histology of Endomyocardial Biopsies
In the early years of cardiac transplantation various grading systems for
endomyocardial biopsy histology were described, most based on the proposals of
Billingham and colleagues (Caves, 1973a and Billingham, 1981). However, each
centre had its individual interpretation (for example: Pomerance, 1985; Kemnitz, 1987;
Kottke-Marchant, 1990). This made it difficult to determine the absolute and
comparative incidence of significant rejection as well as preventing comparison of
immunosuppression regimes between centres.
To address these problems several grading systems have been proposed
culminating in the most recent formulation of the Heart Rejection Study Group
(Billingham, 1990). This is intended to standardise the reporting of EMB, to provide a
framework for further refinements of description of histological rejection and to permit
comparative research between centres. Acute rejection is histologically graded 0 to 4
(Table 1). The grading system, in common with all previous systems, is based on the
degree of cellular infiltration and associated myocyte damage or death. Though cellular
infiltration is important the main feature of acute rejection is cellular damage. Hence
degree of myocyte injury is central to this system. It is assumed that there must be a
connection between myocyte damage and graft dysfunction.
This grading system, as with all others, does not represent an inevitable
progression through grades 1 to 4 for any individual. Each grade of rejection may occur
without there having been previously observed rejection at the next lowest grade. It has
been shown that progression of rejection from one biopsy to the next may follow
particular patterns but not a logical sequence through the grades (Gallo, 1992). It is also
felt that grade 2 (or focal moderate) rejection is a distinct entity which rarely signifies
incipient severe rejection and which usually resolves despite the presence of myocyte
damage (Gallo, 1992).
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Table 1. Working Formulation of Heart Rejection Study Group
'This table shows the working party formulation for the description of rejection on histological slides of
EMB. Alongside the new grades in column one are the new terms in the central column. The old, or
equivalent terms are in the third column. The table is divided half-way down by a double line. This
indicates the grade (IllA) at or above which enhanced immunosuppression is likely to be used to treat
acute rejection. Additional information required by this system is whether there were less than 4 biopsy
fragments, evidence of humoral rejection, presence of "Quilty effect" (with or without myocyte
encroachment), ischaemia (within or beyond three weeks of transplantation), infection or
lymphoproliferative disorder and any otherfeatures.
Grade "NEW" Nomenclature "OLD" Nomenclature
0 No rejection No rejection
IA Focal (perivascular or interstitial infiltrate) Mild rejection
IB Diffuse but sparse infiltrate
II One focus only with aggressive
infiltration and/or focal myocyte damage
"Focal" moderate
rejection




1MB Diffuse inflammatory process "Borderline/Severe"
IV Diffuse, aggressive polymorphous
+/-oedema,+/-haemorrhage,+ /-vasculitis
"Severe acute " rejection
Denoted by a lesser grade: "Resolving rejection"
Denoted by Grade 0: "Resolved rejection"
Grade 3a rejection is commonly used by clinicians as the level at which
additional immunosuppression would be utilised (Cary, 1994 - personal
communication). However, there are no data from controlled clinical trials to support
this arbitrary cutoff point. Histopathologists point out that the grading system does not
necessarily reflect a continuum of rejection and that is it merely a descriptive tool.
Despite this, the histology report is used to guide therapy, in a fashion based on
Billinghams original work. The clinical relevance of the morphological changes
described by Billingham were confirmed by observations in transplanted dogs (Caves,
1973b; Caves, 1975 and Billingham, 1978). In addition, it was found at autopsy that
patients who suffered sudden cardiac death after transplantation had rejection
(Chomette, 1985). Since lesser degrees of rejection were rarely noted it was assumed
that this histological appearance had pathological significance. The UK experience has
reflected this. Histopathological examination of hearts from patients dying suddenly,
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who were not suffering from infection, has shown the presence of rejection as defined
histologically. However, the degree of rejection was not always severe and other
pathologies were also noted, including coronary thrombosis, pulmonary embolism,
tamponade and changes of chronic rejection (Pomerance, 1985).
Since transplanted hearts are generally denervated the earliest indication of acute
rejection might be death, though careful clinical examination might reveal a third heart
sound suggestive of left ventricular dysfunction and reduced voltages may be observed
on the electrocardiogram (ECG). These clinical indications tire relatively insensitive and
hence screening of the state of the myocardium in transplanted patients was instituted
using endomyocardial biopsy. Thus, subsequently, patients were treated empirically
when higher grades of rejection were observed and apparently fewer suffered sudden
cardiac death. Again, there are no controlled studies to support these decisions. In the
early days of transplantation there were few patients on which to base adequate trials
and patient survival was justifiably held to be vital. Any manouevre likely to ensure
survival was embraced.
Now that transplant programmes are larger it is not possible to perform these
trials. They would not be ethical. Comparisons among different immunosuppressive
agents are made but observational sttidies of untreated rejection at higher grades could
not be performed. Transplantation of other organs involves similar questions but it
must be remembered that the immunological behaviour of the kidney and the liver for
example is not identical to that of the heart.
A central question about the relationship between the nature of the rejection
process in relation to cells infiltrating the myocardium cannot therefore be satisfactorily
answered. Hence, studies in this area use the histopathological appearance of the
transplanted heart as a surrogate "gold standard" to judge the well being and likely
prognosis of individual patients, even though this standard has not been validated. This
situation is not satisfactory. This thesis in turn is obliged to use this system for
comparison with results obtained from the various experiments performed.
A newer, objective and more predictive approach is required if the treatment and
prevention of acute rejection is to be formalised and studied in multi-centre trials. It is
also of concern that current treatment regimes, based as they are on the empirical
observations of small numbers of observers, may not be optimum or worse still may be
contributing to patient morbidity and mortality. The role of routine histological
examination of EMB therefore requires to be re-examined.
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2.1.1. Endocardial Lymphocytic Infiltrates
The "Quilty effect" was named after the first patient in whom it was described
(Imakita, 1988). It refers to endocardial and sub-endocardial cellular infiltrates
consisting predominantly of T cells but including B cells and macrophages. The term
"endocardial lymphocytic infiltrates" (ELI) is synonymous. The significance of ELI is
uncertain, although a number of suggestions have been made. Radio and others
suggested that, although ELI may be associated with myocyte damage histologically,
they are distinct from acute rejection (Radio, 1991). Kottke-Marchant et al have
suggested that ELI are consistent with an early lymphoproliferative lesion, such as
those associated with Epstein-Barr virus (EBV) and cyclosporin therapy (Kottke-
Marchant, 1989; Suit, 1989). In one study, comparing the incidence of ELI among
patients treated with different immunosuppression protocols, ELI appeared to be related
only to cyclosporin therapy, being very rare in patients taking azathioprine and steroids
(Forbes, 1990). In addition, other workers have disputed the association of ELI with
EBV. Nakleh et al studied biopsy material from 19 patients using in-situ hybridisation
for EBV genomic sequences and obtained negative results. They also found no
serological evidence of post-transplant infection with EBV (Nakhleh, 1991).
After transplantation some patients develop more florid lymphocytic infiltration
of their allograft - post-transplantation lymphoproliferative disorder. In cardiac
transplant recipients this was associated with the use of the monoclonal antibody OKT3
in immunosuppressive therapy (Swinnen, 1990). A range of studies have examined
patients with post-transplantation lymphoproliferative disorders and reported an
association with EBV (Cleary, 1984a; Cleary, 1984b; Wreghitt, 1989). Abu-Farsakh et
al used in-situ hybridisation (ISH), the polymerase chain reaction (PCR) and dot-blots
for EBV genomic sequences to confirm the presence of EBV in lymphocytes obtained
from the heart of a patient who died from post-transplantation lymphoproliferative
disorder (Abu-Farsakh 1992).
Thus there is evidence to associate lymphoproliferative disorder with EBV but
Nakleh's study indicates that ELI do not appear to have this association. The proposal
that ELI are somehow a precursor of later lesions and that proliferation is EBV driven is
not supported by this work. However, Naklehs study was small and used ISH, rather
than PCR or southern blot analysis which would have been more sensitive for small
copy numbers of viral genome per cell. The earliest lesions might not be associated
with a strong presence of EBV and so serological responses would also be lacking. In
studies on patients with liver allografts Randhawa et al found expression of RNA for an
EBV gene (EBER-1) expressed early on in latent infection, before the development of
clinical or histological evidence of lymphoproliferative disorder (Randhawa,1992).
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Because of the anatomical location of ELI, they could easily be included in
EMB and therefore could influence culture results. Previous studies have not addressed
this question and since the reporting of ELI may not previously have been uniform,
their effect on such studies cannot be assessed.
2.2. Other Methods of Monitoring Cardiac Allografts
Standard non-invasive methods of monitoring cardiac transplant recipients
include clinical assessment, routine biochemical and haematological tests, and radiology
(including chest X-rays and regular coronary angiography to look for coronary
occlusive disease). Other methods of monitoring patients for rejection of heart
transplants have included more traditional means of non-invasively studying the heart
such as the surface ECG (Schroeder, 1974), echocardiography (Valantine, 1987) and
even phonocardiography (Caves, 1974). The ECG was the mainstay of allograft
monitoring in the early days of cardiac transplantation. With the twelve lead ECG it was
found that rejection was associated with a reduction in R wave voltages which reversed
after treatment. Other changes such as right axis deviation and atrial arrhythmias were
also observed (Wallwork, 1984). However, the ECG changes probably lag behind
histologic abnormalities by a period of days and may not be sensitive enough to detect
early rejection. Echocardiography may also detect graft dysfunction but this has to be
quite severe to be detected by this technique. Phonocardiography is primarily of
historical interest in this context.
In addition to these routine clinically indicated tests a number of research tools
have been used to determine if there are non-invasive alternatives to performing
frequent EMB.
Cytoimunological monitoring (CIM) developed in Munich in 1983 is concerned
with detecting activated lymphocytes in peripheral blood samples from cardiac
transplant patients. This method is highly sensitive for rejection (as diagnosed by
histology) but has a false positive rate of 28% (Ertel, 1985 and Hanson, 1988).
However a multi-centre trial of this method found that of 12 centres involved only six
could reliably apply the method (Schubel, 1990).
Reader et al used limiting dilution assays (LDA) in experiments where
peripheral blood lymphocytes from recipients of cardiac transplants were co-cultured in
a range of dilutions for 10 days with irradiated donor splenocytes (Reader, 1990).
These cells were then tested for cytolytic activity against donor cell targets. The
reasoning behind LDA, put simply, is that the series of dilutions allows calculation of
the frequency of cytotoxic T cell precursors (CTLp) present in the original sample.
Complex statistical methods are involved and stringent conditions apply to processing
the data obtained. In this case 12 cardiac transplant recipients were studied. The
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preoperative CTLp frequency did not predict patients likely to undergo postoperative
rejection but when measured longitudinally it appeared that the frequency of CTLp was
higher in patients undergoing rejection compared with those who were not. The authors
concluded that this method would be of value in monitoring cardiac transplant patients.
The small numbers of patients involved and the nature of the method leave this
conclusion open to question. Since the culture period alone takes ten days, any patients
with severe acute rejection would have suffered irreversible damage before a result
from this assay could be available. In addition, without data on the variability of CTLp
frequencies in a larger number of individuals with and without rejection, over a long
period of time it is difficult to see how fluctuations could easily be interpreted. Thus,
this labour intensive method appears to be unlikely to find widespread application in
transplant centres in any application other than as a useful research tool.
In conclusion, to date there are no completely effective non-invasive markers of
acute rejection and so EMB continue to be monitored closely in the early months after
transplantation in order to detect and treat acute rejection. At present no method offers
the ability to predict the likelihood of future rejections episodes.
2.3. The Immunology of Acute Rejection
The relationships between the various cells involved in rejecting solid organ
transplants are complex. A large range of cells and responses involving many
molecules results in the "immune response" to an allograft and it is difficult to detail
them all in the space available. Halloran has recently reviewed the molecular
immunology of transplant rejection (Halloran, 1993). The molecules involved include:
the immunoglobulin (Ig) gene superfamily of receptors, adhesion molecules and
cytokines (and their receptors). These molecules can be divided into:
• Antigen presenting structures
• Antigen recognition structures
• Molecules involved in cellular interactions during antigen recognition
Molecules in the third group can be thought of as 'adhesion molecules', which
can be further grouped into the Ig superfamily, the selectin family and the integrin
family. The cytokines involved in acute rejection are numerous but include interleukins,
interferons, growth hormones and colony stimulating factors.
In terms of cardiac allograft rejection, at a cellular level, these molecules are
found in association with, or elaborated by, T cells, B cells, monocyte/macrophages,
natural killer cells, dendritic cells, endothelial cells and cardiac myocytes. Thus a large
range of cells are involved in potential and actual interactions culminating in the process
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recognised histologically and clinically as "rejection". The relationships of these various
cells and molecules are briefly described below.
2.4. The Major Histocompatibility Complex
In the 1940s Medawar showed that a second skin graft from one rabbit to
another was rejected quicker than the first. If the second graft was accompanied by one
from a different donor than the first, then the additional graft did not suffer accelerated
rejection (Medawar 1944 and 1945). Thus the first graft sensitises the immune system
of the recipient to donor antigens and it therefore responds faster and more powerfully
on re-challenge. Larger grafts were rejected sooner and more aggressively. These
experiments showed that rejection of skin grafts displayed latency, dose effect,
specificity and memory - all key features of an acquired immune response. In addition,
it was subsequently shown that the ability to reject grafts could be transferred with
lymphocytes from a previously grafted individual (Mitchison, 1954). Thus the
functional ability to reject allografts is found in the lymphocyte population.
Further experiments in mice showed that responses against skin grafts were
related to inheritance of H-2 antigens controlled by the genes of the mouse major
histocompatibility complex (MHC) on chromosome 17 (Klein, 1979). The major
histocompatibility antigens on the surface of cells are those against which an immune
response may be mounted. There are also many other "minor" histocompatibility
antigens which do not map to chromosome 17 and which can be responsible for strong
rejection responses against allografts (reviewed by de Bueger, 1993). Medawar's
group showed that similar responses to those demonstrated in mice against skin grafts
occurred in man (Gibson, 1943).
The central process in rejection involves the recognition of graft proteins by the
recipients immune system. Whole proteins are not recognised; rather they are broken
down and processed into peptides before recognition can take place. The means by
which recognition occurs is via MHC presentation of peptides to T cells via T cell
receptors (TCR). The various ways by which peptides can be brought to this interaction
are numerous. There are a number of antigen presenting cells types which may present
peptide in the context of class 1 or class II MHC molecules. In addition there are
various other factors which may strengthen the cellular interactions involved.
The human MHC gene locus on chromosome 6 has approximately 4 million
base pairs encoding genes for class I, class II and class III antigens (Trowsdale, 1991).
Because lymphocytes were used in initial typing experiments of class I and class II
gene products they are also known as "Human Leucocyte Antigens" (HLA). Class I
HLA molecules are involved in cytotoxic T cell responses and Class II HLA molecules
in T helper cell responses and some cytotoxic functions. Class III proteins are involved
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in the complement system. Genes for tumour necrosis factor, an important cytokine,
also lie in this region of chromosome 6 (fig. 1).
The genetic organisation of the MHC is complex. A rudimentary and highly
simplified map is shown (fig.l) but a more detailed and up to date map has been
published (Campbell, 1993). There are three class I genes, A, B and C, though there
are a number of class I-like genes in addition. The gene for fb-microglobulin lies
outside the MHC region (on chromosome 15). The class II region includes genes for
DP (four), DN(one), DO(one), DQ(five) and DR(variable), with a number of
pseudogenes. The MHC genes are highly polymorphic and have hypervariable regions
which correspond with the peptide binding areas on class I and class II molecules.
Figure 1: The Human HLA Complex
(after Germain, 1994)
A schematic representation of the organisation ofgenes of the human HLA
is shown. The key shows which genes code for alpha, beta or heavy chains,
LMP, TAP and CIIPG. The genes for some components of complement lie
within the class III region, as do the genes for 'l'NF(alpha and beta).
LMP/
DP DN DM TAp DO DQ DR B C A
CIIPG
Class II Class III Class I
| [3 J Ot | Heavy chain |j








MHC molecules are part of a family with related structures - the
Immunoglobulin (Ig) gene superfamily, which has evolved through economical use of
the gene for the Ig domain (Williams, 1987). The Ig domain has a molecular weight of
around 12kD and consists of approximately 90 amino acids. Apart from
immunoglobulins, a number of molecules contain Ig domains: the T cell receptor
(TCR), CDS, CD4, Class I and Class II molecules, CD3e, CD2 and a range of
adhesion molecules (e.g. ICAM-1, ICAM-2, VCAM, LFA3). (32-microglobulin, a
component of class I, essentially consists of a single Ig domain with a disulphide bond
(fig.2).
1 2
Class I and class II molecules each have four Ig domains (fig.2). Class I
consists of an a-chain (with three Ig domains) along with [^-microglobulin. Class 11 is
made up of an a-chain and a (3-chain. These are arranged in each type of molecule such
that two of the Ig type domains are aligned so as to form a 'peptide binding groove'.
Class I and II molecules also have binding sites for CD8 and CD4 respectively.
Figure 2: Class I and Class II Molecular Domains
This cartoon shows the organisation of the Ig domains in class I and II molecules (after Germain,
1994). These membrane bound glycoproteins are very similar. Class I has three alpha chains (al and
so on) with two disulphide bonds in the second and third (represented as -s-s-). The fourth domain is
made up ofbela-2 microglobulin (f}2m) which also has a disulphide bond. Class // molecules have two
alpha and two beta chains with a total of three disulphide bonds.
Class Class II
Recently the structure of HLA-DR1 from human B cell membranes was
determined using X-ray crystallography and was shown to be very similar to class I
molecules, as had been predicted (Brown, 1993). It appears that class II forms
heterodimers which themselves may dimerise to form a "dimer of dimers" which might
be able to interact with two TCR complexes. This complex may play a role in T cell
signalling and might stabilise the interaction between antigen presenting cell and T
lymphocyte (Ploegh, 1993). It would appear that a significant difference between class
I and II is in the size of peptides they may bind. Class I has a peptide binding pocket
blocked at either end such that peptides of 8 to 10 amino acids in size can be bound.
Class II on the other hand has an open pocket which can allow peptides to protrude
beyond it, allowing peptides of 15 to 18 residues to be bound (Ploegh, 1993).
Individuals express one or two HLA class I and class II molecules on the
relevant cells, according to whether they are homo- or heterozygous at the MHC locus.
Most nucleated cells, as well as platelets and erythrocytes, express class I antigens, but
class II is found mainly on cells of the immune system and probably some epithelial
cells. Rose et al found little evidence for class I expression on normal myocytes but
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after transplantation demonstrated induction of expression of MHC molecules on
myocytes, particularly class I, which implies a role in the rejection process (Rose,
1986).
It has been shown that class 1 MHC presents endogenously derived peptides
and class II MHC presents peptides from exogenous sources (Brodsky, 1991; Malnati,
1992). Thus CD8+ T cells recognise virally infected cells which express proteins
encoded by viral genes on their cells surface whereas CD4+ T cells recognise peptides
originating from extracellular organisms which have been appropriately processed. This
results from the different means by which class I and II are assembled and transported
to the cell surface. Class I is assembled from component chains in the endoplasmic
reticulum (ER) in the presence of peptide, with which it associates. The class I-peptide
complex is then transported to the cell surface where presentation of the peptide can
occur. The source of the peptide is from cytoplasmic proteins which are broken down
and then transported into the ER. Class II molecules are made in the ER and then
transported to the endosome, an acidic membrane bound compartment. Once there the
class II molecule is able to bind peptides which have been formed by the breakdown of
proteins which have entered the endosome. The source of these proteins may be from
the cell surface via endocytic vesicles, the cell membrane and also from the cytosol
(which is how class II can present endogenously derived peptides). Once peptide is
bound the class I i-peptide complex is transported to the cell surface.
Allograft rejection may be thought of as an inevitable consequence of a normally
functioning immune system which has evolved to defend against infectious agents. The
cellular immune system identifies and kills infected cells by recognising foreign
peptides in association with MHC molecules found on the cell surface. The MHC
antigens are the means by which the body recognises its own cells as "self" and
unfortunately they provide a means by which tissue, such as an allograft, may be
recognised as foreign and destroyed.
The immune system normally attacks its own cells only when they are
expressing novel proteins at the cell surface. This may happen, for example, in the case
of cancer cells. In viral infections cells may be programmed by the virus to produce
certain proteins, which are then presented by the cell in association with MHC class I
molecules. Cytotoxic T cells recognising this combination would kill these and any
other cells with the same class I molecules presenting the peptides in question. They
would not recognise cells with different MHC antigens; a process known as MHC
restricted killing (Zinkernagel, 1974; Zinkernagel, 1979; Rosenthal, 1973). In the same
way the immune system may recognise peptides presented by foreign MHC molecules
and initiate a response against the cells in question. It is not known whether rejection
involves initial destruction of foreign cells and the processing of their MHC molecules
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into peptides to be presented in association with recipient MHC molecules or whether
these molecules are recognised intact on the surface of the allograft cells.
Allogeneic responses are stronger than syngeneic responses and, in this respect
at least, transplant immunology differs markedly from fundamental immunology (Paul,
1993). Antigen specific syngeneic CTL recognise peptide in the context of self-MHC
molecules but is not clear whether alloreactive CTL use a similar mechanism. They may
recognise foreign MHC alone with no peptide bound ("empty MHC") (Elliot, 1990),
they may recognise a conformational change induced in the MHC by the bound peptide,
or they may recognise both the peptide and the foreign MHC together (Alexander-
Miller, 1993). Thus the exact nature of alloreactivity is difficult to determine.
The alloresponse may be engendered by dendritic cells within the allograft as
stated above. However, in the cellular infiltrate in an allograft there are also B cells
which are capable of presenting antigen to CD4+ cells, further complicating the picture.
B cells may bind solublised donor MHC, take it up, process it and then present it in the
peptide binding groove of their own class II MHC molecules. The interaction between
these cells being strengthened by adhesion molecules (Halloran, 1994). Thus the
alloresponse may involve a range of presenting cell types of donor or recipient origin,
which may present different donor peptides in the context of their MHC molecules.
Certain HLA molecules are associated with particular "autoimmune" diseases,
where the immune system appears to be involved in causing tissue damage. For
example, HLA DR3 is associated with dermatitis herpetiformis (Svejgard, 1983), HLA
DR4 with insulin dependent diabetes mellitus (Svejgard, 1983) and idiopathic dilated
cardiomyopathy (Carlquist, 1991) and HLA B27 with ankylosing spondylitis and
Reiters disease (Svejgard, 1983). This may reflect the efficiency of these molecules at
presenting certain processed proteins to the immune system and may relate to why
particular individuals are more prone to develop acute rejection than others.
The role of HLA antigens in transplantation has been extensively studied. It is
known that prospective matching of HLA type between donor and recipient has a
beneficial effect on organ survival. This was shown for renal transplants some years
ago, particularly with regard to matching for HLA DR (Ting, 1978; Gilks, 1987;
Thorogood, 1990). A large study of HLA matching for 1386 cadaveric renal
transplants confirmed this benefit (Takemoto, 1992). There was a one year survival rate
of 88% for matched first grafts compared with 79% for mismatched grafts. More
recently a large collaborative study of cardiac transplants has demonstrated a beneficial
effect ofmatching for HLA A, B and DR on graft survival at three years (Opelz, 1994).
The survival of the 128 donor hearts which had no HLA mismatches with the recipient
was 83% at three years, compared with 71% for hearts with three to six mismatches.
As a result of this study the authors and others have suggested that prospective
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matching should eventually be introduced to cardiac transplantation in a similar fashion
to that employed in renal transplant centres. It is also proposed that less
immunosuppression may then be necessary since well matched grafts may not require
such intensive regimes (Morris, 1994). The HLA system is so polymorphic that Opelz
et al's study would not have the power to determine the relationship of individual HLA
types to rejection or graft loss.
2.5. Antigen Presenting Cells
In order to respond to antigen, naive CD4 T cells (primary response) require
appropriate presentation of antigen in the context ofMHC class II molecules along with
certain co-stimulatory signals. Cells which are able to function as antigen presenting
cells (APC) in this context are macrophage/monocytes, dendritic cells and B cells
(because these three cell types express class II molecules and can be present in the
allograft). The APC for early rejection responses may be of donor origin but recipient
APC may be involved in subsequent episodes. The route whereby antigen is presented
in the context of donor APC is sometimes said to be "direct presentation" and for
recipient APC to be "indirect presentation".
In secondary responses any cell which bears MHC class II can function as an
antigen presenting cell. There is evidence that dendritic cells are still potent in this
regard.
Maximal stimulation of CD4+ T cells occurs when antigen is presented along
with the appropriate costimulatory signal (the so called "second signal"). It appears that
the main molecules involved in costimulation are those known as B7 and B7.2, which
bind to CD28 and CTLA-4 receptors on T cells. In the absence of a co-stimulatory
signal on the APC, T cells which recognise antigen may become anergic and fail to
proliferate (Janeway, 1994).
There is evidence that donor APC may be responsible for the initial presentation
of antigen to host T cells. The most likely candidates for this function are dendritic cells
which are very potent stimulators of T cell responses (Austyn, 1991). These leucocytes
are present in most tissues of the body and are able to present antigens along with
signals for T cell activation. Dendritic cells are able to stimulate the mixed lymphocyte
reaction (MLR) and can activate both CD4+ and CD8+ cells (Inaba, 1987). Dendritic
cells have therefore been described as 'passenger leucocytes', present in donor
allografts and able to elicit proliferative responses among recipient T cells (Austyn,
1993). In a murine cardiac transplant model, migration of donor leucocytes from
cardiac allografts into the recipient's spleen has been demonstrated (Larsen, 1990).
Dendritic cells may acquire antigen in the allograft and then migrate to lymph nodes (or
the spleen) where they may lose some cell surface markers, upregulate class II
16
expression and begin associating with clusters of T cells (Knight, 1993). Tyerman et al
showed in a rat cardiac allograft model that pretreatment of the graft to reduce dendritic
cell content contributed to prolongation of graft survival (Tyerman, 1990).
Another possible interface between the allograft and recipient lymphocytes is the
vascular endothelium. Endothelial cells are able to function as antigen presenting cells
(Pober, 1991), can be induced to express class II molecules and may rapidly change
following transplantation from being of donor to recipient origin through re-
endothelialisation (O'Connell, 1991). There is evidence for an antibody response to the
endothelium in cardiac transplants and immunoctyochemical evidence of endothelial
damage in rejecting cardiac allografts has been shown (Dunn, 1992; Hengstenberg,
1990). Jutte et al have shown cytotoxic T cell responses against donor heart endothelial
cells among allograft infiltrating cells cultured from EMB taken from four patients
(Jutte, 1993).
Thus there is more than one candidate for stimulating allogeneic responses
against the allograft. Dendritic cells may present donor peptides in the context of
foreign MHC or host dendritic cells may infiltrate the graft and subsequently act as
APC. Vascular endothelial cells may present donor peptides in the context of self-MHC
and may themselves suffer immune mediated injury as a result, which might provide a
favourable environment for amplification of the immune response to the graft.
2.6. Cytokines, Th1 and Th2 Cells
Cytokines are proteins which bind to specific receptors and provide cellular
signals. The range of cytokines is diverse and they are involved in controlling the
functions of haemopoietic cells, lymphopoietic cells and cells involved in immune
responses. They include the interleukins (IL-1 to 10), the interferons (a, (3 and y)
tumour necrosis factor (TNFa and [3) and the colony stimulating factors (CSF),
granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor
(M-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF). These
substances are produced by and act on T cells, B cells, macrophages, monocytes,
endothelial cells, fibroblasts and bone marrow stem cells.
CD4 cells are the lymphocyte subset most closely associated with cytokine
production though many cell types can elaborate these substances. In the mouse there
are patterns of cytokine expression which differentiate in vitro cultured CD4+ T helper
cells into two groups: Th 1 and Th2 cells (Mosmann 1989). ThI cells secrete IFNy, IL-
2 and TNFJ3. Th2 cells secrete 1L-4, IL-5, IL-6 and IL-10. Both THl and Th2 can
produce IL-3, TNFa and GM-CSF. THl cytokines can be produced by large granular
lymphocytes and CD8+ cells. There are no monoclonal antibodies which mark out THl
or Th2 cells as distinct from among CD4+ cells. In addition, these activities are yet to
be described in man.
The roles of these cells appear to centre on regulating B cell responses but they
may also have effects on CD8+ cells. ThI cells are able to induce delayed type
hypersensitivity responses whereas Th2 cells are not. The effects of ThI cells on B
cells are to selectively promote IgG2a responses, but they can also elicit IgM and IgG3
(Coffman,1988). TH2 cells on the other hand can promote IgGl and IgE responses
effectively, as well as IgM, IgG3 and IgA (Kuhn, 1991). Another feature of THl and
Th2 cells is that they can crossregulate each other, each tending to inhibit or antagonise
the effects of the other (Mosmann, 1991a).
In transplantation, the stimulation of ThI type responses could result in
rejection processes along the lines of a delayed type hypersensitivity response. The
regulation of the response to allograft antigens by CD4+ T cells would be through
cytokine production and it may be that the murine pattern of TH1/TH2 is reflected in the
analogous situation in man. Janeway and Bottomly suggest that the presence of MHC
class II dinrers may influence the type of response produced as a result of differing
ligand density on cells. They argued that MHC class II dimers presenting self-peptide
would not stimulate CD4+ cells whereas the presence of foreign peptide on one or other
member of the dimer would result in a Th2 type response. THl type responses might
be seen with higher concentrations of foreign peptide such that it is bound to both
members of the class II dimer (Janeway, 1994).
Ruan et al (Ruan, 1992) demonstrated, using immunohistochemical techniques,
the presence of IL-2 in lymphocytes observed in rejecting EMB. They showed that
IFNy expression increased with degree of rejection and they occasionally detected IL-6.
This study suggests that both THl and Th2 type responses were occurring and
supports a role for cytokines in the rejection process in human heart transplants.
2.7. Adhesion Molecules
The interactions between lymphocytes binding to MHC associated with peptide
are assisted by proteins present at the cell surface of both the antigen presenting and the
responding cell. As stated above these consist of the selectins, the integrins and Ig
superfamily members (reviewed in Moody, 1992).
The selectins consist of L-selectin, found on leucocytes; E-selectin found on
endothelial cells and P-selectin which is present on platelets and endothelial cells. They
are involved in weak early binding interactions between lymphocytes and endothelial
cells. The selectins have transmembrane and intracytoplasmic segments as well as an
N-terminal lectin domain, an epidermal growth factor like domain and then several
'short consensus repeats'. The ligand for L-selectin is E-selectin. L-selectin is the
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ligand for the other two selectins. E-selectin is induced on endothelial cells by IL-1 and
TNF.
The integrins are probably involved in secondary binding interactions and their
adhesion interactions are stronger than those of the selectins. The integrins are made up
of a and (3 chains and they are found expressed on a range of leucocytes, platelets and
other cells. They divide into (31, (32 and (33 sub-groups. The (31 subgroup consists of
very late antigens (VLA) 1 to 6, the (32 group includes leucocyte functional antigen-1
(LFA1), and the (33 group includes gpllb and Illb as well as 'VNR' (Halloran, 1993).
These molecules are probably involved in cellular interactions once activation has
occurred. Their ligands include laminin, collagen, fibronectin, vascular cell adhesion
molecule-l(VCAM-l), intercellular adhesion molecule-1 (ICAM-1) to 3, vitronectin
and fibrinogen.
The third group of adhesion molecules, the Ig superfamily members, includes
ICAM-1, ICAM-2, ICAM-3, LFA-2, LFA-3 and VCAM-1. These are found on
endothelial cells and a range of leucocytes. Their ligands are mostly integrins with
which they form fairly strong interactions and their expression tends to be increased by
IFNy, TNF and IL-1.
The complexity of the total number of possible interactions between these
molecules cannot easily be represented as there is such a large number. One important
aspect of these molecules is that they may have a role in cellular signalling in addition to
cell adhesion.
In human cardiac transplant recipients the expression of ICAM-1, VCAM-1
(vascular cell adhesion molecule) and ELAM-1 (endothelial leucocyte adhesion
molecule) has been studied using immunohistochemistry. Briscoe et al found that
ICAM-1 and VCAM-1 increased in capillaries in the presence of cellular rejection but
they did not find evidence of ELAM-1 expression with rejection (Briscoe, 1991). In a
study involving 83 patients, Qiao et al found little evidence of ELAM-1 expression.
They did however find ICAM-1 staining in capillary endothelial cells and lymphocytes
in EMB from patients with rejection (Qiao, 1992). There was also ICAM-1 staining in
lymphocytes from ELI in 9 of 10 cases in this study. Though no causal inferences can
be made merely from the presence of these adhesion molecules, their presence in the
context of rejection does hint at a potential role.
2.8. The T Cell Receptor
T cells bear on their surface receptors which belong to the Ig gene superfamily
and which strongly resemble membrane-bound Fab fragments of immunoglobulin.
Designed to recognise antigen in the context of MHC molecules, the T cell receptor
(TCR) subserves an analogous function in T cells as bound immunoglobulin does in B
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cells. The human T cell receptor in health and disease has recently been reviewed by
Moss et al (Moss, 1992).
There are two different TCRs consisting of heterodimers of different chains.
The a[3 TCR performs most of the functions required by T cells and is the most
common form of TCR, observed on 95% of T cells. The y5 TCR has unknown
function and constitutes a minority of T cells (5%). The structure of the human TCR is
illustrated below (fig.3). The molecule is found in association with the CD3 molecule
which itself is composed of five different chains (y, 8, e, C, and T| in the mouse).
The structure of the TCR relates to its function in that it may allow alignment
with the MHC molecule so as to bring the more variable regions of each molecule to
interact with the MHC presented peptide. This interaction was modelled by Davis and
Bjorkman (Davis, 1988). The complex would involve CD3 molecules flanking the
TCR along with the relevant CD4 or CD8 molecule according to the T cell phenotype
(Collins, 1993). CD4 and CD8 molecules probably function as co-receptors, binding to
structures on the antigen presenting cell and enhancing activation of the T cell. CD4
binds to class II MHC molecules and CD8 to class I (Collins, 1993).
Figure 3. Structure of The Human T Cell Receptor
The cartoon shows the structure of a typical human TCR (after Roitt, 1989). The molecule is a
heterodimer of these two chains which have variable (V), constant (C), diversity (D. in the P and 5
chains) and joining (J) regions in an analogous fashion to immunoglobulin. The chains have intra-
chain disulphide bonds (shown) as well as an inter-chain disulphide bond. The molecule also has a
membrane spanning and inlracytoplasmic portion. TCR are found associated with CD3 molecules (see
text).
The gene for the a chain of the human TCR lies on chromosome 14, for (3 and




T cell receptor genes are organised into segments of V (variable), D (diversity), J
(joining) and C (constant) genes. These genes combine in developing T cells to produce
V(D)J exons which are then spliced together with the C region at the RNA level (Moss,
1992). This organisation, with a large number of gene segments, gives the potential for
a great deal of genetic diversity. This is contributed to by the addition of "N region"
nucleotides (at V-D-J junctions or Ja-Ca junctions) which are not encoded in the
germline. For a(3 and y5 TCR there are something like 1()16 possible junctional
combinations. Somatic hypermutation, in a fashion analogous to that observed for
immunoglobulins, does not occur (Moss, 1992). Thus, of the three potential
mechanisms of generating diversity (as seen in Ig): possessing a large number of
genes, somatic hypermutation and somatic recombination, the first and third appear to
occur with TCR. Presumably the absence of somatic hypermutation helps prevent the
generation of T cell clones which have already been selected out at the thymic level.
There are two ways in which the TCR can interact with the MHC. The first is
the predominant form of interaction which involves recognition by the TCR of
processed peptide presented by MHC molecules. The second involves so-called
superantigens which bind to MHC class II molecules and by interacting with specific
Vp elements of the TCR bring about proliferation of T cells. There appear to be
endogenous and exogenous superantigens. Endogenous superantigens were detected in
mice initially, being predominantly coded for by murine mammary tumour virus
sequences and as yet they have not been demonstrated in man (May, 1989). Exogenous
superantigens include substances such as staphylococcal enterotoxins (Choi , 1989),
toxic shock syndrome toxin-1 (Choi, 1990) and streptococcus pyogenes toxins (Abe,
1991). These antigens do not require MHC matching of APCs and effector cells in
order to exert their effects. The clinical effects of these toxins are dramatic and
consistent with their ability to activate approximately 50% of T cells. However, the role
of superantigens in human disease remains unclear.
2.9. T Cell Activation and lnterleukin-2 Receptors
T lymphocytes are normally in a resting state. When they come into contact with
antigen presenting cells (APCs) bearing processed foreign antigen, or directly with
foreign cells, they become activated. The cells become metabolically active and enlarge
prior to proliferation. Cell to cell interaction between T cells and antigen presenting cells
involves adhesion molecules. CD2 (or LFA-2) molecules on T cells may interact with
LFA-3 (CD58) (Takai, 1987), CD59 (Hahn, 1992) and CD48 (Kato, 1992) on the cell
surface of antigen presenting cells. As well as functioning as an adhesion molecule,
CD2 may also play a role in T cell activation by transmitting intracellular second
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messengers (reviewed in Bromberg, 1993). Intercellular Adhesion Molecule 1 (ICAM-
1, CD54) and LFA-1 (CD1 la/CD 18) may be present on both the APC and the T cell
and interact in either direction (Suthanthiran, 1993).
The process of activation proceeds via binding of antigen, which is presented
bound to MHC (class 1 or II), with the T cell receptor (TCR), found on the T cell
surface in association with the CD3 complex. The CD4 or CD8 molecule is also
involved in this complex and may help to stabilise the cell to cell interaction.
Binding of antigen to the complex triggers a series of intracellular events
culminating in phosphorylation of cytoplasmic and membrane proteins. These changes
regulate transcription of genes involved in proliferation. A number of receptors which
regulate the proliferative response are subsequently expressed on the cell surface. One
of the key receptors is the interleukin-2 receptor (IL2R). Interleukin-2 (IL-2) is a 15kD
polypeptide produced by T helper (CD4+) cells. Antigen activated T lymphocytes will
not divide unless IL-2 is bound (Cantrell, 1984). The effects of the potent
immunosuppressive agent, cyclosporine, appear to involve inhibiting the transcription
of the IL-2R gene. These effects also seem to apply to other immunosuppressive drugs
(FK-506, rapamycin) though these are not the only effects these drugs have (reviewed
in Sigal, 1992).
The IL2R has two main polypeptide chains, a (Leonard, 1983) and (3
(Hatakeyama, 1989) and a third, y, has recently been described (Takeshita, 1992). At
rest mostly a-chains are present on the cell surface. On activation more (3-chains are
produced than a-chains. There are high affinity receptors for IL-2, made up of a, (3,
and y chains. Low affinity receptors for IL-2 are a-chains alone, intermediate affinity
receptors being [3- and y-chain heterodimers. Intermediate affinity receptors can mediate
cell activation in the presence of high concentrations of IL-2. This may occur with
natural killer cells which, at rest, possess more cell surface a-chains than T cells.
Concentrations of IL-2 of the order of 500 - 2000 units/ml can activate natural killer
cells to produce Lymphokine Activated Killer (LAK) cells, though not all LAK cells
derive from NK cells (Philips, 1986). LAK cells may be tested for anti-neoplastic cell
activity for example. IL-2 also has effects on other cells bearing IL2R, including B cells
and monocytes.
On activation 1L2R are present at the cell surface for 7 days and then disappear
unless further expression is triggered. In-vitro culture of T lymphocytes therefore
requires periodic re-stimulation in order to maintain proliferation and functional activity.
Activated T cells, expressing IL2R, will respond to interleukin-2 with rapid
proliferation.
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2.10. Rejection in Cardiac Transplant Recipients
As with other solid organ transplants, the major obstacle to successful heart
transplantation is the host's immune defences, which recognise an allograft as foreign
tissue. In the immediate post-transplant period "hyperacute rejection" may occur,
mediated by pre-formed cytotoxic antibodies (Weil, 1981). This process is dependent
on activation of the complement system and the clotting cascade following binding of
antibodies to the allograft and results in rapid destruction of the allograft (Forbes,
1982). Once initiated this process cannot be halted. The presence of antibodies to donor
blood group antibodies would result in this type of response which is why cardiac
allografts must be matched for blood group (blood group antigens are expressed on
endothelial cells). Other types of pre-formed antibodies include those against
endothelial antigens of other species as well as anti-MHC antibodies in individuals
previously exposed to allogeneic tissues. In xenogeneic transplants (between species)
hyperacute rejection is the major process by which organs are rejected, with pre-formed
antibodies to glycoproteins on the vascular endothelium being responsible. Depletion of
complement using cobra venom factor can reduce the severity of this response (Forbes,
1978).
Subsequently there may be "acute rejection" mediated by the cellular immune
system as discussed above. At later stages "chronic rejection" may occur, which
manifests as vascular disease, known as "coronary occlusive disease" in cardiac
transplant recipients (Hunt, 1983). This is a form of atherosclerosis which may affect
both small and large vessels and which is rarely amenable to coronary artery bypass
grafting. At four years after transplantation 25% of cardiac transplant recipients were
shown to have this form of disease (Baumgartner, 1979). Chronic rejection, as well as
being related to cellular mechanisms of rejection, might also be mediated by the
humoral immune system (Dunn, 1992). Cramer et al showed in a rat cardiac allograft
model that more intensive immunosuppression with FK-506 was able to reduce the
atherosclerotic changes consistent with chronic rejection (Cramer, 1990).
Hyperacute rejection is avoided by adequate cross-matching and
lymphocytotoxicity testing pre-transplantation, although it may still occur despite
satisfactory results from these tests. Immunosuppressive therapy is required to prevent
destruction of the allograft by acute rejection. This therapy puts the recipient at
increased risk of opportunistic infection, which may be fatal. The risks of
immunosuppression must be balanced against the risks of acute rejection, particularly in
the early months when rejection is most common. In the first three months after
transplantation approximately two-thirds of patients will have at least one rejection
episode (requiring augmented immunosuppression) (Rose, 1989). Since no specific
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anti-rejection agents are available, the therapy used is of a broad nature and does not
solely affect those cells responsible for acute rejection. Chronic rejection, on the other
hand, cannot be treated, would not necessarily be detected on EMB histology and is a
major source of graft loss and mortality in the later stages after transplantation. Regular
coronary angiography is required to monitor the development of this complication,
which may warrant re-transplantation.
2.11. Mechanisms of Cardiac Transplant Rejection
There are a number of possible mechanisms by which a cardiac allograft might
undergo rejection including antibody mediated damage (Weil, 1981), lymphocyte
mediated cytotoxicity, DTH-type reactions and natural cytotoxicity (discussed in
Cramer, 1987). The precise effector cells of allograft rejection are not known but a
number of possibilities exist. Cytotoxic CD8+ T cells, macrophages and natural killer
cells have all been implicated in cardiac transplant rejection. T cells of CD4+ subtype
may be involved with any or all of these mechanisms and it may be that rejection
consists of a balance of these processes affected by various recipient and donor factors.
The phenotype of the cells involved has been studied by Hoshinaga et al who
used an immunoperoxidase method to stain EMB for cell surface markers (Hoshinaga,
1984). They found that in the early phase of acute rejection, CD4+ cells showed the
greatest influx into the EMB whereas at later stages CD8+ cells and macrophages
predominated. Cells more usually associated with acute inflammation and other immune
reactions (neutrophils, basophils and eosinophils) can also be present when rejection is
severe (Kemnitz, 1987).
It has been shown that cytotoxic T cells with specificity directed against
myocytes can be obtained from the myocardium of transplanted hearts in animals and in
man (Bradley, 1992). Once a recipient is sensitised to an allograft further responses of
CD8+ T cells can become independent of CD4+ help and these cells can then effect
rejection on their own account (Andersson, 1975; Gurley, 1986). However, it is
known that CD8+ cells alone are not sufficient to cause cardiac allograft damage.
Allograft specific cytotoxic CD8+ T cells given to heart transplanted animals depleted of
native T cells could not cause rejection alone (Hall, 1987). The precise role of CD8+
cytotoxic T cells in cardiac transplant rejection is therefore not clear.
The means by which CD8+ cells may damage cardiac cells is not known.
Granzyme A and perforin are proteins produced by activated cytotoxic T cells and they
appear to be involved in the functional activity of these cells (Young, 1987; Tschopp,
1988). At least one study has shown evidence of myocyte damage due to perforin in
humans (Young, 1990). Griffiths et al used ISH to look for expression of RNA for
granzyme A and perforin in EMB from recipients of cardiac transplants. RNA for
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granzyme A and perforin was found in patients undergoing rejection and in those who
went on to develop rejection (Griffiths, 1991). Thus one means by which CD8+ CTLs
may damage human myocytes in rejecting allografts is via the delivery of pore forming
proteins to the surface of myocytes.
CD4+ cells are known to be able to mediate cytotoxic responses, mediated by
class II, but probably they are mostly concerned with providing help for CD8+ cells,
monocytes and possibly natural killer cells. Macrophages can certainly be observed in
the monocellular infiltrate within cardiac allografts (Hoshinaga, 1984) and hence the
components of a delayed hypersensitivity type response are present. Whether this type
of response is causing myocyte damage in cardiac transplants is not known.
There must be other mechanisms capable of damaging cardiac transplants as
well as cellular immune responses since electrical and mechanical dysfunction can occur
in transplanted hearts in the absence of significant myocytolysis (Myles, 1987;
Schroeder, 1974). There is evidence pointing towards an intrinsic defect of myocyte
function, despite normal high energy phosphate stores, in patients with cardiac
transplants (DiSesa, 1991). Soluble factors that might influence cardiac function are
many, but in mice that have undergone cardiac transplantation mRNA for IL-1, -2, -3,
-4, -5, -6, TNFa and IFNy was expressed by infiltrating cells (Dallman, 1991). In
addition toxic effects of leucotrienes, which may be produced by monocytes,
eosinophils and neutrophils, were shown against rat cardiac myocytes by Maisch et al
(Maisch, 1987).
Cytotoxic T cells require some of these cytokines for their activation,
particularly IL-1, IL-4 and IFNy (Mizel, 1989). In addition, IFNa, IFNy, and TNFa
can have effects on allograft cells such as inducing MHC class I and II expression
(David-Watine, 1990), which might enhance their susceptibility to T lymphocyte
mediated responses. In situations where CD8+ cells are observed yet myocyte damage
does not occur, such as in Halls study (Hall, 1987), it may be that there are limiting
amounts of cytokine present, not allowing growth and effector function to develop.
A number of studies in animals, chiefly in rats and mice, have shed some light
on the mechanisms of cardiac allograft rejection. It has been shown that soluble class I
antigen of donor type infused into rats with cardiac allografts suppresses rejection via a
mechanism which involves blocking CTL recognition of graft antigens (Sumimoto,
1990). Heidecke et al were able to show that it was possible to separate alloreactive T
cells from "bystander cells" in rat cardiac allografts (Heidecke, 1990). This supports
the idea that not all the infiltrating cells observed in the myocardium of cardiac
transplant recipients are involved in rejecting the graft, providing further reasons why
histology of EMB is not as accurate as it ought to be.
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Hancock et al studied accelerated rejection as a model of hyperacute rejection
(Hancock, 1990). They found that, in addition to the known antibody mediated
damage, there was a cellular response. This was evidenced by graft infiltration by
mononuclear cells producing IL-2, IFNyand TNF, which was able to be reduced by
cyclosporine therapy or treatment with IL-2R monoclonal antibody. In another study,
Imagawa et al demonstrated the ability of anti-TNFa and (3 antibodies to prolong
cardiac allograft survival in rats (Imagawa, 1990). These studies provide evidence of
both CD8+ and CD4+ T cell involvement with cardiac allograft rejection and suggest
potential therapies for use in man in the future.
Two highly simplified traditional models by which an allograft might be
damaged are illustrated below (fig. 4). In the first, T helper cells recognise class II
molecules on allograft cells and are then stimulated to produce cytokines which act on
macrophages to promote cytotoxicity against the graft. This is similar to a delayed-type
hypersensitivity reaction (Brent, 1958). In the second, T helper cells recognise class II
molecules and then provide help to cytotoxic T cells which recognise class I molecules
on allograft cells and bring about cytotoxic T cell mediated killing (Hayry, 1970 and
Cerottini, 1974).
Rose et al demonstrated induction of expression of MHC molecules on
myocytes, particularly class 1, after transplantation (Rose, 1986). Suitters et al
demonstrated the induction of class I expression on cardiac myocytes in cardiac
transplant recipients which appeared to correlate with the presence of rejection (Suitters,
1987). They also found evidence for class II expression on interstitial structures in
these patients. Caforio et al used a double labelling technique (with antibodies to human
factor VIII, specific for endothelium, as well as class II) and found that class II
expression on cardiac endothelium in the transplanted human heart is upregulated in the
face of impending rejection (Caforio, 1990a). These studies suggest that donor
myocardium and endothelium can express the MHC molecules required to sustain
cellular immune responses.
Neither of the mechanisms illustrated takes account of the possible role of
vascular endothelium as a target for T cell responses yet there is evidence for such a
role (Hengstenberg, 1990; Caforio, 1990a; Dunn, 1992; Jutte 1993). Also not
illustrated is the role of antigen presenting cells (APCs). Donor APCs may present
donor peptides directly to recipient lymphocytes or recipient APCs may take up and
process donor proteins, for example class I, and present these in the context of their
own class II molecules.
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Figure 4. Two Simplified Mechanisms of Allograft Rejection
a. Similar to delayed-type hypersensitivity
This figure represents the possible interactions between the key cells involved with
this mechanism. The transplant celt is recognised by the T-helper (CD4) cell which
is then activated to secrete cytokines which in turn activate macrophages. Here, cell
killing is non-specific.
b. Cytotoxic T Cell Killing
In this model recognition of the transplant cell occurs via cytotoxic (CD8) and 7
helper (CD4) cells, each seeing class I and class II molecules respectively. Specific
destruction of myocytes occurs, with CD4+ cells providing "help". The CD8 cells
deliver a letlml hit to individual cells and hence killing is specific.




2.12. The Phenotype of Cells Infiltrating Cardiac Allografts
In early studies of animal models of cardiac allograft rejection, cell suspensions
were harvested from explanted allografts. T lymphocytes and monocytes were
predominant in these preparations (Tilney, 1975). Subsequently, the major cellular
components of the myocardial infiltrate in rejecting hearts were shown to be: CD4+ T
cells, CD8+ T cells and monocyte/macrophages, though cells with the natural killer
phenotype were also described (Yacoub, 1983; Marboe, 1983; Hoshinaga, 1984).
These cells may be involved in low grade rejection, with perhaps a perivascular
infiltrate not associated with myocyte damage (grade la), or alternatively there may be
larger numbers of cells aggressively infiltrating the myocardium and injuring adjacent
myocytes (grade 3a). This implies a developing process whereby lymphocytes
marginate on blood vessels of the allograft and then begin to infiltrate the parenchymal
structures, proliferating as acute rejection develops. The proximity of these proliferating
cells to the endothelial surface presumably relates to how they may be cultured from
EMB. There is no study which assigns a particular phenotype to any of these functions
or anatomical locations. In addition it is difficult to show that particular grades of
rejection are associated with particular phenotypes.
Ahmed-Ansari et al performed phenotyping of cells infiltrating EMB using
monoclonal antibodies and an immunoperoxidase method (Ahmed-Ansari, 1988). They
found few B cells, monocytes or macrophages but a small number of biopsies (8 to
16% depending on rejection grade) contained cells bearing the NKH-1 marker (found
on natural killer and other cells). The majority of cells observed were T cells, with
CD4+ cells predominating (about 65 to 74% of infiltrating cells compared with 23 to
33% being CD8+). Using antibodies to HLA-DR they found evidence of activation in
75 to 83% of the infiltrating cells. In this study EMB were also placed in culture. The
resulting lymphocyte cultures were phenotyped and comparison made with results
obtained from the in situ immunoperoxidase staining. The data in this paper were
presented poorly (percentages of cells positive for each marker were quoted along with
standard deviations, which were often very large) and the overall patient numbers were
rarely stated. However, it appeared that the phenotype of the infiltrating cells observed
histologically and by immunoperoxidase staining correlated broadly with the cells
subsequently cultured from EMB taken at the same time. It was stated that some
individuals EMB grew predominantly CD4+ cells when the in situ phenotype was
predominantly CD8 and vice versa, but these data were not shown.
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2.13. Lymphocyte Culture from Endomyocardial Biopsies
One approach to the problem of elucidating the nature of cells infiltrating
allografts, originally applied to renal transplants in 1985, has been to culture graft-
infiltrating T-cells from small biopsy fragments. The culture medium employed was
supplemented with interleukin-2 in order specifically to enhance proliferation of cells
bearing IL-2 receptors, which would include activated T cells, but also natural killer
cells and monocyte/macrophages. Several groups using this method have described
phenotypic and functional aspects of cells cultured from EMB. Some of the chief
conclusions from these studies were that: cultured cells were of a particular phenotype
at particular times after transplantation, ability to culture lymphocytes was correlated
positively with presence of histological rejection in concurrent biopsies and that culture
of lymphocytes in the absence of rejection predicted subsequent rejection. It therefore
appeared that this approach allowed culture of T cells which related to the in-vivo
rejection process.
2.14. Methods Used to Study Cultured Lymphocytes from EMB
Many of the studies relating to lymphocyte culture from EMB have used similar
experimental conditions. To inform discussion of these studies a table summarising the
methods used in the majority of these studies is given below (table 2). In addition some
of the conditions and methods used are described in more detail.
A. Lymphocyte Culture
In most studies small (approximately lmm^) fragments of tissue biopsies
(kidney, heart) were placed in tissue culture wells in culture medium. The culture
medium was invariably based on the Roswell Park Memorial Institute Medium-1640
(RPMI-1640) with various additional supplements, detailed below.
(i) Interleukin-2
The most important supplement was IL-2, quantified in terms of international
units(iu). Most studies used concentrations of 5 to lOOOiu/ml. Some studies used tissue
culture supernatants rich in IL-2 and therefore describe a percentage of IL-2 present
according to how much of the supernatant was added (Zeevi, 1986; Pfeffer, 1988;
Farrel, 1990, Jutte, 1990, Ouwehand, 1991). The usual source of IL-2 is now
recombinant IL-2 and most studies made use of this form (Kaufman, 1990 for
example). The various studies differed in how often and how much IL-2 is added to
cultures once they are in progress.
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This plant lectin (a plant protein which can bind to and cross-link cell surface
glycoproteins) activates all T cells non-specifically via the CD2 molecule on the cell
surface. Only a few workers have used PHA in their studies (Carlquist, 1988 and
Frisman, 1990).
(iii) Feeder Cells
These are peripheral blood mononuclear cells (PBMC) which may originate
from the donor, the recipient or an unrelated third party. The cells are treated to prevent
them from being able to proliferate (with irradiation or chemically with mitomycin-C).
The rationale for their use is that they provide cell to cell contact, local co-factors for
growth and they produce various lymphokines which help to maintain an appropriate
environment for cultured T cells.
Recent studies have used oxidised irradiated PBLs as described by Fleischer
(Fleischer, 1988). Fleischer's method involves rendering a sample of lymphocytes
from a given subject incapable of proliferation by exposing them to radiation. The cells
are then oxidised although the role of oxidation in this process is unclear. In this
condition they provide an appropriate milieu for dividing lymphocytes, with cell to cell
contact, cytokine production and other ill-defined effects.
Briefly, cells were suspended in RPMI-1640 medium and then subjected to
irradiation. Cells were then spun down and resuspended in "oxidation mix", containing
neuraminidase and galactose oxidase, and then incubated. The cells were then washed
in a solution containing galactose to remove any residual galactose oxidase activity.
Approximately 5 x 1 (r per ml oxidised feeder cells were added per tissue culture well.
In 9 of the 19 studies listed in the table feeder cells were used. It was most
common to use irradiated autologous feeder cells but allogeneic cells were also used.
B. Phenotyping
(i) Immunocytochemistry
Once sufficient cells have been cultured many groups have proceeded to
phenotype the cell population (Zeevi, 1986; Carlquist, 1988; Ahmed-Ansari, 1988;
Ouwehand, 1991; Carlquist, 1993). CD markers are functional molecules on the
surface of cells (particularly T cells) which allow them to be identified and which may
also indicate the function of a given population of cells. Listed below are some of the
cell surface markers against which monoclonal antibodies have been raised for use in
such experiments (table 3).
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Table 3. Antibodies to Cell Surface Markers
This table lists some of the various cell surface markers against which antibodies have been raised. In
the first column the table gives the cluster designation number according to the international workshop
definition. In the middle column is given any other designation. A brief description of the cells carrying




C D 2 LFA-2 T cells
C D 3 OK-T3 T cells
C D 4 Leu 3, OK-T4 T helper cells






C D 1 9 B cells





W6/32 Class I MHC All cells
HLA-DR Class II MHC
B cells, Monocytes
Activated T cells
There are two methods of staining routinely used in these studies:
immunoperoxidase and immunofluorescence. Both may utilise monoclonal antibodies
to cell surface markers in order to stain the cells of interest. A secondary antibody may
then be employed to detect the primary antibody. This may be conjugated to an enzyme
(horse radish peroxidase, alkaline phosphatase) or a flourescent molecule (fluorescein
isothiocyanate, phycoerythrin). In some experiments a third antibody is used against
the secondary antibody in order to increase sensitivity and it would be this final
antibody which would bear the conjugated molecule. Some protocols, particularly with
immunoperoxidase staining, use avidin-biotin systems to increase sensitivity.
Immunofluorescence staining can be used in association with flow cytometry,
whereby cells are detected according to granularity, size and fluorescence, to quantify
the cell populations stained with a particular fluorescent molecule. Alternatively
preparations of cells may be made by spinning them in a centrifuge at high speed onto a
microscope slide (cytospin). The slides are subjected to the staining protocol and
visualised microscopically to be counted. Either immunoperoxidase or
immunofluorescence can be used with cytospin preparations.
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(ii) HLA Typing
In order to determine which HLA class I and class II molecules are present on
an individual's lymphocytes, and sometimes on cultured cells, defined anti-sera to
particular HLA antigens are added to cells along with complement molecules (Terasaki,
1965). If the antibodies in the sera bind to the cells and fix complement then lysis
occurs. Thus where cells are lysed they bear the antigen known to be recognised by the
test serum. Some workers used the information gained from HLA typing to select third
party cells as targets for cytotoxicity experiments. Other methods for performing HLA
typing involve restriction fragment polymorphisms. Also, the polymerase chain
reaction can be used to amplify DNA from lymphocytes for molecular identification of
their HLA phenotype (Joysey, 1993).
C. Functional Testing
(i) Response to IL-2
A crude measure of the ability of cultured lymphocytes to grow is to test their
ability to proliferate in response to exogenous IL-2. This is based on the observation
that activated T cells express increased numbers of IL2R on their surface. Thus, some
workers took aliquots of lymphocyte cultures and added defined amounts of IL-2
(Weber, 1989; Kaufman, 1989). Proliferation was measured by tritiated thymidine(3H-
thymidine) incorporation and compared with the rate of proliferation in IL-2 with other
cultures and sometimes with PBMC from the recipient. The uptake of ^H-thymidine
depends upon the rate of cellular DNA synthesis. Thymidine is one of the bases used in
the construction of DNA and proliferating cells use it when replicating DNA for
subsequent cell division. The uptake of'H-thymidine from culture medium is therefore
an indirect measure of proliferation.
(ii) 2 Day Mixed Lymphocyte Reaction(MLR)
This assay consists of adding cultured lymphocytes to irradiated (or mitomycin-
C treated) PBMC from a relevant subject (donor, recipient, third party) and then
incubating them for 48 hours. If the cultured cells have been 'primed', that is they have
already undergone a primary response to the antigens borne by the target cells in-vivo,
they will proliferate rapidly when re-exposed to the same antigen. Significant
incorporation of tritiated thymidine will only occur if this is the case.
(iii) Primed Lymphocyte Testing(PLT)
This is essentially the same as the two-day MLR except that the incubation
period is extended to three days, allowing greater time for a response to develop. The
original method (Frandelizi, 1975) was adapted for use with cells cultured from EMB.
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The majority of workers in this field have used this form of the experiment (Zeevi,
1986; Weber, 1988; Ahmed-Ansari, 1988 and Kaufman, 1989).
(iv) Cell Mediated Lympholysis (Cytotoxicity)
This involves testing T cell populations (effector cells) for ability to kill target
cells (European CML Workshop, 1980). When positive it demonstrates that the
population tested has previously been exposed to and developed activity against the
antigens borne by the target cells. In these experiments target cells, usually donor or
third party PBMC, would be labelled with 51Cr beforehand. The test cells would then
be added and co-incubated for four hours. A range of effector to target cell ratios would
normally be employed. Where cell killing occurs 51Cr is released into the medium.
Cultures are then filtered onto paper and the amount of 51Cr in the culture medium
counted by scintillation counting.
Calculations are facilitated by measuring spontaneous release(S) from a culture
to which no effector cells are added. In addition 100% lysis(M) is produced, often
using a detergent such as Triton X-100. A figure (specific lysis) is derived which
reflects the ability of the effector cells to kill the targets. The equation used to calculate
specific lysis for each test is as follows:
% specific lysis = (E - S) X 100
(M - S)
(where E = experimental value, S = spontaneous release, M = maximum lysis)
Specific lysis >10% is usually taken as a significant result.
Several studies used these methods to test for cytotoxicity in cultured cells
(Pfeffer, 1988; Kaufman, 1989).
(v) Natural Killer Activity
This is tested by measuring cytotoxic activity against a cell line known to be
sensitive to this kind of cellular killing (K562 cells), (Ahmed Ansari, 1988 and Pfeffer,
1988).
2.15. Phenotypic and Functional Studies, Relation to Rejection
The phenotype of cells cultured from small numbers of renal biopsies in the two
original reports of this technique was mixed, with CD8 and CD4 positive T cells being
present (Mayer, 1985; Miceli, 1985). CD8+ cells predominated in Mayer's study of 8
biopsies. When the phenotype of infiltrating cells cultured from cardiac biopsies was
examined it was also found that CD4 and CD8 cells were present in various
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proportions. Monocyte/macrophages and B cells were also observed (Ahmed-Ansari,
1988; Carlquist, 1988; Suitters, 1989).
Mayer demonstrated evidence of cytotoxic function among cells cultured from
renal allografts, directed against cells bearing class I antigens identical to those of the
donor (Mayer, 1985). There was very little cytotoxicity against third party cells hence
this activity was donor-specific. In experiments on cells grown from human cardiac
allograft biopsies, Zeevi et al demonstrated proliferative responses to cells which shared
MHC molecules with the donor but not to third party cells (Zeevi, 1986). Ahmed-
Ansari et al showed that there was both proliferative and cytotoxic T cell activity in cells
grown from EMB (Ahmed-Ansari, 1988). This study also found some natural killer
activity. Pfeffer et al also showed, in similar experiments, that there was donor specific
cytotoxicity but not natural killer activity among cultured lymphocytes (Pfeffer, 1988).
Ahmed-Ansari demonstrated that the phenotype of lymphocytes grown from
EMB in bulk culture, as determined by flow cytometry and immunofluorescence
staining, generally correlated with the phenotype observed directly in EMB taken at the
same time (the in situ phenotype), using immunoperoxidase staining (Ahmed-Ansari,
1988). This suggests that the culture method used produces cell populations which, in
their phenotype at least, are representative of the cells present in vivo. There were some
deficiencies in the presentation of data in this paper and so only the most general
conclusions can be drawn. This study also found no relationship between circulating
IL-2R or cyclosporin levels and phenotype of cultured cells. Interestingly, there was no
correlation between the in-situ phenotype and the grade of rejection. This might suggest
that any phenotype (CD4 or CD8 predominantly) can be associated with, or mediate,
acute rejection. This might support there being more than one rejection mechanism at
work. Alternatively, it may represent the inability of histology to accurately reflect in
vivo pathophysiological processes.
A number of other authors have sought to relate the ability to culture
lymphocytes from allograft biopsies to the presence or absence of rejection on
histological examination of simultaneously obtained biopsies. Some authors have not
addressed this at all. Mayer obtained biopsies only from renal transplant patients who
were known to be undergoing rejection in the first place (Mayer, 1985). Carlquist et al
reported in one study that there was a relationship between ability to culture
lymphocytes from EMB and rejection but in another study they were unable to find
such a relationship (Carlquist, 1988; Carlquist, 1989). Pfeffer found that 20 of 35
(57%) biopsies with histological evidence of rejection grew lymphocytes whereas only
17 of 56 (30%) without rejection produced positive cultures (Pfeffer, 1988).
The ability to culture lymphocytes from histologically negative biopsies may be
used to predict subsequent rejection. Weber showed that there was an increased
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cumulative incidence of subsequent rejection within 30 days (Weber, 1989). Carlquist
showed that the overall incidence of subsequent rejection was greater for those patients
with positive culture but negative histology, compared to those with negative culture
and negative histology (Carlquist, 1989).
2.16. Cardiac Transplantation and EMB: Summary
Cardiac transplantation is an important therapy for patients with end-stage
cardiac failure. However, the occurrence of acute rejection significantly affects
survival, having its greatest effect in the early post-transplant period. Rejection is
diagnosed histologically on EMB, taken at regular intervals, and is treated with
additional immunosuppression. The grading system for rejection is based on the degree
of cellular infiltration and myocyte damage but includes observations of other features
such as endocardial lymphocytic infiltrates (ELI). There are several potential
mechanisms by which allografts may be damaged and which of these operate in
individual patients is not clear. The use of IL2-supplemented media to culture activated
T cells from EMB has allowed in-vitro studies of the nature of graft infiltrating cells but
has also been investigated with a view to possible use as a prognostic tool.
This study was undertaken to test the hypothesis that supplementing a basic
culture medium containing IL-2 with polyclonal stimulators of T cell proliferation such
as phytohaemagglutinin or anti-CD3 antibodies, would increase the number of positive
cultures compared with a medium supplemented with IL-2 only. Previous studies have
utilised culture medium supplemented with IL-2 in various concentrations but have also
included phytohaemagglutinin, irradiated feeder cells (allogeneic and autologous) and
different types of serum supplements.
The study was also designed to observe the incidence of subsequent rejection in
patients with positive culture results but no rejection on histological examination of
associated biopsies. This was done to confirm the notion that T cell culture might have
potential clinical use in monitoring cardiac transplant recipients.
In addition it was planned to compare the effects of presence or absence of ELI
in cases with positive or negative culture results. If ELI were contributing to positive
culture results, but were not related to rejection then they could easily distort the
usefulness of this technique in predicting subsequent rejection. The hypothesis was
therefore that ELI were confusing the results of lymphocyte culture from EMB.
Previous studies have also not addressed the question of MHC antigen mis¬
matches at Class I or Class II loci. Rejection is not an all or none phenomenon; it is
possible to have grade 2 rejection on biopsy and remain entirely well with no cardiac
dysfunction, despite the presence of cells infiltrating the myocardium. There may be
patients whose immune response to the allograft is stronger than other patients and
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whose target is Class I or Class IT bound peptides recognised more strongly for certain
HLA molecules than for others. If this were the case then some patients with mis¬
matched allografts would have more infiltrating cells and be more likely to have a
positive culture result from EMB. Therefore data were collected on HLA A, B and DR
mis-matches among these patients to determine if patients with mis-matches at one or
more loci were more likely to have positive lymphocyte cultures obtained from their
EMB.
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3. Lymphocyte Culture from Endomyocardial Biopsies:
Patients, Materials and Methods
3.1. Patients
Endomyocardial biopsies (n=94) were obtained from 73 cardiac transplant
recipients (7 female, average age 47 years, range 16-63 years) and from 5 patients who
were not transplanted (age range 20-49 years, 1 female), 4 of whom had idiopathic
dilated cardiomyopathy and 1 had alcoholic cardiomyopathy. The pre-transplant
diagnosis was ischaemic heart disease (IHD) in 45 (62%) patients and idiopathic dilated
cardiomyopathy (DCM) in 28 (38%) patients.
Transplant patients were receiving routine immunosuppression with
azathioprine, cyclosporin and prednisolone at the time of biopsy. Multiple biopsies
(average 10) were obtained at routine diagnostic biopsy in each patient and one of these
was used in the culture studies described. Informed consent was obtained and the study
was approved by local ethical committee.
3.2. Endomyocardial Biopsy
Biopsies were obtained from the right ventricle via the right internal jugular
vein, under local anaesthesia, using a standard bioptome with fluoroscopic guidance at
a median of 8 months following transplantation (range 1 week to 96 months). Thirty-
one biopsies were taken within three months of transplantation. A total of 94 biopsies
were obtained for culture studies from 73 cardiac transplant recipients (17 patients were
biopsied twice and 2 three times). Biopsies were obtained over a fourteen month period
commencing May 1990.
3.3. Lymphocyte Culture
Each biopsy sample was collected into the basic medium used in these studies
which contained the substances listed below:
• RPM1-1640 medium (ICN-Flow, High Wycombe, Bucks),
• Penicillin lOOi.u. per ml (ICN-Flow),
• Streptomycin lOOjig per ml (ICN-Flow),
'
• L-glutamine 2mM (ICN-Flow),
• Sodium bicarbonate 0.2% (ICN-Flow),
• 10% human AB-negative serum (ICN-Flow)
• 5i.ti. per ml recombinant interleukin-2 (IL2, Human recombinant DNA IL2,
National Institute for Biological Standards and Control, South Minims, Herts)
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Samples were collected in a sterile universal container at room temperature and
transported to the laboratory within three hours.
Under sterile conditions in a tissue culture hood the biopsy was placed on a
petri dish and finely divided into up to three approximately equal fragments using a
scalpel. Each fragment was placed in a single well of a round bottomed 96-well tissue
culture plate containing 200jil of medium as below. Biopsies were cultured at 37°C in
5% CO2 in air. Irradiated feeder cells were not used. Fragments from each biopsy were
cultured in at least one of the following media for the first three days:
1 ) basic medium plus 4 |ig/ml phytohaemagglutinin (PHA, ICN-Flow);
2) basic medium with monoclonal antibody to the CDS cell surface marker
(1:10,000 final concentration of cell culture supernatant from cell line CRL
8001 OKT3 obtained from ECACC. The optimum concentration was
determined by assays for proliferation of PBMC, see below)
3) IL2 alone.
After three days, and every third day thereafter, half the medium in each well
was removed and replaced with the basic medium alone.
Fifty-seven biopsies were sufficiently large for a fragment to be grown with
each of the three media (PHA+IF2, CD3+IF2 and IL2 alone); 73 biopsies were large
enough for pieces to be grown in medium with PHA+IF2 and in lF2-alone; 18 biopsies
were cultured in medium with PHA+IL2 only. Wells were observed daily for
outgrowth of cells on an inverted stage microscope. A biopsy was considered to be
positive when lymphocytes could clearly be seen exuding from it and proliferating, as
previously described (Carlquist, 1988). Effete red cells were observed and discounted
and fibroblast-like cells were sometimes observed, forming a monolayer as previously
described (Mayer, 1985).
3.4. Immunophenotyping
Cells from a group of twelve consecutive cultures were counted and subjected
to indirect immunostaining with a panel of monoclonal antibodies to confirm their
phenotype. Cells were suspended in RPM1-1640 medium and an aliquot was counted
on a haemocytometer by trypan blue exclusion to ensure that cell viability was greater
than 95%. After counting, the cells were resuspended in serum-free medium and spun
on to microscope slides in a cyto-centrifuge for 10s at 1000 rpm. The slides were left to
dry in air overnight and were then fixed in acetone at 4°C for 15 minutes. After drying,
the cells were then stained with a panel of monoclonal antibodies to the following cell
surface markers: CD8 and CD4 (Dept. of Immunology. Royal Free Hospital, Fondon),
CD16 (Dako, High Wycombe, Bucks), CD19 (Serotec) and CD68 (Dako) at room
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temperature for 60 minutes. After washing with phosphate-buffered saline and 0.1%
Tween, the cells were incubated with fluorescein isothiocyanate conjugated Fab'2
fragments of mouse anti-human immunoglobulins (Dako) for 60 minutes at room
temperature. At least two hundred cells were stained using each antibody. Control
slides were incubated in serum-free medium in place of primary antibody. Positive
staining was observed using ultra-violet light microscopy (Zeiss Axioskop. Carl Zeiss,
Oberkochen, Germany. HBO 50 high pressure mercury lamp with red attenuating
filter).
3.5. Histology
Routine histology was performed on haemotoxylin and eosin-stained serial
sections of the remaining nine formalin-fixed biopsies for each subject by the
Histopathology Laboratory at Papworth Hospital. Biopsies were graded, without
knowledge of the culture result, according to the International Society for Heart and
Lung Transplantation working formulation, by Dr N Cary (Billingham, 1990).
3.6. Separation of Peripheral Blood Mononuclear Cells (PBMC)
Venous blood was obtained (lOmls) into a sterile universal container with 100
units of preservative-free heparin. Under sterile conditions in a tissue culture hood the
blood was layered onto 7.5mls of Lymphoprep solution (Nycomed Pharma AS, Oslo,
Norway) in a fresh sterile universal container. This was centrifuged in an IEC Electra-8
centrifuge at 2000 r.p.m. for 15 minutes with no brake applied. The lymphocyte layer,
at the interface between serum and the solution, was aspirated using a Pasteur pipette
into another sterile universal container. The cells were resuspended in lOmls of
phosphate buffered saline (PBS) and spun at 2,000rpm (with brake). The PBS was
aspirated and the cells were twice more resuspended in PBS and spun at 1200rpm.
After the final step cells were counted by trypan blue exclusion. A 5()pl aliquot was
mixed 1:1 with trypan blue solution and counted on a haemocytometer using an
inverted stage microscope. Dead cells were recognised by blue staining and
preparations were always assessed to ensure greater than 95% viability of cells. Finally
cells were resuspended in the appropriate solution and concentration, depending on the
requirements.
3.7. Proliferation Assays
Peripheral blood mononuclear cells were prepared as under 3.6. After the final
washing step cells were resuspended in RPMI-1640 medium supplemented with 10%
fetal calf serum (ICN-Flow) at 2 x 1()6 viable cells per ml. From this solution 1 OOpil
was placed into each of 54 wells of a sterile 96 well tissue culture plate with "U"
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bottomed wells giving 18 sets of triplicate wells. The supernatant from cell line CRL
8001 OKT3 (obtained from the European Collection of Animal Cell Cultures) was
added to each triplicate in the following dilutions:
1:100 1:200 1:400 1:800 1:1200 1:1600
1:2000 1:4000 1:5000 1:6000 1:8000 1:9000
1:10000 1:12000 1:14000 1:16000 1:2000
The plate was sealed in cling film and cultured in a humidified incubator in
5%CC>2 in air at 37°C. On the evening of the third day in culture, tritiated thymidine
(Amersham International pic, Amersham, Bucks) was added to each well (lpCi per
well). After 16 hours incubation the cells were harvested using a Skatron cell harvester
(Flow) onto discs of filter paper. These were dried by incubation at 37°C for an hour.
The discs were then placed into scintillation vials (Beckmann, High Wycombe, Bucks)
for counting along with 0.5ml "Optiscint" scintillation cocktail (Amersham). All vials
were then counted in a scintillation counter (Packard Tri-Carb 1500 Liquid Scintillation
Analyser. Canberra Packard Instrument Co.,Pangbourne, Berks) for 1 minute per vial.
Three vials containing filter discs and scintillation fluid but no cells were counted as a
background control. Results were produced in the form of counts per minute and were
corrected for the background count.
3.8. HLA Typing
HLA typing was performed by the tissue typing laboratory at Addenbrookes
Hospital, Cambridge. For routine tissue typing the NIH (National Institutes of Health)
method was used as originally published by Terasaki (Terasaki, 1965). Instead of
staining cells with eosin however, ethidium bromide and acridine orange were used
with ultra-violet light examination to determine cell viability (dead cells fluoresce red
and live ones green). Typing was performed using a reliable panel of antisera used for
transplant analysis.
3.9. Statistical Methods
To compare time to observed outgrowth between different media the log rank
test was used, with the fragments which failed to produce lymphocytes being excluded.
The Mann-Whitney U Test was used to compare two median times, for example time
since transplantation was performed, for patients with and without ELI. Logistic
regression was used to assess the relationship between culture supplement and
rejection, time since transplantation was performed and so on. Results for the
likelihood ratio test are provided. Other tests used were the Chi-square test and Fishers
exact test.
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4. Results: Endomyocardial Biopsies
4.1. Lymphocyte Culture Results
A total of 94 biopsies from 73 cardiac transplant patients were obtained in order
to study the ability to culture lymphocytes. 17 patients underwent biopsy twice and two
patients had three biopsies each in this study. No lymphocytes grew from biopsies
taken from the 5 control (non-transplanted) patients, and histology in these showed no
evidence of T cell infiltrates. Biopsy fragments remained in the wells until cultures were
discarded. An example of a positive culture is shown below (fig. 5).
Figure 5. Lymphocytes Exuding from Endomyocardial Biopsy
This photomicrograph, (Nikon 35mm camera on Nikon inverted, stage microscope, film speed ASA
400, magnification X40, exposure UlSsec), shows a large dark area, which is the bulk of the
endomyocardial biopsy, from which many small cells can be seen exuding. This picture was taken at an
early stage (dayfive) in culture.
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From the culture conditions chosen and their similarity to previous studies it
was assumed that T-lymphocytes would be grown from EMB, as opposed to any other
cell type. The morphology of the cells, their behaviour in culture and
immunophenotyping confirmed that this was the case. Only cultures consisting of
significant numbers of T-lymphocytes were accepted as positive, as described earlier in
the methods section. Pure cultures of monocytes or fibroblast-like cells were
occasionally observed and discounted. The photomicrographs in figures 5 (above) and
6 (below) show typical T lymphocytes exuding from biopsy fragments. The appearance
of these cells contrasts with a culture consisting of monocytes as shown in figure 7.
Figure 6. Lymphocytes Exuding from Endomyocardial Biopsy
This picture, (ASA400, X 100, l/15sec), was taken at day eight. A larger number of lymphocytes can
clearly be seen. Again the biopsy is seen only as a dark mass to one side of the picture.
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Figure 7. Monocytes cultured from an Endomyocardial Biopsy
1 his photomicrograph, (ASA400, X 100, 1 iHsecj, shows a culture consisting almost entirely of
monocytes, as was later confirmed by immunophenotyping with the CD68 marker. These cells are
larger than T lymphocytes and have a more granular 'spiky' appearance.
Lymphocytes grew from 60 of 94 (64%) biopsies in medium supplemented
with PHA and IL-2, 37 of 57 (65%) in medium with CD3 and IL-2 and 36 of 76 (47%)
in medium with IL-2 alone. The individual results are shown in the table which
follows (table 4). For biopsy fragments taken within three months of transplantation,
cultures were positive in 19 of 31(61%) in medium with PHA and IL-2, in 12 of
20(60%) in medium with CD3 and IL-2 and in 15 of 25(60%) in medium with IL-2
alone (table 5).
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Table 4. Lymphocyte Culture from EMB: Results
The table shows a list ofpatients whose biopsies were subjected to culture. They are placed in order of
those who only had one biopsy fragment cultured proceeding to those who had three cultured. The time
since the recipient underwent transplantation (in months) is shown in the second column. The results
of attempts to culture lymphocytes in each of the three media used are in the third, to fifth columns
(with the number of days to positive culture being observed shown for positive results and 'NEC
indicating failure of lymphocytes to grow). In column six the histology grade of the biopsies taken at
the same time as the EMB used for culture experiments is shown, along with the total number of
biopsy fragments taken at that time in brackets. Also denoted is the absence ofELI (as -) or presence of
ELI (+) or ELI plus myocyte injury (++). Column seven shows the histology (where available) on the
next biopsy obtainedfrom that individual. The final column shows the patients diagnosis (1 =ischaemic
heart disease, 2=dilated cardiomyopathy).
Histology Histology
Patients Months Growth in: on initial on next Diagnosis
(& repeats) from Tx PHA IL-2 CD3 biopsy biopsy
1, 59 4 KE3 3a+ (8) 2+ (10) 1
2, 42 7.5 1 0 0- (9) 2- (10) 1
3, 21 3 8 1 a- (8) 3a- (10) 1
4 7.75 8 1 a++ (9) 1 a+ (8) 1
5, 22 1 .5 8 1 a- (9) 1 a- (9) 1
6, 31, 79 2.25 1 0 1 a- (8) 2- (8) 2
COCO 24 8 1 a- (8) 1 a+ (8) 2
00 GO o 24 KEG 2- (8) 1 a+ (10) 2
9 1 .5 KE3 2- (10) 1 a- (10) 2
10, 29 1 .5 KEG 0- (10) 0- (12) 1
1 1 3.5 7 1 a- (5) 0- (10) 2
1 2 35 7 1 a+ (10) 3a+ (8) 1
1 3 3 7 1 a- (8) 3a- (7) 1
1 4 62 7 1 a- (10) 0- (8) 2
1 5 37 KEG 1a+ (14) 1a+ (9) 1
1 6 96 7 0- (10) 0- (10) 1
1 7 72 7 0- (10) 0- (10) 1
18, 24, 49 1 4 7 1 a- (10) 3a- (9) 2
19, 32 8 8 3a+ (10) 1 a+ (10) 1
20, 43 9 KEG 0- (9) 1 a- (7) 1
21, 3 4 KEG 3a- (10) 1 a- (11)
22, 5 2.5 6 6 1a- (9) 3a- (9)
23 1 2 KEG KEG 0- (9) 3a- (7)
24, 18, 49 1 1 6 6 3a- (9) 1 a+ (10)
25 5.5 1 4 5 3a- (8) 2+ (9) 1
26 1 3 KEG KEG 0+ (9) 0++ (9) 1
27, 46 0.5 1 4 1 4 1 a- (13) 0- (9) 1
28 0.5 1 4 1 4 0- (10) 1 a- (12) 1
29, 10 1 .5 1 4 1 4 0- (10) 1 a- (10)
30 24 KEG KEG 2+ (8) 2- (12) 1
31, 6, 79 3.5 KEG KEG 2- (8) 3b- (10)
32, 19 8.75 7 KE3 1 a++ (10) 0+ (10)
33, 7 25.75 7 KEG 3a- (7) 2- (8) 2
34 48 7 KEG 1 a++ (10) 0- (9) 2
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(& repeats) from Tx PHA IL-2 CD3 biopsy biopsy
35 6.25 1 2 NBG 1 a- (8) 1 a- (11) 2
36 5.25 NEG NEG 1 a+ (9)
* 2
37 0.25 KEG NEG 0- (8) 3a- (11) 1
38, 53 3.25 7 7 7 0- (8) 1 a- (9) 1
39 1 6 7 NBG NEG 1a- (7) 2+ + (10) 1
40, 67 6 NEG NBG NEG 3a++ (7) 1 a- (12) 1
41, 58 0.75 NBG NEG NEG 0- (8) 1 a- (12) 1
42, 2 1 4 NEG NEG NEG 1 a- (7) 3a- (8)
43, 20 22 KEG NEG NBG 2++ (8) 2+ (8) 1
44 1 1 NBG NEG NBG 0- (7) 2- (9)
45 62 1 1 7 7 0++ (7) 0++ (7) 2
46, 27 3 l\EG NEG NEG 0- (8) 1 a- (7)
47 24 7 1 2 7 1 b+ (8) 3b+ (10) 1
48 2.25 1 2 NEG NEG 1a- (10) 0- (12) 2
49, 18, 24 25 1 2 1 2 1 2 1 a- (9) 0+ (9)
50, 56 0.25 6 6 6 1 a- (10) 2- (10) 1
51, 64 1 KEG NEG NBG 1 a- (12) 1 a- (9) 1
52, 86 22 6 6 6 0++ (12) 0++ (8) 1
53, 38 4 9 NBG NBG 1 a- (9) 0- (8)
54 8 6 6 NEG 3b- (10) 3a- (11) 2
55 1 5 KEG 6 6 3b- (10) 1 a- (10) 2
56, 50 0.5 6 6 6 2- (10) 1 a- (10)
57 1 NBG NEG NEG 1 a- (9) 1 a- (10) 1
58, 41 1 NEG NEG NEG 1a- (8) 1 a- (10)
59, 1 7.5 2 2 6 3b++ (8) 1 a++ (8)
60, 8 2 9 6 2 3 3a- (9) 1 a- (9)
6 1 13.5 5 8 NEG 1 a- (11) 0++ (6) 2
62 1 .5 8 5 5 3b- (8) 1 a+ (9) 1
63 24 1 1 1 3b++ (8) 2++ (11) 2
64, 51 1 .25 NBG NEG NEG 1 a- (9) 1b- (10)
65 1 4 1 0 1 0 2 1 a- (7) la+ (8) 1
66 3 7 1 0 NBG 1 0 1 a++ (12) 0+ (8) 2
67, 40 7 1 0 1 0 1 0 1 a- (12) 1a- (9)
68 0.5 NBG 1 0 1 0 2- (11) 0- (9) 1
69 5.5 1 0 1 0 1 0 3b+ (11) 3b+ (10) 1
70 1 2 1 0 1 4 1 0 1 a- (8) 3a- (7) 2
7 1 2 1 0 1 0 1 0 1b- (12) 1 a++ (10) 1
72 2 NEG 1 3 9 2- (9) 1 a- (9) 1
73 72 NBG 9 9 U (10) 3a- (9) 1
74 1 5 NBG NEG NEG 1 a- (8) 2- (6) 2
75 0.25 9 9 9 3b- (9) 3a- (12) 2
76 0.5 9 9 9 3b- (10) 3b- (10) 1
77 72 NBG NBG 1 3 1 a- (10) 0- (6) 2
78, 85 0.25 NEG NEG 1 3 0- (11) 0- (9) 2
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Histology Histology
Patients Months Growth in: on initial on next Diagnosis
(& repeats) from Tx PHA IL-2 CD3 biopsy biopsy
79, 6, 31 7.75 6 6 6 0- (9)
*
80 1 6 6 6 3a+ (11) 1a- (12) 1
8 1 1 2 1 6 1 3a++ (11) 1 a+ (9) 1
82 1 6 6 6 3a+ (10) 3a- (10) 2
83 1 2 8 NBG 8 0+ (7) 1 a+ (9) 1
84 26 5 fEG 1 1a+ (7) 3a++ (6) 1
00 en 00 1 .5 5 5 LEG 3a++ (8) 3a+ (11)
86, 52 26 fEG fEG hEG 0+ (8) 0- (6)
87 1 2 LEG fEG 5 0- (8) 3a- (7) 2
88 1 8 7 fEG 7 2- (10) 0- (10) 1
89 1 5 7 fEG 2 3a+ (15) 1 a-i- (12) 2
90 72 1 3 fEG 1 3 3a+ (13) 3a++ (8) 2
9 1 1 9 NB3 LEG LEG 1 a- (9) 3a+ (9) 1
92 3 6 LEG 6 3a- (9) 0+ (10) 1
93 1 2 1 LEG 1 1 a+ (7) 0- (8) 2
94 1 0 NB3 NEG NEG 0- (9) 1 a- (6) 1
Table 5. Lymphocyte Culture in Relation to Medium Used and
Time from Transplantation
The table shows the numbers of biopsies which produced positive cultures. This is broken down by
each of the three different supplements to the basic medium. Results are shown as number of positive
cultures against total number ofbiopsies placed in culture in that particular supplement. The patients
are divided into those within and those beyond three months of transplantation. The overall figures for
positive culture are also shown in the bottom row.
Time from PHA + IL2 CD3 + IL2 IL2 Alone
Transplant (medium 1) (medium 2) (medium 3)
<3 months 19/31 12/20 15/25
(61%) (60%) (60%)
>3 months 41/63 25/37 20/48
(65%) (68%) (42%)
All biopsies 60/94 37/57 35/73
(64%) (65%) (48%)
The median time to positive culture for each biopsy fragment grown in medium
with PHA and IL-2 was 7 days (range 1-14); 7 days (1-14) in medium with CD3 and
IL-2; and 6.5 days (1-14) in medium with IL-2 alone. The overall median time to
47
positive culture for all fragments (n=224) was 7 days (1-14). Because no new cultures
were observed after 14 days the study was ended at this point.
The rate of appearance of lymphocyte outgrowth was similar for each medium
(fig.8). Variation between media in time to observed outgrowth using the Log-Rank
test was close to significant at traditional levels (p=0.077). Comparing lymphocyte
cultures grown in IL-2 alone (medium 3) with the other two media separately gave
similar results when adjusted for multiple testing (medium 3 vs. medium 1, p=(). 132
and medium 3 vs. medium 2 p=0.082).
Figure 8. Rate of Appearance of Positive Cultures in Different
Media Supplements
This cumulative frequency graph shows the accumulation of positive culture results for biopsy
fragments grown in each of the three media supplements. The first day on which a culture was deemed
to be definitely positive has been plotted for all the positive cultures. It can be seen that by day 14 all
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4.2. Effect of T Cell Activators on Endomyocardial Culture
Fragments from 57 biopsies were grown in all three media. In 36(63%), the
culture result was identical irrespective of the culture conditions. Lymphocytes grew
from 22 of these 36 cultures and no growth was seen in 14. In the remaining 21
biopsies, concordant results were observed in media 1 and 3 in 6 (3 positive, 3
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4.3. Rejection Grades
The distribution of rejection grades amongst all the biopsies studied was as
follows: grade 0 in 23 (24%) biopsies, grade la in 37 (39%), grade lb in 2 (2%),
grade 2 in 9 (10%), grade 3a in 15 (16%) and grade 3b in 8 (8%). No biopsies showed
grade 4 rejection.
Positive culture results for fragments grown with each of the three supplements
are shown below (table 6) in relation to the histological grade of rejection found on
biopsies taken at the same time. The distribution of positive culture results among the
rejection grades follows what would be predicted if the distribution occurred by chance.
Table 6. Culture Result by Medium Used and Rejection Grade
This table shows the results of lymphocyte culture for fragments grown in each of the three media
broken down by the grade of rejection observed on biopsies taken at the same time. The figures given
are the number of positive cultures obtained against the total number of fragments grown in that
medium, also expressed as a percentage in brackets.
Rejection PHA + IL2 CD3 + IL2 IL2 Alone
Grade (medium 1) (medium 2) (medium 3)
0 10/23 8/12 7/19
(43%) (67%) (37%)
1 a 27/37 9/20 8/26
(73%) (45%) (31%)
1 b 2/2 2/2 2/2
(100%) (100%) (100%)
2 2/9 4/5 3/7
(22%) (80%) (43%)
3 a 12/15 7/9 8/14
(80%) (78%) (57%)
3b 7/8 7/8 8/8
(88%) (88%) (100%)
4 0 0 0
All Grades 60/94 37/57 36/76
The series of results for fragments grown in 1L-2 alone is also shown as a bar
graph (fig. 9). The lb group of rejection results is too small (n=2) to be meaningful and
so this is amalgamated with la rejection in the figure.
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Figure 9. Rejection Grade and Positive Culture in IL2 alone
The bar graph shows the percentage ofpositive cultures resulting from fragments grown in medium
supplemented with IL-2 only. The. apparent trend is towards more positive cultures with higher grades
of rejection. Rejection grades la and lb have been amalgamated into grade 1 alone.
Figure 10. Rejection Grade and Positive Culture for all three
Supplements
This bar graph contains similar information to fig.9. Results for fragments grown in each of the three
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Results for all three media supplements used are shown in figure 10. Here
comparison is made between culture results at each rejection grade for each of the three
supplements used. The graph shows that the trend towards increasing ability to culture
lymphocytes with higher grades of rejection is not so apparent with media 1 and 2.
4.4. Comparison of Culture Results with Rejection
There was a tendency to a higher percentage of positive cultures with higher
grades of rejection (approximately 90% for grade 3b versus 50% for grade 1), but this
was not significant (for example p=0.08 for medium 1, also see fig. 10). However, if
patients whose biopsies revealed grade 3a rejection or higher were designated
"rejecting" and those with grades less than 3a as "non-rejecting", then a significant
relationship between positive culture and rejection was found for biopsies grown in
medium 1 (p=0.025) and medium 3 (p=0.004, see Table 7).
Table 7. Culture Result and Presence or Absence of Rejection
This figure shows the number ofpositive cultures for each fragment grown in each of the three media
according to whether the biopsy was taken from patients whose accompanying biopsies showed
rejection or not. It can be seen that for IL-2 alone andfor PIIA+IL-2, there is a significant difference
between culture result in the presence or absence of rejection. The results for CD3+IL-2 are close to
significance.








19/23 (83%) 14/17 (82%) 15/20 (75%)
No rejection
(<3a)
41/71 (58%) 23/40 (58%) 20/53 (38%)
All 60/94 (64%) 37/57 (65%) 35/73 (48%)
(p=0.025) (p=0.062) (p=0.004)
4.5. Prediction of Rejection
The ability to predict rejection was examined by determining how many patients
without rejection on biopsy histology had biopsies which were able to produce a
lymphocyte culture. In previous studies patients with such "culture positive, histology
negative" biopsies were more likely to be found to have clinically significant rejection
when next biopsied (Weber, 1989; Carlquist, 1989). This study found no such
correlation, with a low predictive value for subsequent rejection in having a "culture
positive, histology negative" biopsy (17.5% predictive value for biopsies grown in
medium with PHA - see table 8).
Overall, 25% of the patients studied had rejection (grade >3a) diagnosed on
their next biopsy. Of those patients with rejection on the initial biopsy, 40% still had
rejection at subsequent biopsy. Approximately 21% of those patients without rejection
at initial biopsy went on to develop it on subsequent biopsy. The ability to grow
lymphocytes from biopsies with no evidence of rejection did not predict subsequent
rejection for any group (Table 8). In the two tables that follow (8 and 9) only the results
for patients with no rejection at initial biopsy are shown. This is because it is this group
in which the early detection of rejection would be useful. Patients with rejection at first
biopsy receive additional immunosuppressive drugs which would alter the subsequent
incidence of rejection. The lowest row in the tables represent the results for all patients
(including both positive or negative culture results) for comparison purposes. The
subsequent biopsies available for this comparison were performed at a median of 31
days (range 6-400 days) after the first biopsy.
Table 8. Incidence of Rejection at Next Biopsy according to
Original Culture and Histology Results
This table shows data for those patients whose original biopsy was not found to show rejection (that is
less than grade 3a). The figures are divided according to whether lymphocytes were able to be cultured
from associated biopsies taken at the same time. These patients all underwent repeal biopsy at a later
dale. 'The figure given is the number ofpatients developing rejection as observed on this later biopsy as
a % of number at risk. No figures are given for patients with rejection and this is why the total figures









Positive 7/40 5/22 4/19
Culture (18%) (23%) (21%)
Negative 6/29 2/17 7/33
Culture (21%) (12%) (21%)
All 20/92 14/56 18/73
Subjects (22%) (25%) (25%)
In order to reduce errors in the figures introduced by those patients who had
been transplanted a long time ago, and who therefore were not re-biopsied soon, data
are also presented for patients re-biopsied within one month of the original biopsy. The
results for these patients are shown below. These data apply to half of the patients
studied.
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Table 9. Rejection at Next Biopsy for Patients Re-biopsied
within One Month
This table, similar to table 8, shows how many patients, of those re-biopsied within one month, had
rejection on their second biopsy. The /number developing rejection as % of no. at risk is given.
No Rejection PHA + IL2 CD3 + IL2 IL2 alone
(medium 1) (medium 2) (medium 3)
Positive 4/11 0/6 0/8
Culture (36%) (0%) (0%)
Negative 2/15 1/6 3/10
Culture (13%) (17%) (30%)
All 10/45 5/25 7/36
Subjects (22%) (25%) (20%)
A comparison of the incidence of rejection found on original biopsy with the
incidence on the next biopsy is shown below (table 10) for all patients and for those re-
biopsied within one month of the original biopsy.
This comparison should determine the efficacy of treating >3a grade rejection
since subsequent incidence should be reduced in those re-biopsied soon, as a result of
treatment with additional immunosuppressive therapy.
Table 10. Original and Subsequent Rejection
This table shows numbers of patients with rejection on original and subsequent biopsies. These are
divided into groups according to whether the patients were re-biopsied within one month of the original
biopsy and compared with the whole group ofpatients as a whole. It can be seen that patients treated
for rejection and re-biopsied soon have a greater change, in incidence of rejection compared with the
whole group, for each of the three media supplements used.
PHA + IL2 CD3 + IL2 IL2 alone



















% Change -47 -54 -61
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4.6. Patients Within Three Months of Transplantation
As seen above (table 5), 31 patients had a biopsy within three months of
transplantation which was subjected to lymphocyte culture study with PHA+IL-2 as the
supplement, 20 with CD3+IL-2 and 25 with IL-2 alone. The overall ability to culture
lymphocytes from these biopsies was similar to that obtained for biopsies taken from
recipients beyond the three month period (see table 5). Where the medium was
supplemented with IL-2 alone, there appears to be an increase in the ability to culture
lymphocytes in patients within three months of transplantation, compared with beyond
three months, but this is not significant. Below is a table showing the incidence of
rejection on next biopsy (table 11).
Table 11. Prediction of subsequent rejection for patients within
three months of transplantation.
This table shows data for those patients within three months of transplantation who did not have
rejection, in much the same way as table 7. Again, the figure given is the number of patients
developing rejection as observed on this later biopsy as a % of number at risk. No figures are given for
patients with rejection. The numbers given arc too small for statistically meaningful calculations.
PHA + IL2 CD3 + IL2 IL2
(medium 1) (medium 2) (medium 3)
Positive 3/12 0/6 1/9
Culture (25%) (0%) (11%)
Negative 1/12 0/7 1/9
Culture (8%) (0%) (11%)
All 8/31 4/20 6/25
Subjects (26%) (20%) (24%)
Endocardial Lymphocytic nfiltrates
ELI were found in 29 of the 94 biopsies (31%). In 13 (45%) of these the ELI
were associated with encroachment onto or damage of myocytes (designated as 'injury'
in table 12). The median time from transplantation in patients with ELI was 13 months
(range: 1-72 months) compared with a median of 4 months (range: 1 week to 96
months) for patients with no ELI, (p=0.002). There was no association between the
presence of ELI and outgrowth in-vitro in any of the three media used (table 12).
However, rejection (grade 3a or greater) was present in 12 of 29 biopsies with ELI as
opposed to 11 of 65 without (p=().()13). Adjusting for time from transplantation, using
logistic regression, there was still a significantly larger number of subjects with
rejection among patients with ELI compared to those without ELI (p=().()l 1).
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The apparent discrepancy between the ability to grow lymphocytes from EMB
taken from patients with and without ELI when grown in medium with IL-2 alone, as
compared with EMB cultured in the polyclonally stimulating media, does not achieve
statistical significance. For example, for EMB grown in medium supplemented with IL-
2 alone, the Chi-square value for the difference between culture results in the presence
or absence of ELI (without injury) was 2.795 (5/14 versus 12/36). If those EMB
grown in polyclonal media were compared with those grown in IL-2 alone, the
apparent lower rate of cultures in IL-2 alone is not statistically significant (5/14 versus
18/25, Chi-square value 3.499).
Table 12. Culture Result according to Presence of ELI with or
without Myocyte Injury
This table shows the culture results for fragments grown in each media according to presence ofELI
and myocyte damage. Each figure is the number ofpositive cultures grown from the biopsies which
were associated with the given histological findings. The figures are broken down by medium
supplement as previously. There appear to be more positive cultures with the polyclonally stimulating
media but no effect of IL-2 alone. This is not statistically significant.
Histology
PHA + IL2 CD3 + IL2 IL2 alone
(medium 1) (medium 2) (medium 3)
No ELI 39/65 22/38 24/36
(60%) (58%) (67%)
ELI 10/16 8/9 5/14
(62%) (89%) (36%)
ELI + 11/13 7/10 6/12
Injury (85%) (70%) (50%)
Totals 60/94 37/57 35/73
(64%) (65%) (48%)
4.8. Phenotyping
Phenotyping of lymphocytes grown from 12 biopsies showed that all contained
CD8+ cells. CD4+ cells were present in seven cases and there were no CD19 positive
cells observed. In seven patients CD 16+ cells were present and in two, where
monocytes had been noted on direct microscopy, the CD68 stain was positive. This
stain was also used on cultures not thought to contain monocytes where it proved
negative. Cell numbers in individual cultures averaged 1.27 X 105 (range 0.36 - 4.3 X
105) at two weeks.
A table showing the phenotyping results is shown below (table 13).
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Table 13. Phenotyping Results
This table shows which cell surface markers were detected by monoclonal antibodies incubated with
cytospun preparations (see methods). Twelve consecutive positive cultures were studied and the
presence or absence ofcells bearing each markers listed is noted.
Subject C D 2 C D 4 CDS C D1 6 C D 68
1 + . + + -
2 + + + - +
3 + - + . -
4 + + + + -
5 + + + + +
6 + + + + -
7 + - + + -
8 + + + + -
9 + + + - -
10 + - + - -
1 1 + + + + -
12 + - + - -
Totals 1 2 7 1 2 7 2
4.9. Ability to Culture Lymphocytes and HLA Mis-matches
Data on HLA antigens were available for 84 patients. The average number of
mismatches between HLA antigens of the donor and the recipient at the A locus was
1.4, at B 1.5 and at DR 1.3. The culture results among these patients conformed to the
overall results for the whole group as shown by the totals in the table below (table 14).
For HLA typing, testing was performed for 12 HLA A antigens, 18 B and 10 DR
antigens.
Table 14. Positive Culture Results in relation to Donor and
Recipient HLA Mis-matches
This table shows the results for biopsy fragments grown in each of the three media supplements. The
table is in three sections arranged horizontally according to number ofmis-matches at class I loci(A or
B), class II loci(DR) or all three. The figure given is the % of positive cultures obtained from
fragments taken from patients with the specified number of mis-matches. The data are broken down





HLA mis-matches PHA + IL2 CD3 + IL2 IL2 Alone
at given loci (medium 1) (medium 2) (medium 3)
<1 at A or B 56% 50% 33%
(14/25) (8/16) (7/21)
2 at A or B 68% 73% 44%
(40/59) (24/33) (20/46)
<1 at DR 63% *59% 51%
(32/51) (19/32) (21/41)
2 at DR 58% *88% 42%
(19/33) (14/16) (10/24)
<1 at All Three 46% 44% 18%
(6/13) (4/9) (2/11)
2 at All Three 67% 80% 43%
(12/18) (8/10) (6/14)
All patients 62% 64% 50%
(52/84) (30/47) (42/84)
* = p<0.()5 (Fishers exact test)
4.10. Patients Undergoing Repeat Biopsy
Of the 73 patients studied, nineteen had two biopsies of whom two went on to
have a third biopsy. These biopsies were performed at a median of 21 days apart (range
6 to 365 days). The table shows the results for each of these biopsies along with the
histological grade of rejection (table 15). Among the 17 patients who had two biopsies
performed, all had both biopsies cultured in medium with PF1A, 7 in medium with CD3
and 8 had both biopsies cultured in medium with IL-2.
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Table 15: Initial and subsequent culture results in patients who
underwent two biopsies
This table shows the. culture results at initial and subsequent biopsy for the patients who were biopsied
twice in this study. The results are given as initial results followed by a hyphen and then the
subsequent result (pos = positive culture result, neg = negative culture result) for each of the three
possible media supplements used.
Pos - Pos Neg - Neg Pos - Neg Neg - Pos Total
PHA 5 3 4 5 17
CD3 1 2 3 1 7
IL-2 1 3 3 1 8
Two patients underwent three biopsies each, one male and one female. The
results for these two patients are shown (table 16).
Table 16. Results for two patients who each underwent
three biopsies
This table shows the culture results along with the histology observed on concurrent biopsy for the
two patients who were biopsied three times during this study. There appears to be no consistent
pattern of lymphocyte growth in patient A but EMB from patient B produced lymphocyte cultures each
time.
Biopsy: Culture Histology Time between
Patient A Result biopsies (days)
1 Pos la -
2 Neg 2 36
3 Pos la 21
Patient B
1 Pos la -
2 Pos 3a 20
3 Pos la 14
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4.11. Extension of Culture Period
As noted above, no new cultures were observed beyond 14 days. However,
attempts were made to extend the culture period thereafter. Overall, most cultures were
maintained for approximately one month before they began to die off. Outgrowth into
round bottomed wells of 96 well culture plates was limited by the number of cells
which could grow in the space available. Therefore cultures were split. However when
this was done no growth occurred in the daughter wells, though cells left in the original
well were able to be maintained for longer. It was concluded that the specific antigenic
stimulus of the biopsy fragment was required to promote growth. It was not clear
whether any (normal) heart would serve this purpose or whether donor heart would be
required. If donor specific antigens were required it was felt the closest solution would
be donor originated fibroblasts - which would not be heart specific, as cardiac
myocytes could not readily be cultured. Therefore a means of separating cardiac
antigens was required which might be applied to EMB fragments.
59
5. Cardiac Transplantation and EMB: Discussion
5.1. Lymphocyte Culture and Phenotype of Cultured Cells
This study compared the effects of adding polyclonal stimulators of T cell
proliferation, PHA and anti-CD3 antibodies, to a basic medium containing IL-2 alone.
This comparison was made primarily to see if it was possible to enhance the ability to
culture lymphocytes from EMB in order to increase the sensitivity of this method as a
diagnostic tool. Part of this work has been published (Harcombe, 1993).
Rejecting myocardium would contain activated lymphocytes expressing IL-2
receptors, which should proliferate in the presence of IL-2 (Smith, 1986). IL-2 has
been used in all the previous studies of T cell growth from EMB (table 1). Media
containing polyclonal activators might favour outgrowth of any T lymphocytes present
in the biopsy, even if they were not activated and by implication not participating in the
rejection process. T lymphocytes possess the cell surface marker CD2 (reviewed in
Bierer, 1993) and it is through this that PHA predominantly exerts its proliferative
effects (Nowell, 1960). Furthermore, all T cells express CD3, and anti-CD3 antibodies
are known to mediate proliferative signal transduction through this molecule (Van
Wauwe, 1980).
Natural killer cells possess CD 16 cell surface marker (the IgG Fc receptor or
FcRIlI) as well as low levels of CD2. They also express IL-2 receptors and might be
capable of proliferation in this culture system (Nagler, 1989). They may therefore grow
in all three media, but undergo greater expansion in media supplemented with PHA or
CD3, making a positive culture result more likely. Against this hypothesis is published
evidence showing that lectins such as PHA and Concanavalin A are not able to induce
NK cells to proliferate, even in the presence of autologous accessory cells (London,
1985; Ythier, 1985). However, there are data to show that PHA may increase the
ability of non T-cell large granular lymphocytes to respond to IL-2 (Hercend, 1982;
Roberts, 1988), although these effects are not large when examined in terms of
proliferation frequencies by EDA (Vose, 1983).
This study confirmed that it is possible to culture lymphocytes from EMB
efficiently as 48 to 65% of EMB produced positive cultures, depending on medium
supplement used. The study did not select biopsies in that patients who did not have
rejection clinically, including those more than a year post-transplantation, were
included.
Polyclonal stimulation did not significantly affect the ability to produce
lymphocyte cultures but there was a trend to more positive cultures with medium 1 and
2. This comparison, made directly using the Chi-square test, does not produce a
significant difference, as shown in the results section. Furthermore, analysing the data
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by linear regression confirms this finding. In most previous studies IL-2 alone was
used as a culture supplement; rarely have polyclonal stimulators of T cell proliferation
been used and no comparisons made (table 1).
It was found that cultures were positive at a median of 7 days (range 1-14).
This compares with figures varying from 10+/-6 days (mean+/-SD) to 12.9+/-9.1
days, depending on degree of rejection on histology, reported by Carlquist et al
(Carlquist, 1988). Other studies of similar nature (table 1) have not commented on this
aspect of lymphocyte culture from EMB. Whereas the present experiments examined 94
biopsy fragments from 73 patients at all stages after cardiac transplantation, Carlquist
studied 125 biopsies from 14 patients only, between 48 and 361 days after cardiac
transplantation. By beginning their study at 48 days they excluded many early
aggressive episodes of rejection, when more active infiltrates of T cells would be
present. This could account for the difference observed in this study.
48% of biopsies grew lymphocytes in a medium supplemented with IL-2 only,
which agrees closely with Carlquists figure of 49% (61 of 125) biopsies (Carlquist,
1988), in a similar but not identical medium (RPMI-1640 supplemented with 5%
human group AB serum and 160 units/ml human IL-2). Similarly, Ahmed-Ansari et al
(Ahmed-Ansari, 1988) also used a high concentration of IL-2 in their study of 238
biopsies between 2 and 390 days after cardiac transplantation. Biopsies were cultured
in RPMI-1640 supplemented with 10% human serum and 10% IL-2 or lOOOunits/ml r-
IL-2 (both were used but it was not made clear for which patients). They found 43%
(102/238) positive cultures, again comparable with the figure of 48% from this study.
Thus, using IL-2 at such high concentrations is clearly unnecessary.
However, Suitters et al(Suitters, 1989) cultured T cells from EMB using
RPM1-1640 supplemented with 28u/ml r-IL2, only 27% (28/104) of cultures grew.
This cannot be explained by IL-2 concentration and it is interesting to note that Suitters
group did not use human serum. The provision of hitherto undefined growth factors by
serum may be important in lymphocyte outgrowth in addition to IL-2. Perhaps other
lymphokines such as IL-1, IL-4, IL-6 and IL-10 are provided by human serum in
limited amounts. IL-1, along with anti-CD3 antibody, is able to induce proliferation and
IL-2 production in CD4+ and CD8+ cells, whereas CD3 antibody alone induced IL-2R
expression but not proliferation or IL-2 production (Stein, 1992). IL-4 can function as
a T cell growth factor and is able to stimulate proliferation even in the absence if IL-2
(Cherwinski, 1987; Kurt-Jones, 1987). In addition, as well as promoting T cell growth
and acting as a B cell growth factor, IL-4 increases class II expression on B cells (Paul,
1987). IL-6 has many effects but may play a role in cytotoxic T cell differentiation (Van
Snick, 1990) as might IL-10 (Mosmann, 1991).
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In this study the results of phenotyping showed a predominance of CD8+ cells
(present in all twelve cultures) with CD4+ cells in 7. There were no CD19 positive cells
(B cells) observed. In seven patients CD16+ cells were present and in two, the CD68
stain(monocytes) was positive. The phenotype of cells cultured from needle biopsies of
renal transplant allografts was also CD8 and CD4 positive T cells, though CD8+ cells
predominated (Mayer, 1985; Miceli, 1985). These studies were performed in clinically
and biochemically rejecting kidney allografts and direct comparison is difficult.
The results presented are similar to those of Carlquist, who found in 12 of the
61 cultures studied, CD8+ cells in all 12 cultures, 5 of 11 contained CD4+ cells, 4 of
10 had CD57 (Leu 11) positive cells, B lymphocytes were found in 4 of 10 and one
culture had cells bearing a monocyte/macrophage marker (Ml) (Carlquist, 1988). B
cells were not found in the present study, but in all other respects the results are very
similar. Carlquist looked for CD57+ cells, but this is a poor marker for natural killer
cells. In transplant patients these cells are probably found as a subpopulation of CD8
cells. Suitters et al phenotyped 28 cultures and found CD8+ predominance in 57% and
CD4 predominance in 36%, results which are similar to those presented here (Suitters,
1989).
As already stated, natural killer cells possess IL-2 receptors, may be present in
EMB and might proliferate in this culture system. There are data from other studies to
confirm the ability of NK cells to grow in vitro (for example: London, 1985). The
phenotyping data indicate that cells positive for the CD 16 marker, which include natural
killer cells, are indeed present. These cells also possess the CD2 cell surface marker
through which PHA exerts its proliferative effects.
Natural killer cells, though detectable, are not a dominant feature of cellular
infiltrates in acute rejection (Marboe, 1983), thus cultured NK cells should not correlate
with histological acute rejection. Ahmed-Ansari's group tested for NK activity and less
than 5% of CD4+ cultures had any, 3 of 28 CD8+ cultures had weak NK activity
whereas 2 of 5 CD3+ CD4- CD8- cultures had NK activity (Ahmed-Ansari, 1988).
Thus culture of T lymphocytes from EMB can be achieved efficiently using
either IL-2 alone or IL-2 with polyclonal T cell activators. A relationship between
ability to culture lymphocytes and clinically significant rejection was found when EMB
fragments were cultured in PHA+112 and with IL-2 alone, but not with CD3+IL2.
Therefore a medium containing IL-2 alone is satisfactory for these studies and it may
promote culture of a population of cells which bear some relationship to the rejection
process. However it is not certain that these cultured cells mediate rejection. Future
studies should test for functional differences between phenotypically similar
populations of cultured cells. They should also examine the relationship between the
functional attributes of lymphocytes observed histologically in EMB and those cultured.
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In animal models, as discussed earlier, allograft rejection is mediated by both
CD8+ and CD4+ cells. Infiltrating lymphocytes of each phenotype can be grown from
murine cardiac allografts by a culture system similar to that discussed here (Carlquist,
1990b). It is also known that not all cells infiltrating grafts are involved in the rejection
process (Heidecke, 1990). Therefore it may be possible to perform experiments in
animals which would help to answer questions which cannot be answered safely in
man.
An additional aspect for further study might be the long term culture and cloning
of cells. This would allow analysis of the functional repertoire of individual cells,
though of course would be even further removed from the in-vivo situation.
Lymphocytes grown from EMB might be bulk cultured initially and then cloned by
limiting dilution. Clones with cytotoxicity against cells of donor origin could be tested
for their fine specificity against proteins suspected of being involved in responses
against cardiac myocytes. Target cells for LDA using these clones would be a problem
and it would be best to set up a prospective study whereby donor splenocytes were
available for these experiments. Experiments should be performed on clones originating
from cultures obtained with and without polyclonal stimulators in the culture medium in
order to determine whether there are any functional differences in these cells.
In the short term, bulk cultures could be tested using the polymerase chain
reaction for expression of cytokine mRNAs to determine if particular patterns of
cytokine expression are associated with particular patterns of histological rejection. The
results may be rather confusing in that a range of cytokine mRNAs might be detected.
This study might then be extended to cloned cells since these would produce a relatively
pure pattern of cytokine expression. It may be possible to differentiate Thl from Th2
type responses among these cells (Mosmann 1989). This could then be correlated with
ISH for mRNA on EMB taken from cardiac transplant recipients to determine if the
cells bulk cultured and then cloned from the EMB present a true picture of in vivo
cytokine expression. The relationship to histological evidence of rejection could also be
examined. It might then be possible to manipulate the immune response in patients with
these patterns of rejection (by using monoclonal antibodies to the relevant cytokine for
example).
Another approach to the problem of fine-tuning immunosuppressive therapy
might be to use anti-sense oligonucleotides against sequences of transcribed cytokine
genes. This might allow a more specific form of modulation of the immune response
than current therapy and could be tailored to use only those oligonucleotides directed
against cytokines expressed in the patients EMB. This would have to be carefully
studied in animal models since there may be unpredictable effects on other aspects of
the recipients immune system which might be adverse. There are few studies at the
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molecular level conducted in the field of clinical heart transplantation and it may be that
this area is going to prove fruitful in solving the problem of rejection.
5.2. Rejection, and Prediction of Rejection
The occurrence of acute rejection of cardiac transplants has always been the
major source of morbidity and death, particularly in the first three months post¬
transplantation. Thereafter, opportunistic infection, resulting from the inevitable
immunosuppression caused by the drugs used to induce tolerance of the graft, assumes
a similar importance. The balance between sufficient immunosuppression to prevent
graft rejection and excessive treatment leading to infection is difficult to maintain.
Patients with acute rejection (grade 3a or greater) receive short (several days) pulses of
high dose intravenous steroids. In this study therefore, the cut-off point for "rejection"
versus "non-rejection" was selected as grade 3a, because it has direct clinical relevance.
The absence of clinical trials or experimental evidence to confirm that this policy
is correct is of concern, it is crucial to the study of human cardiac transplant rejection
that the histological changes observed be validated. However, it has been shown that
heart failure (as opposed to sudden death) in association with histological evidence of
rejection can be reversed by augmented immunosuppression, which also reverses the
changes of rejection (Myles, 1987). It may be that animal studies using the working
formulation for rejection histology will be the only practical way to approach this
problem. Clinicians feel (informal discussions with members of the Transplant team at
Papworth) that as long as there is a balance between patients succumbing to rejection
and to infection then the immunosuppression regime is probably being used
appropriately. This of course begs the question as to whether the regime might be used
even more appropriately so that fewer people die of either complication.
Trials of augmented immunosuppression in grade 3a rejection might be
performed in a comparative fashion but the very real concern that a patient might
succumb to acute rejection would probably prevent this since the main endpoint would
be death. However, it may be that patients are succumbing to infection as a result of
excessive immunosuppression. Despite these concerns, five year survival in cardiac
transplant recipients is quite high with modern management (Heck, 1989) and thus
change is difficult to envision. It would appear that the traditional approach of
histological examination of EMB cannot take this situation forward. The search for a
more specific, truly predictive, test for acute rejection should continue.
Since acute rejection is a major cause of graft loss, its early detection is of
paramount importance. It is difficult to detect rejection clinically in many cases. A
patient may present with a fever, heart failure, arrhythmia or even sudden death.
Therefore, routine endomyocardial biopsy remains the test performed to detect sub-
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clinical rejection prior to the development of serious cardiac dysfunction. It is this
biopsy material which has been studied in reports of T cell culture from these patients.
Previous studies have claimed that the ability to culture lymphocytes from EMB
where the associated histology shows no rejection (so-called "culture positive, rejection
negative biopsies") allows prediction of subsequent rejection (Carlquist, 1989; Weber,
1989). In these studies patients whose EMB were able to produce cultures, when
rejection was not apparent on histological grounds, went on to develop rejection more
frequently than those without rejection whose biopsies were not able to produce
lymphocyte cultures. It was therefore suggested that the use of lymphocyte culture
would allow clinicians to detect those patients at increased risk of developing rejection
in the future.
In this study media 1 and 3 enabled a significantly increased number of biopsies
to produce positive cultures in the presence of rejection. Thus, a relationship between
ability to culture lymphocytes and rejection (grade >3a) was demonstrated. In the
earliest studies of this nature too few samples were involved to determine if there was
such a relationship (Zeevi, 1986). Carlquist described a correlation between ability to
culture lymphocytes and rejection (Carlquist, 1988) but this study was performed on
small numbers of subjects (14). Farrell et al also reported a correlation between ability
to culture lymphocytes and rejection (Farrell, 1990). However, Ouwehand et al studied
535 biopsy fragments from 87 subjects and reported no difference in ability to grow
lymphocytes from biopsies from patients with rejection compared to those without
rejection (Ouwehand, 1990).
In this study, when lymphocytes were grown from a biopsy and associated
histology did not show rejection, it was not possible to predict an increased likelihood
of subsequent episodes of rejection. In contrast, Carlquist et al found the incidence of
subsequent rejection, in patients with no histological rejection but positive cultures, was
higher than for those patients whose biopsies did not grow lymphocytes (Carlquist,
1989). Among Carlquists' subjects, whose cultures were positive when an associated
biopsy showed no rejection; 24 of 45 (53.3%) experienced worsening rejection (by one
grade or more), 18(40%) had no change and 3(6.6%) had a reduction in histological
grade. Of 24 patients with rejection, and a positive culture result, 16(66.6%) required
treatment for acute rejection. The authors concluded that the culture system as described
could be of value in the diagnosis and prognosis of acute rejection in cardiac allograft
recipients. From the data presented in this publication, an abstract which was not
followed by a more substantial publication, it is difficult to agree with this conclusion.
The grading system used for rejection was not defined, the grades were not given and
the histological grade at which additional immunosuppressive treatment would be used
was not indicated.
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Weber et al also reported that lymphocyte culture in the presence of negative
histology predicted subsequent rejection episodes (Weber, 1989; Duquesnoy, 1988). In
one study they examined 113 biopsies from 55 patients (who had not previously
suffered rejection) taken at various time intervals post-transplantation (0 - 10, 11 - 20 or
21 - 30 days) (Weber, 1989). Of biopsies which were histologically negative for
rejection, 40% were associated with positive lymphocyte culture, compared with 81%
where rejection was identified. Patients who had not previously had a rejection episode
and whose biopsy produced a positive culture had a higher cumulative incidence of
subsequent rejection within 30 days than those whose biopsy did not grow
lymphocytes. However, for patients beyond twenty days after transplantation, the
incidence of subsequent rejection within 30 more days was no longer significantly
different between patients with and without positive cultures. The results presented
therefore confirm that after the early post-transplant period it is not possible to use
positive culture results in the absence of rejection to predict for subsequent rejection.
Given that small numbers of patients were involved in each sub-group (12 to 16) in
Webers study, the authors reference to a statistical software package, without a
description of how it was used, left the reader unfamiliar with "BDMP Statistical
Software" unable to critically evaluate the data. The validity of the authors' conclusions
is therefore in question. The culture period in this paper was quoted as being 10 to 14
days. This would be too long to allow any predictive value to be clinically useful, since
patients would be developing rejection before they could be recalled for repeat biopsy.
Finally, the key role of the histological grading system in use (Billingham's criteria)
was not discussed. Histological findings at grade 2, 3 or 4 were designated as
rejection, and minor differences of interpretation could result in major differences in
correlation with rejection. It should also be noted that Billingham's grade 2 would not
now be labelled as clinically significant rejection and would not require treatment with
augmented immunosuppression.
The data presented in the current study do not show any predictive value in
"culture positive rejection negative" episodes. Therefore, as far as the value of
lymphocyte culture from histologically negative EMB in predicting subsequent rejection
is concerned, there is little real evidence in favour. Given the time course of lymphocyte
culture in these studies the likelihood of this method proving useful seems low.
5.3. Culture Media
A basic culture medium, containing IL-2 and supplemented with PHA, anti-
CD3 antibodies or nothing, was used to culture lymphocytes from EMB. This study
compared the effects of the different supplements to those of IL-2 alone.
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In the past a variety of culture medium supplements have been used to support
T-cell outgrowth from EMB. It is known however that medium supplemented with
IL2- alone is able to support outgrowth of lymphocytes from such biopsies (Ahmed-
Ansari,1988; Carlquist, 1990a). In this study the use of medium supplemented by
polyclonal T cell activators, compared with 1L-2 alone, did not significantly affect the
ability to grow lymphocytes from EMB fragments. Furthermore the supplement used
did not affect the time taken to detect T cell outgrowth. Thus all three media used were
associated with a similar number of lymphocyte cultures grown from EMB, which
were detected after the same number of days in culture.
This study did, however, find an association between T cell outgrowth and
clinically significant rejection requiring treatment (>grade 3a). This was only significant
when medium with PHA+IL2 and with IL-2 alone was used, suggesting that these
conditions favour the growth of a population of cells which is participating in acute
rejection. Carlquist et al, using medium supplemented with human IL-2, also reported
that outgrowth of T-lymphocytes from endomyocardial biopsies was associated with
rejection (Carlquist, 1988). Ouwehand et al and Farrel et al reported similar findings
with different media supplements; in the former irradiated autologous peripheral blood
mononuclear cells(PBMC) and in the latter tissue culture supernatant from PHA
stimulated normal human PBMC (Farrell, 1990; Ouwehand, 1990). Weber et al, used
RPMI-1640 supplemented with 10% human group AB serum, 200 units/ml of r-IL2
and irradiated autologous peripheral blood lymphocytes (10^ per culture well) as feeder
cells (Weber, 1989). This study found a relationship with rejection. Perhaps the
addition of feeder cells in some way affected these results. The presence of feeder cells
would promote cell to cell contact and they might secrete undefined factors into the
medium which may affect cell growth.
It would therefore seem that the results obtained in the current study are
consistent with those previously published. It is not clear however why the use of anti-
CD? antibodies as a culture medium supplement is not associated with a relationship
between positive culture and rejection. This supplement has not been used previously.
It does not allow more positive cultures to be produced (65% versus 64% for medium
with PHA) and so it is not acting in some general way to increase the efficiency of the
culture system. It merely seems to reduce the specificity of culture as a test of the
presence of significant rejection.
This finding might suggest that, in the presence of anti-CD3 antibodies, some
cells present in an EMB fragment are inhibited in their ability to grow, and these are
related to rejection. On the other hand cells which are not related to rejection might
experience an enhanced proliferative stimulus. Experiments might be conducted using
cells cultured in the presence of anti-CD3 antibodies. These cells could then be labelled
67
with fluorescent markers. The blast cells could then be separated by fluorescence
activated cell sorting (FACS) and then examined for their functional activity. In such
experiments cells grown in IL-2 alone and in IL-2 plus PHA must be used for
comparison.
It may also be possible to clone cells from the CD3 cultures. The function of
cells which have responded may then be studied, although a large number of
established clones would be required. It is possible that the optimal dilution of anti-CD3
antibodies, established in proliferation assays performed on PBMC from healthy
individuals, bears no relationship to that required to promote growth in an EMB
fragment. This may be difficult to study but using cloned cells the proliferative
response to CD3 antibodies may be measured and compared with those initiated with
PHA or IL-2 alone.
In the current studies it was observed that when attempts were made to sub¬
culture positive cultures they died if the biopsy was not present. Therefore the antigenic
stimulus of the EMB itself was required. If it were possible to determine which
protein(s) produced this effect then specific antigenic stimulation could be provided to
sub-cultures for cloning purposes. Further experiments could be conducted to attempt
to establish the cellular components most effective at promoting proliferation of cells
cultured from EMB.
Human myocardium could be fractionated and the fractions tested for
differential effects on growth of cloned cells, in small concentrations. The fractions
could then be further separated, perhaps by molecular size, and again examined for
ability to promote proliferation. By this means, provided a stable clone was available
for a series of tests, it might be possible to narrow down the identity of the molecules
against which the T cell response is directed in acute rejection. This approach can be
employed for T cell responses and it has been used with myocardial proteins. Paque et
al fractionated myocardium in their study of murine coxsackievirus myocarditis (Paque,
1979) and Guile et al separated mycobacterial proteins by two-dimensional
electroelution in their study of T cell responses to mycobacteria (Guile, 1990).
If a particular protein was implicated proliferation experiments, where
lymphocytes matched or mis-matched at class 1 and class II could be used as antigen
presenting cells, could be performed in an attempt to define the specificity of the T cell
response. If class I responses predominated then cytotoxicity experiments might be
performed. LDA might be employed to determine the fine specificity of T cell clones of
CD8+ phenotype with cytotoxic activity. Target cells could be matched lymphocytes
primed with the relevant peptides.
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5.4. Endocardial Lymphocytic Infiltrates
In this study 31% of biopsies contained ELI. This is higher than the 5 to 17%
previously reported (Imakita, 1988; Radio, 1991; Kottke-Marchant, 1989; Suit, 1989).
This may in part reflect the recent requirement to document their presence (Billingham,
1990). Alternatively it may be due to sampling error in previous studies. In this study at
least ten biopsy fragments were obtained from each patient and nine examined
histologically. In previous studies it is seldom reported that more than four or five
fragments were obtained. Thus other workers may have underestimated the frequency
of ELI.
The possibility that such infiltrates might preferentially affect lymphocyte
outgrowth was considered. Occupying a sub-endocardial position these cells lie in close
approximation to the areas of tissue taken at biopsy. They do contain T cells and hence
could be associated with positive cultures. The study specifically examined this
possibility but the results showed no such effect. No data are available from other
studies to compare with the absence of an effect on ability to culture lymphocytes
observed in this study.
In contrast to the previous findings of Kottke-Marchant (Kottke-Marchant,
1989) and Radio (Radio, 1991), but in agreement with Forbes (Forbes, 1990) an
association was found between ELI and presence of acute rejection of the deep
myocardium. This finding is very different and challenges current assumptions that
these infiltrates are not related to acute rejection. The relationship may reflect a role for
cells contained in the ELI in mediating rejection. Alternatively the presence of these
cells may be secondary to an ongoing process of rejection, with locally secreted
substances recruiting these cells into areas where acute rejection is occurring.
From Forbes study, in patients taking azathioprine and steroids the occurrence
of significant ELI was almost wholly limited to biopsies with rejection. An incidence of
15% of ELI was reported by Forbes et al for patients taking cyclosporine. There was a
significant relationship between ELI and rejection, with more ELI being observed in
patients with moderate rejection, than in those with mild or no rejection. Thus the data
presented in the current study are consistent with those of Forbes et al. In any event this
study suggests that ELI require further examination in terms of their relationship to
rejection and a larger scale histological study should be performed concentrating on this
aspect alone (Forbes studied 172 patients from 4 to 16 months after transplantation
only).
Like Kottke-Marchant (Kottke-Marchant, 1989) it was found that approximately
half the ELI's were associated with myocyte encroachment and injury. This lends
further support to the proposition that these cells are able to damage myocardium.
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Without functional data on these cells it is difficult to investigate their role. The culture
system employed does not allow the isolation of these particular cells and so alternative
methods are required in order to study this further.
The incidence of ELI increased with time from transplantation, as found by
Radio (Radio, 1991). This suggests that ELI are a phenomenon which may be related to
chronic as opposed to acute rejection. Or it may be that the infiltrates are indolent and
slowly accumulate, being more readily detected after long time periods. The possibility
that these cells are related to an early form of lymphoproliferative disorder also exists.
The fact that they are less likely to be present at an early stage after transplantation is
against their having a role in acute rejection, which is commonest in the first three
months.
As alluded to in the introduction, the significance of ELI is debated. Their true
role is as yet undefined, but it is tempting to speculate that further studies on ELI may
yield valuable information about the nature of cells which invade the heart and yet do
not appear to be related to myocyte damage. There, is in addition, work to suggest a
relationship between ELI and subsequent lymphoproliferative lesions (Kottke-
Marchant, 1989; Suit, 1989). Suggestions that these lesions are associated with EBV
are disputed by Nakhleh et al (Nakhleh, 1991). If ELI are associated with EBV, which
in turn is associated with post-transplant lymphoproliferative disorder, then the precise
inter-relationship between the various factors inducing the appearance of ELI needs to
be worked out carefully. Since the immunosuppressive agents most commonly
employed appear to induce ELI, particularly cyclosporine, this area requires detailed
study with a view to preventing myocyte damage, and in the long term, the
development of lymphoma.
It may be that ELI are indeed related to EBV infection, though this remains to be
shown. If they are then the lymphocyte proliferation responsible for these infiltrates
would be determined by viral gene products. Studies might then examine which
proteins played the most important part in stimulating proliferation and how such
proliferation might be blocked. The activation of lymphocytes in ELI, though unrelated
to rejection directly, may yet be deleterious since these cells may elaborate cytokines
which might promote responses against the allograft in other lymphocyte populations.
This would then imply a relationship between the ELI and rejection which might be of
functional significance. Alternatively, ELI may not be a product of viral stimulation and
may not be related to rejection. If so they would merit study since they represent a
diverse population of cells present within the allograft and not responding against it to
cause injury. The mechanisms by which these cells are brought to be benign in terms of
rejection might be employed to produce similar effects in other cell populations. To
date, the intriguing question as to why ELI are present is unanswered.
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5.5. HLA Antigens and Culture Results
The work in this thesis included examination of the HLA mis-matches between
donor and recipient to determine if there was a relationship between number of
mismatches and ability to culture lymphocytes. The hypothesis was that recipients of
hearts from donors mis-matched at major histocompatibility loci would be more
susceptible to rejection and therefore more likely to be associated with biopsies able to
produce lymphocyte cultures.
The results did not in general bear out this hypothesis. However, there was a
significant increase in positive results in the presence of 2 HLA DR mismatches when
biopsies were cultured in medium containing IL-2 and CD3 antibodies (medium 2), but
not in IL-2 alone or when supplemented with PHA. It may be that a co-stimulatory
effect of the anti-CD3 antibodies allows a greater proliferation of lymphocytes in
response to this medium compared with the other two. This might suggest that the CD3
complex, in association with class II, plays a major role in the proliferation of graft
infiltrating Iymphocytes.
HLA DR molecules are usually recognised by CD4+ lymphocytes which may
then proliferate and secrete cytokines which activate monocytes and perhaps CD8+
cytotoxic cells. The increase in positive results for biopsies taken from patients with
this degree of mis-match, compared with those without the mis-match, may indicate
that recognition of HLA DR molecules on the surface of donor myocardial cells has a
role in the process of acute rejection.
Carlquist et al examined 289 EMB taken from 41 heart transplant recipients at
the time of routine biopsy (Carlquist, 1990). Simultaneous biopsies were obtained for
histopathology, lymphocyte culture and immunocytochemical staining for HLA DR
expression. They observed two patterns of DR staining: vascular and interstitial, as
previously described by Rose et al (Rose, 1986). When associated biopsies showed
vascular DR staining, lymphocytes were cultured more often (65%) than when
associated biopsies showed interstitial DR staining(35%). Vascular and interstitial
staining were both more likely to be observed if rejection was detected.
It is not clear whether the rejection detected is the result of high levels of
expression of these molecules or if expression of DR is induced by host factors as a
result of, or as part of, the rejection process. If the findings of Carlquist (Carlquist,
1990) are interpreted in terms of the MI IC antigens expressed by the donor then it
might be that recipients with certain mis-matches with the donor at particular HLA loci
would be more likely to experience rejection. This fits with the Carlquist data but of
course it is not known whether DR expression on the surface of myocytes in the
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biopsies in the current study was increased or not. Future studies might encompass this
aspect in order to further investigate the role of DR expression.
These results are interesting in the light of recent work demonstrating a
beneficial effect of matching for HLA A, B and DR on graft survival at three years
(Opelz, 1994). It has been shown that HLA DR mis-matches are more likely to result in
the ability to culture lymphocytes from EMB in this study and that such mis-matches
are associated with poorer outcome in Opelz study. These findings lend themselves to
speculation that the ability to culture lymphocytes is more related to MHC mis-matches
than directly to histological rejection, though this can only be suggested for HLA DR.
The relationship of ability to culture lymphocytes with rejection may be an indirect one
with MHC mis-matches at HLA DR the primary influence. The HLA antigen system is
highly polymorphic so that a very much larger study to test for a significant relationship
between ability to culture lymphocytes and any one HLA antigen, or group of antigens
would be required. The fact that this study was able to detect any difference for the DR
mis-matches may indicate a very large effect. It should also be pointed out that failure
of this study to detect any effect of HLA A or B antigen mis-matches does not mean
that none exists.
Future studies might examine a larger number of patients with reference to HLA
DR mis-matches and determine, over a longer time period, if patients with two mis¬
matches at this locus in comparison with those with one or no mis-matches experience:
1) more episodes of clinically significant rejection; 2) a greater ability to culture
lymphocytes from their EMB and 3) whether cultured and in situ lymphocyte
populations are of consistent phenotype (such as CD4+ as might be expected) in these
patients. The ability of the cultured lymphocytes to proliferate when co-cultured with
irradiated lymphocytes bearing donor HLA DR antigens which have been primed with
peptides of myocardial origin might also be studied.
5.6. Conclusions
These studies have shown that efficient culture of T lymphocytes from 48 to
65% of EMB from cardiac transplant recipients at all stages after transplantation is
possible. The ability to culture lymphocytes relates to presence or absence of clinically
significant rejection when medium with 1L-2 alone or IL-2 supplemented with PHA is
used but not medium supplemented with anti-CD3 antibodies. The absence of rejection
on histology of the EMB when lymphocytes are able to be cultured does not predict
subsequent rejection. More cultures are obtained in the presence of 2 HLA DR mis¬
matches than in those patients with only one or no mis-matches at this locus.
The results suggest that the positive cultures would most easily be obtained
from a biopsy taken from a patient undergoing acute rejection where there were 2 HLA
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DR mis-matches between donor and recipient. Biopsies would best be cultured in IL-2
alone but PHA supplemented medium could be used and might produce larger cell
numbers dtie to its polyclonal activating effect.
It is concluded that the use of polyclonal activators in culture medium confers
no advantage over the use of IL-2 alone in the ability to grow lymphocytes from EMB.
Furthermore anti-CD3 antibodies obscure a relationship between acute rejection and in-
vitro outgrowth of lymphocytes from EMB. Because no association was detected
between lymphocyte outgrowth and future rejection, this technique may have little to
offer in clinical management. However, the use of IL-2 culture to isolate functional
lymphocytes from EMB may allow characterisation of lymphocytes directly involved in
the rejection process.
Future studies should examine the role of ELI in acute rejection and in particular
functional testing of cultured cells from ELI should be undertaken. This might be
achieved in animal experiments but would be difficult in man since the isolation of these
infiltrates from cells involved in deep rejection of the myocardium would be very
difficult.
There are many other difficulties involved in taking this work further. Cell
numbers have not been sufficient to allow many experiments that might otherwise be
planned. Flow cytometry for example requires at least 10,000 cells per sample and thus
phenotyping a typical culture in these experiments would use up a significant number of
the cultured cells if a full panel of antibodies were used. Sub-culturing cells might be of
assistance but this resulted in death of cells deprived of antigenic stimulus from the
EMB fragment. Therefore some means of artificially providing the equivalent antigenic
stimulus in order to maintain functionality of these cells should be sought. This might
be achieved by the experiments described above whereby fractionated human






6. Alcoholic Cardiomyopathy - Introduction
6.1. Historical Perspective
The Ancient Egyptians believed that beer was invented by the goddess Osiris
(Ghalioungui, 1979) and its use, along with wine, was widespread. By the twelfth
century AD the distillation of fermented alcohol was introduced and alcoholism became
a social problem (Singer, 1956). By the mid-eighteenth century in England,
consumption of alcohol among the general population was perceived to be excessive.
The Gin Act, intended to limit the retailing of alcohol, was passed as law in 1751 and
eventually it had the desired effect (Webb, 1903). The ill-effects of alcohol were thus
recognised and legislative steps taken to control its use. Meanwhile it was appreciated
that the problem was more than simple intoxication. In 1852 Huss attributed the effects
of chronic alcoholism to tissue damage (Huss, 1852). It is now well recognised that
chronic ethanol consumption in excess may affect many organs or tissues.
6.2. Alcohol Abuse and Alcoholism
Many people consume alcohol. Given the wide variation in individual habits it
is not easy to define where drinking ends and alcohol abuse begins. Recommended
limits of weekly alcohol consumption are 21 units for men and 14 units for women.
One unit of alcohol (half a pint of normal strength beer or lager, a glass of wine or a
single measure of spirits) approximates to eight grams of ethanol.
In 1981 Turner suggested that the dividing line between moderate and heavy
drinking should be ().8g/kg body weight per day (with an absolute limit of 80g or 10
units of ethanol daily) or an average of 0.7g/kg over a three day period (Turner, 1981).
According to this definition, in the USA in 1987, 24% of people were moderate
drinkers and 9% heavy drinkers (NIAAA, 1987). In Britain about 10-15% of the
population may be considered chronic alcohol abusers (Royal College of Physicians,
1987).
Arbitrary normal limits relating specifically to consumption do not allow for
those who may drink more than the proposed limit with little or no consequence.
Conversely, some people may drink less than a given limit but still suffer from the
syndrome recognised as alcoholism. Thus one difficulty in studying alcohol related
problems is that of case ascertainment. It appears that significant consumption for a
long time is required to produce most of the major ill-effects of drinking alcohol and
that to achieve the necessary intake requires abnormal drinking habits. But what exactly
is excess alcohol use and what is alcoholism? The population variability in the
consumption of alcohol is such that the dividing line between those who are and those
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who are not alcoholics tends to be placed at the point where drinking leads to social,
psychological or medical problems.
There is no single pattern of alcohol misuse and rather it should be considered
not as a single disease but as a variety of behaviours (Paton, 1994). There are heavy
drinkers who intermittently or continuously indulge in binge drinking and these people
might soon experience harm. Problem drinking is where social, domestic work or
medical problems result from drinking and can be avoided or reduced if drinking can be
curtailed. Dependence is where a true form of addictive behaviour occurs and it proves
difficult or impossible to stop drinking. All of these patterns may overlap and an
individual may exhibit all three types of behaviour. According to these definitions an
estimate of the prevalence of these conditions in Britain would give 7.3 million people
drinking above sensible limits (as defined above), 4 million heavy drinkers, 800,000
problem drinkers and 400,000 dependent drinkers (Paton, 1994).
In the United States the National Institute on Alcohol Abuse and Alcoholism
(NIAAA) defined alcohol abusers as drinkers who had suffered one or more severe, or
moderately severe, consequences of alcohol use, such as job loss, arrest or illness
during the previous year (NIAAA, 1986). Alcoholics were defined as people who had
suffered one or more symptoms of alcohol withdrawal or one loss of control symptom
plus one other symptom of dependence in the last year.
The true incidence of alcoholism therefore will always be difficult to ascertain
and prior to the NIAAA studies others had proposed criteria in order to conduct
research in this area (Feighner, 1972).
After the NIAAA definitions, the Guze criteria (table 17) were published and
provide a guide to symptoms that a physician should be aware of, whether using a
structured approach to taking a drinking history or not (Guze, 1988).
There is little doubt that chronic alcoholics as described above may develop
important medical complications as a result of their alcohol consumption. Since there
are as yet no useful objective measures of alcohol consumption, the best approach to
diagnosis remains a careful history. Key aspects of the Guze criteria feature in the
CAGE questions (C - Considered stopping? A - Anger when questioned about
drinking? G - Guilt about drinking? E - Eye opener or early morning drink?)
Having ascertained that a given individual is alcoholic the problem may still
remain as to whether a given pathology is a result primarily of excess alcohol
consumption or whether it is secondary to malnutrition, neglect or concurrent ingestion
of toxic substances. Thus, confusion existed until very recently over whether there was
such an entity as alcoholic cardiomyopathy since, for certain subjects, vitamin
deficiency or toxic chemicals were shown to be responsible. Once it was shown that
cardiac complications could develop in well nourished patients the possibility that a
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specific heart muscle disease might be related to alcohol became stronger. This will be
discussed further.
Table 17. The Guze Criteria
This table shows those features identified by Guze as symptoms of alcoholism or alcohol abuse. A
diagnosis of "definite alcoholism" according to these criteria requires three symptoms in each of three
symptom categories. "Probable alcoholism" requires two symptoms in each of two symptom groups.









chronic brain syndrome Family objects to level of individuals
Blackouts drinking
Benders Self-admitted excessive drinking








6.3. Alcoholism and Inheritance
Alcoholism may be a multifactorial condition, partly determined by inheritance
of a gene or genes which predispose the individual to alcoholism, and partly determined
by environmental factors. A search for a specific alcoholism gene is likely to be difficult
and, as with ischaemic heart disease for example, a large number of factors, perhaps
including inheritance of a particular combination of certain genes predisposing to
alcoholism coupled with a significant environmental effect, are likely to play a part.
However, definition of the genetic element involved in alcoholism may be a key means
of designing treatment strategies for people who suffer from alcoholism. Such studies
are in progress (Cook, 1990).
Studies of twins show a significant genetic effect on susceptibility to alcoholism
in males (Kaij, 1960; Hrubec, 1981), but the evidence for females is less convincing
(Goodwin, 1977; McGue, 1989). Other studies of adoptees (Cadoret, 1978) and half-
siblings (Schuckit, 1972) provide further support for a genetic effect. Whatever the
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factors are, it is clear that younger adult males are the group at highest risk of
alcoholism.
Perhaps the best evidence on this aspect of alcoholism is provided by Sweden
where good records of alcohol consumption have been kept for many years. Various
studies up to 1978 have shown the incidence of alcoholism to be 7% in the general
population (Cloninger, 1990), rising to 12% in grandsons of alcoholics (Kaij, 1975),
20% in adopted-away sons of alcoholics (Bohmann, 1978), 33% in dizygotic twins and
70% in monozygotic twins (Kaij, 1960).
6.4. The Metabolism of Alcohol
Ethanol is the least toxic of a series of hydrocarbon based chemicals, the
alcohols with general formula CnH2n+]OH, whose distinctive feature is the possession
of a hydroxyl group. This renders the smaller molecules of this series highly polar and
imparts their ability to function as a useful solvent. Ethanol has been produced since
ancient times and many civilisations have made social and religious use of its
intoxicating properties. Many early physicians believed it had healing powers but
ethanol itself is toxic and a single carbon lost from the ethanol molecule, forming
methanol, produces a highly toxic substance.
Ethanol has no known cellular receptor, its small size and polar properties
ensure that it freely diffuses into cells, even across the blood brain barrier, to rapidly
exert effects. It is toxic to all cells and in sufficient quantities will cause cell death. It is
cleared from the circulation by the liver and to a lesser extent by the lungs, the basis of
the well known "breathalyser" test for motorists. At the legal limit for driving of 8()mg
alcohol per lOOmls blood(or 17.4mmol/l), functional testing reveals effects of alcohol
already beginning to show and the risk of a road accident is more than doubled (Paton,
1994). Measured as parts alcohol per 10,000 parts blood (Blood alcohol level, BAL)
this is approximately 0.05 and at this level subjects experience positive feelings such as
relaxation, well-being and euphoria (Hales, 1986). At higher levels subjects experience
negative feelings, including gradual loss of control of speech, balance and emotions.
When the BAL reaches 0.1 a subject is drunk (with symptoms of headaches, nausea,
stomach pain, fatigue, weakness, mood alteration, depression and paranoia), at 0.2
(160 to 2()0mg/100mls) some people become unconscious, at 0.3 some collapse and at
0.4 (400mg/100mls or 86.8mmol/l), death is possible. To put this in perspective, at
160mg/100mls (34.7mmol/l) the risk of road accident rises to tenfold.
In the liver, the predominant route of alcohol metabolism is via oxidation to
acetaldehyde (fig. 11; please note the equations are not balanced for simplicity),
catalysed by alcohol dehydrogenase found in the cytoplasm (presumably alcohol
dehydrogenase is present in man to deal with endogenously produced alcohols from
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fermentation of carbohydrate). There are also microsomal NADP dependent oxidising
systems. Acetaldehyde is able to enter mitochondria where aldehyde dehydrogenase can
further oxidise it to acetate. Acetate is eventually oxidised to carbon dioxide and water.
The initial reaction also produces NADH, which cannot be used directly and requires to
be oxidised back to NAD. Thus the ability of the liver to metabolise alcohol depends on
its capacity to transport reducing equivalents from the cytosol to the microsomes, via
glycerol phosphate and malate-aspartate shuttles (Devlin, 1986). The NADH produced
by oxidation of acetaldehyde is present in the mitochondria and can therefore be
oxidized by molecular oxygen using the apparatus of oxidative phosphorylation.
Figure 11. The Oxidation of Alcohol
This figure illustrates the key reactions involved in the oxidation of alcohol which lake place in the
cytosol and the mitochondria. The equations are not balancedfor simplicity. Alcohol is first acted on
by alcohol dehydrogenase and then the acetaldehyde produced is transported, to the mitochondrion where
it is oxidised by aldehyde dehydrogenase.
Oxidation of Ethanol in Liver Cytosol
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There is much variation in individual capacity to metabolise alcohol, particularly
in relation to aldehyde dehydrogenase, which has several functional isoenzymes located
both in the cytosol and the mitochondria (Smith, 1973). The most widely known aspect
of this type of genetic variation is aldehyde dehydrogenase deficiency among oriental
populations, who have a marked intolerance of alcohol, due to excess levels of
circulating acetaldehyde produced by even small amounts of alcohol consumption
(Goede, 1979).
The interest in these metabolic differences lies in the possibility that they may
play a role in predisposing people to become alcoholics. Despite the well characterised
deficiency states in some groups, this remains to be proven.
6.5. Alcoholic Cardiomyopathy
Alcohol is clearly associated with heart failure in certain well defined
circumstances. For example "Wet" Beri-Beri (Biankenhorn, 1946), heart failure due to
thiamine deficiency, is correctable by restoration of a normal diet. Toxic factors present
in alcoholic drinks, such as cobalt, have also been reported (Kesteloot, 1968).
In addition, alcohol is associated with hypertension (Klatsky, 1967) and may be
associated with a protective effect against ischaemic heart disease in moderate amounts,
but a deleterious effect at higher doses (Klatsky, 1990a). However, in some alcoholic
patients heart failure is present despite an adequate diet (Steinberg, 1981). This typically
presents with arrhythmias and or symptoms of heart failure in a person who has been
consuming a large amount of alcohol for a long time. The precise incidence is
unknown.
Since the late 1950s the literature has referred to "alcoholic cardiomyopathy". A
cardiomyopathy is by definition a condition of unknown aetiology. Some authors (for
example Richardson et al, 1986) prefer the term "alcoholic heart muscle disease" to
"alcoholic cardiomyopathy" since it suggests a specific disorder for which the aetiology
is known. Whatever term is applied, the definition of this condition is difficult and
often centres on a particular level of alcohol consumption daily (or cumulative lifetime
dose) in order to have a cut-off point below which subjects are not "alcoholic", for an
arbitrary number of years. Turners level of 8()g (or 10 units) per day is the commonest
choice in these circumstances (Turner, 1981) and five years is a widely used arbitrary
time period.
The condition which is labelled in clinical and haemodynamic terms as alcoholic
cardiomyopathy generally differs from idiopathic dilated cardiomyopathy only in
respect of the history of alcohol consumption. Both conditions are characterised by
ventricular failure with subsequent dilatation and a predisposition to arrhythmias.
Steady deterioration may occur resulting in death without appropriate therapy, which
80
may mean transplantation. Therefore it is difficult to define a group in whom alcohol is
the definite cause of myocardial dysfunction. In 1980 the ISFC/WHO study group felt
unable to define alcoholic cardiomyopathy and stated that they could not "define a
causal versus a conditioning role of alcohol nor apply precise diagnostic criteria"
(Oakley, 1980). This was despite the addition, in the Ninth Revision of the
International Classification of Diseases (WHO, 1977), of the sub-category "alcoholic
cardiomyopathy" (425.5) to the category of cardiomyopathy (425). Thus physicians
continue empirically to attach this label to patients consuming excess alcohol in whom
heart failure has been shown not to be due to ischaemic heart disease, or other specific
heart muscle disorder.
There is a large body of evidence associating alcohol with ventricular
dysfunction. Congestive Cardiomyopathy resulting from alcohol intake is said to have
first been recognised in a case report by Walshe in 1873(Walshe, 1873) but Wood
discussed alcohol as a factor in heart failure as early as 1855 (Wood, 1855).
A clearer idea of what alcoholic cardiomyopathy might be emerged when
Brigden (Brigden, 1957) and other authors began publishing papers on the subject in
the late 1950's and early 1960's. Brigden discussed 13 patients with "severe
alcoholism" from a series of fifty patients with isolated heart muscle disease in his 1956
St Cyres lecture (Brigden, 1957). Brigden and Robinson discussed "alcoholic heart
disease" in 1964 (Brigden, 1964). These papers identified many of the key clinical
features of the condition but did not define the relevant level of alcohol consumption
required to produce it.
Tobin and others studied 39 alcoholic patients identified from a group of 119
patients who were less than 50 years old and who had "idiopathic primary myocardial
disease" in 1967 (Tobin, 1967). This study provided early evidence that there was a
significant incidence of alcoholism among patients with what is now called idiopathic
dilated cardiomyopathy. Furthermore it demonstrated that cessation of drinking would
lead to clinical improvement and that continuing to drink after the diagnosis is made
leads to a poor prognosis.
One of the problems with the studies above, and their associated commentaries,
has been the failure to exclude significant ischaemic heart disease or specific diseases of
the myocardium. The widespread introduction of coronary angiography and
endomyocardial biopsy has facilitated further studies in this area. In addition,
epidemiological studies have lent further weight to the theory of a connection between
alcohol consumption and heart disease. Klatsky found a relative risk for death from
cardiomyopathy in persons drinking 6 or more drinks per day to be increased eight
times compared with lifelong abstainers, though the low numbers of deaths in this
group meant that statistical significance could not be detected. This study found a "J-
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shaped" mortality curve, with non-drinkers having a higher mortality from
cardiovascular disease than light drinkers and heavy drinkers having the highest
mortality (Klatsky, 1990b).
The Kaiser-Permanente studies, based on questionnaires distributed to persons
joining a health insurance scheme, have examined alcohol in relation to many forms of
heart disease. One such study found that hospital admissions for cardiomyopathy and
congestive heart failure, among more than a thousand subjects at risk, were
significantly more frequent among those consuming six or more drinks daily (Klatsky,
1981).
Codd et al conducted a population based study of idiopathic dilated
cardiomyopathy and found 46 cases (incidence of about 7.9/100,000), of whom 12
(26%) had a history of significant alcohol consumption (Codd, 1989). Smith showed
that increases in alcohol consumption in Western Australia were associated with
increases in mortality rates from alcoholic cardiomyopathy for males and females
(Smith, 1990). He also reported that a subsequent decline in alcohol consumption was
associated with a decrease in mortality from alcoholic cardiomyopathy among females,
though less so among males.
A study in 1981 among patients with idiopathic dilated cardiomyopathy
suggested that around 20% consumed significantly large amounts of alcohol (Fuster,
1981). In addition, studies of chronic alcohol abusers have shown sub-clinical evidence
of heart dysfunction in anything up to twenty per cent of cases. Studies have also
shown that in such patients, cessation of alcohol consumption leads to resolution of
symptoms and signs in about thirty per cent of patients (Weishar, 1977), with
stabilisation in another fifty per cent and continued deterioration in the remainder. Other
follow-up studies of alcoholics with cardiomyopathy who stop drinking suggest that
anything up to two-thirds of patients may survive to three years with no evidence of
residual cardiac disease, whereas in those who continue to drink, the majority die
(Brigden, 1964; Alexander, 1967 ; Schwartz, 1975).
In a study of prognostic features for patients with cardiomyopathy undergoing
assessment for transplantation, Keogh et al described 20 of the 232 (9%) patients as
having "alcoholic/idiopathic" cardiomyopathy, which meant typical clinical features of
idiopathic dilated cardiomyopathy along with consumption of 60g alcohol or more per
day (Keogh, 1990). This is a much lower prevalence of excess alcohol consumption
among patients with idiopathic dilated cardiomyopathy than those of either Codd
(Codd, 1989) or Fuster et al (Fuster, 1981). This might reflect the mortality of
alcoholic cardiomyopathy since the highest prevalence is in the community based study
(26%), the next highest in a hospital cardiology practice (20%) and the lowest (9%) in
those who survive to be assessed for transplantation. Alternatively it may suggest that
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there is a low detection rate for alcoholic cardiomyopathy with patients being
undiagnosed or mis-diagnosed as idiopathic dilated cardiomyopathy.
6.6. The Heart in Alcoholic Patients
Early studies of the histopathology of hearts from patients with alcoholism
found no specific features. However, using electron microscopy, Alexander described
abnormalities affecting the contractile elements and the mitochondria in the majority of
45 patients studied (Alexander, 1966). These abnormalities included fragmentation of
contractile elements with large numbers of swollen damaged mitochondria, but there
were no inflammatory cells present. These changes were not found in a normal heart
nor in hearts from patients with valvular or congenital heart disease. However, hearts
from patients with idiopathic dilated cardiomyopathy were not examined.
Several studies have examined alcoholic patients to determine if alcohol
consumption causes clinical appearance of heart disease. Examination of alcoholic
subjects known not to have heart disease should allow detection of sub- or pre-clinical
abnormalities of cardiac function. In 1977 Levi et al (Levi, 1977) used non-invasive
measurements (electrocardiogram, phonocardiogram and carotid pulse tracing) in
patients with chronic alcoholism, excluding those at risk of ischaemic heart disease,
>40 years age and other heart disease, compared with non-drinking controls. This
study found evidence of left ventricular dysfunction in the alcoholic group compared
with non-drinkers.
Urbano-Marquez et al studied a group of 50 asymptomatic alcoholic men
admitted to an alcohol problems unit and assessed both skeletal and cardiac muscle
function (Urbano-Marquez, 1989). As well as abnormalities of skeletal muscle
function, they found that alcoholic patients had a significantly lower ejection fraction
compared with controls (59 versus 67%). They also found that the estimated total
lifetime dose of ethanol correlated inversely with ejection fraction and directly with left
ventricular muscle mass.
Bertolet et al studied "an apparently healthy alcohol abuse population" with a
range of investigations (Bertolet, 1991). They found no correlation between the amount
of alcohol consumed daily, or total lifetime dose, and left ventricular dysfunction. The
other finding of note was that "routine" investigations, such as ECG or Chest X-Ray,
were very poor at detecting those patients with left ventricular dysfunction as defined
by radionuclide ventriculography.
More recently, 25 patients with chronic alcoholism, aged less than 40 years,
who were being admitted to hospital for alcohol dependence treatment, were studied
(Cerqueira, 1991). Using echocardiography and rest and exercise radionuclide
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ventriculography the results were broadly similar compared with a group of age and sex
matched controls.
Another study used radionuclide angiography in 15 otherwise asymptomatic
patients who drank at least 60g alcohol daily "for several years", who were admitted for
colorectal surgery (Tpnnesen, 1992). Left ventricular function was reduced (pre-
operatively) in patients who drank excess alcohol (54% versus 68%) compared with
age, sex and operation matched controls who drank less than 25g alcohol daily. The
figures for ejection fraction in this study are strikingly similar to those obtained by
Urbano-Marquez(Urbano-Marquez, 1989).
6.7. Effects of Alcohol on the Heart
Ethanol may have a number of other effects on the heart. It has been described
as predisposing to arrhythmias, particularly after binge drinking - the "holiday heart
syndrome" (Ettinger, 1978). It also has a negative inotropic effect following acute
administration (Regan, 1966).
Ethanol metabolism does not occur to a great extent in the myocardium, but
studies have shown the presence of fatty acid ethyl esters in the heart in persons
exposed to alcohol (Lange, 1983). Furthermore, reduced fatty acid oxidation (Kikuchi,
1970), increased myocardial triglyceride content (Kako, 1973) and impaired
mitochondrial function (Cederbraun, 1974) have all been described as a result of
exposure to ethanol. Therefore, attention has focused on the effects of ethanol itself. It
is difficult for in-vivo studies to separate the effects of alcohol from the effects of its
metabolites, such as acetaldehyde and this must be continuously borne in mind.
One of the obstacles to a clearer understanding of the effects of alcohol on the
heart has been the lack of a suitable animal model. It is possible to produce alterations
in function in animals consistent with sub-clinical heart disease but not a condition akin
to the human disease referred to as alcoholic cardiomyopathy with myocardial
dysfunction in the resting subject (Regan, 1987). However, it has been shown that
ethanol may depress myocardial function acutely in various studies; the feline papillary
muscle in-vitro (Spann, 1968) and in-vivo studies on dogs (Regan, 1966) as well as
man (Gould, 1971).
It is known that cardiac protein synthesis may be altered by toxic substances
such as alcohol (Schreiber, 1980) but in-vitro studies in the guinea pig did not have this
acute effect .
The effects of acetaldehyde on cardiac function may be more important than
those of ethanol. Acetaldehyde has been shown to decrease cardiac protein synthesis,
by 50% (Schreiber, 1972). In a study in which guinea pigs were chronically fed ethanol
a decrease in cardiac protein synthesis in-vivo was found (Schreiber, 1982). This
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model was one where the right ventricle was subjected to a pressure load and the left
was not and the decrease in protein synthesis was confined to the right ventricle.
Other animal studies have demonstrated reduced mitochondrial respiration,
suggesting that the site of action of either ethanol or acetaldehyde, or both, is at the
level of the mitochondria(Pachinger, 1973; Segel, 1979). Bing et al showed that
chronic consumption of alcohol in dogs led to reduced calcium binding and uptake by
mitochondria and sarcoplasmic reticulum (Bing, 1974).
In man it has been shown that coronary sinus blood of alcoholics contains
higher levels of mitochondrial enzymes than controls, perhaps suggesting release of
these enzymes by damaged mitochondria (Wendt, 1965). Richardson et al showed that
patients consuming excess alcohol (8()g daily or lifetime >250kg) had increased
myocardial enzyme levels (creatine kinase, lactate dehydrogenase, a-hydroxybutyric
dehydrogenase, malic dehydrogenase and aspartate aminotransferase) (Richardson,
1986).
It may be that ethanol exerts its effects on cardiac protein synthesis via
acetaldehyde. In-vitro studies using homogenates of normal animal heart, where
ethanol was added to the system, showed no decrease in protein synthesis (Rawat,
1979). However, in a similar system, the addition of acetaldehyde did reduce protein
synthesis (Schreiber, 1974; Siddiq, 1993).
The finding of the ability of acetaldehyde to reduce cardiac protein synthesis is
significant. It is known that inhibition of protein synthesis leads to the development of
heart failure in rat hearts working against increased afterload (Zuchlke, 1966).
However, acetaldehyde has other actions, perhaps the most important of which is its
ability to bind covalently to a range of proteins. This binding occurs predominantly to
lysine residues (Tuma, 1987), though it may also bind to tyrosine and valine. This is
discussed further below.
The possibility that acetaldehyde may be responsible for cardiac disease does
mean that therapy may be available for patients who are unable or unwilling to cease
drinking once alcoholic cardiomyopathy is diagnosed. It has been shown that human
blood acetaldehyde concentrations can be lowered in vitro by doses of pantethine and
that liver levels of acetaldehyde can be lowered similarly in vivo in rats (Watanabe,
1985). Furthermore, another study in rats showed protection against lethal doses of
acetaldehyde by combinations of thiamin, L-cysteine and L-2-methylthiazolidine-4-
carboxylic acid (Sprince, 1974).
6.8. The Immune System and Antibodies in Heart Disease
Studies of immune function in patients with idiopathic dilated cardiomyopathy
have suggested defective T suppressor cell function (Fowles, 1979), though Lowry et
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al suggested that this was found in any form of heart failure (Lowry, 1987) and others
dispute any defect (Anderson, 1981). Reduced natural killer cell activity has also been
shown (Anderson, 1982; Itagaki, 1988). Gerli et al demonstrated several abnormalities
including: raised CD4/CD8 ratios, greater ability to help B cell differentiation,
suppressor cell defects and elevated IgM levels in comparison with patients with IHD
or healthy controls (Gerli, 1986). Arbustini et al showed an apparent relationship
between expression of HLA DR4 and 5 and DCM (Arbustini, 1989). This raised the
possibility that the immune system plays a role in this form of heart disease. Early
experiments with animal models showed that it is possible to raise anti-heart antibodies
by injecting native or foreign heart tissue. It was further shown that these antibodies
could have a cytopathic effect on myocytes in tissue culture (Gery, 1961).
Using direct immunofluorescence in patients with idiopathic dilated
cardiomyopathy, Sanders and Ritts demonstrated gamma globulin bound adjacent to,
and beneath, the sarcolemmal sheath (Sanders, 1965). Das et al found bound gamma
globulin in three patients with "congestive cardiomyopathy". In two of these bound
complement was also demonstrated (Das, 1971). The same group later studied 35
patients using indirect immunofluorescence and found sarcolemmal or subsarcolemmal
staining in 6 patients and antinuclear antibodies (against mouse liver) in 15 (Das,
1972).
Maisch et al used indirect immunofluorescence in a study of 79 patients with
dilated cardiomyopathy ("primary cardiomyopathy") and 61 with "secondary
cardiomyopathy", of whom 30 had alcoholic cardiomyopathy (criteria not stated)
(Maisch, 1983). They compared results with 200 healthy controls. Anti-interfibrillary
antibodies were described in 67% of patients with alcoholic cardiomyopathy versus
41% with primary cardiomyopathy and 3% in healthy controls. In alcoholic
cardiomyopathy these antibodies were IgG in 77% and IgM in 19%. Complement
fixation occurred in 3% only. Anti-myosin antibodies were found in 17% patients with
alcoholic cardiomyopathy, 20% with primary cardiomyopathy and 4% of controls.
Non-organ specific antibodies were also detected: antinuclear antibodies in 30%
patients with alcoholic cardiomyopathy, 24% with primary cardiomyopathy and 8% in
controls.
Schultheiss examined 18 patients with dilated cardiomyopathy and found that
17 had antibodies against the adenine nucleotide translocator but none of the 7 alcoholic
patients studied had these antibodies (Schultheiss, 1985).
In 1989 a Czech group used direct and indirect immunofluorescence to study
118 patients with 'congestive cardiomyopathy', of whom 38 were labelled as
"definitely alcoholic" and 34 as "presumably alcoholic". They found antiheart
antibodies by direct immunofluorescence, which was said to be strong, in 25% of the
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"definitely alcoholic" group and 37% in the "presumably alcoholic" group. It appears
that of the positive results for direct immunofluorescence, 68% had IgG bound, 51%
had IgM bound and 35% IgA(Hogye, 1989).
Neumann and others used Western blotting to detect IgG antibodies against an
extract of normal human heart. They studied 71 patients with idiopathic dilated
cardiomyopathy, 17 patients with acute myocarditis and 15 healthy volunteers. There
was no difference in the mean number of antigens recognized by serum from each
group. There was an increased prevalence of antibodies to 40-49kDa and 100-109kDa
antigens in patients with idiopathic cardiomyopathy. Using indirect
immunofluorescence they showed high titre IgG antibodies to heart in 59% of patients
with myocarditis, 20% idiopathic cardiomyopathy and none in controls. Since they did
not exclude alcoholics some of these results may relate to patients consuming alcohol
(Neumann, 1990).
Caforio and others excluded patients consuming excessive amounts of alcohol
and, using indirect immunofluorescence found that 17 of 65 (26%) patients with
idiopathic dilated cardiomyopathy had organ-specific cardiac antibodies compared with
7 of 200(3.5%) normal subjects (Caforio, 1990b).
Ansari found no serum activity against heart in alcoholic patients (by Western
immunoblotting, EL4SA against myosin, or immunofluorescence) except in one case
who had similar results to the DCM patients (autoantibodies against the adenine
nucleotide translocator and to the branched chain alpha-ketoacid dehydrogenase)
(Ansari, 1991).
There may also be a role for enteroviruses in inducing autoantibodies in dilated
and perhaps alcoholic cardiomyopathy. There is a large literature on the possibility that
enteroviruses, such as coxsackie virus B, may cause acute myocarditis which then
subsequently leads to the development of dilated cardiomyopathy (Cambridge, 1979;
Woodruff, 1980; Alvarez, 1987). Hence, in patients with dilated cardiomyopathy some
autoantibodies may have been virally induced. Sophisticated molecular techniques have
been used to detect coxsackievirus sequences in the hearts of patients with idiopathic
dilated cardiomyopathy. There were several initially promising reports (Bowles, 1986;
Bowles, 1989; Jin, 1990) though subsequent studies have not confirmed the presence
of coxsackievirus in these patients (Grasso, 1992). Bowles did not comment on alcohol
consumption in the 1986 paper (Bowles, 1986) but at least two subjects were drinking
to excess, both of whom were negative for viral RNA, in the later study (Bowles,
1989). Jin et al made no comment on alcohol consumption (Jin, 1990) and Grasso et al
stated that patients with alcoholic cardiomyopathy were not included in their study
(Grasso, 1992).
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Rose et al discuss the possible role of coxsackieviruses in inducing
autoantibody responses which become self-sustaining and go on to damage the heart
chronically (Rose, 1988). They have performed studies in mice which support this
contention (Neu, 1987). It may be speculated that alcohol consumption to excess
during viral infection with coxsackie B viruses allows damage to myocardial cells to
occur, exposing myosin at a time when antibody responses against enteroviral proteins
are at their height and cross-reaction is most likely. A range of virally induced
abnormalities could contribute to the development of myocardial disease under these
circumstances - the mechanisms for which might include molecular mimicry, alteration
of host immune responses and alteration of endogenous host antigens (Rose, 1988).
Thereafter further alcohol consumption would again damage myocytes provoking a
stronger antibody response. A chronic injury cycle could then be established. From the
studies performed to date there is no evidence for or against this contention.
6.9. Acetaldehyde Can Render Proteins Immunogenic
Acetaldehyde has a number of interesting properties being a toxic substance
with a propensity for stimulating antibody responses. It is therefore of great interest in
the area of alcohol mediated disease because it is produced in significant quantities in
the liver and can form antigenic compounds with a large range of cellular proteins.
A number of studies, mostly based on analysis of liver disease, have
demonstrated that acetaldehyde-modified proteins can be highly immunogenic.
Acetaldehyde may bind to lysine-rich proteins (fig. 12)(Tuma, 1987) such as the
enzyme ornithine decarboxylase (Rettig, 1979) to form unstable adducts. These adducts
are therefore produced continuously during chronic consumption of alcohol. The
formation of "acetaldehyde adducts" can occur at concentrations of acetaldehyde
comparable to those found in the blood of alcoholics (Sorrel, 1985; Turna, 1985).
Both mice and rats which have been chronically fed with alcohol have been
found to produce antibodies against acetaldehyde-modified proteins (Israel, 1986;
Worral, 1989). If haemoglobin or albumin protein is incubated in-vitro with
acetaldehyde, so-called synthetic acetaldehyde adducts are produced. High titres of
antibodies to these synthetic acetaldehyde adducts have been demonstrated in patients
with alcoholic liver disease (Hoerner, 1986; Hoerner, 1988; Niemela, 1987). 37kDa
and 52kDa acetaldehyde protein adducts have been reported in the livers of rats which
have been chronically fed with alcohol (Lin, 1988; Lin, 1989; Behrens, 1988).
A recent study found that 70% of patients with alcoholic hepatitis had
circulating IgA antibodies against a 2()()kDa acetaldehyde adduct in liver. Similar
antibodies were found in only 20-30% of control subjects (Koskinas, 1992). In these
Western blotting experiments sera were tested for antibody binding to four different
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preparations made from normal healthy liver. The first of these was essentially
untreated normal liver. The second was incubated with acetaldehyde alone. The third
was incubated with sodium cyanoborohydride alone and the fourth with acetaldehyde
and cyanoborohydride. The reducing agent, sodium cyanoborohydride, was used to
prevent breakdown of the adducts, which are inherently unstable. Thus, when the
electrophoresis gels were run, the sample lanes were arranged in sets of four in order to
accommodate the necessary controls. The lane of most interest was lane four where
stable adducts were present. The importance of this finding is that acute exposure to
alcohol would presumably not be sufficient to induce antibody formation because the
adducts would quickly be lost. However, chronic consumption would lead to continued
production of these adducts, sufficient to produce an antibody response in particular
individuals.
Figure 12. Acetaldehyde Binding to Protein via Lysine Residues
In this figure the acetaldehyde molecule is shown binding to a protein via the cpsilon amino group of a
lysine residue. This is a favoured site of binding for acetaldehyde but not the only possible means of
forming protein adducts. 'The adduct so produced remains part of a polypeptide chain and is highly
immunogenic.














Alcoholics have higher blood acetaldehyde levels than non-alcoholic subjects,
following consumption of similar quantities of alcohol (Majchrowicz, 1970; Korsten,
1975; Lindros, 1982; Nuutinen, 1984). This is due to reduced aldehyde dehydrogenase
activity, with preserved or even enhanced alcohol dehydrogenase function (Lieber,
1970; Takase, 1989). In the rat, levels of acetaldehyde in the heart exceed those in the
plasma (Espinet, 1984). Comparable data are not available for man.
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6.10. Alcoholic Cardiomyopathy - Summary
The evidence presented suggests that there is a distinct condition which is
widely referred to as alcoholic cardiomyopathy. This is the result of an ill-defined
number of years consumption probably of more than 8()g alcohol daily, or more than
250kg lifetime total. It presents with symptoms and signs of ventricular failure, with or
without arrhythmias, typically in a younger male. Most patients who stop drinking can
expect to recover, but continued alcohol abuse may result in deterioration and death.
The mechanism whereby myocardial failure is caused is unknown but one possibility is
immune mediated damage resulting from circulating antibodies produced against cardiac
acetaldehyde adducts.
On the basis of the evidence presented above the following hypothesis could be
proposed. Subjects who consume large amounts of alcohol over a prolonged period
will develop antibodies directed against acetaldehyde-adducts of myocardial proteins.
Such circulating antibodies could be involved in the pathogenesis of alcoholic heart
muscle disease through inhibition of enzyme function or direct damage to cells.
The work in this part of the thesis is concerned with the identification of




Patients, Materials and Methods
The aim of this study was to detect circulating antibodies to acetaldehyde
adducts of normal human heart in the serum of patients with alcoholic cardiomyopathy.
Serum was reacted with Western blots of appropriately treated heart tissue.
7.1. Patients
Serum samples were obtained from 12 patients with alcoholic cardiomyopathy
and also from 12 patients with dilated cardiomyopathy who did not drink more than 21
units of alcohol per week (males) or 14 units per week (females), (tables 18 and 19).
Sera were obtained as a kind gift from Dr Peter Richardson, Cardiac Department,
Kings College Hospital, Denmark Hill, London. The samples had been collected
prospectively for a separate project but sufficient residual serum was available for this
study. The diagnosis of alcoholic cardiomyopathy was based on the finding of left
ventricular dysfunction (ejection fraction <50% or echocardiography showing moderate
or severe LV dysfunction) on a background of excess alcohol consumption (greater
than 80g per day or lifetime consumption of >250kg) for longer than five years, in
patients who had undergone invasive cardiac investigations to exclude ischaemic heart
disease or other causes of heart failure.
Samples were also collected from patients at Addenbrookes Hospital,
Cambridge via Dr PL Weissberg and Dr G Alexander. These patients included 2 with
alcoholic cardiomyopathy diagnosed by the above criteria, 8 patients with dilated
cardiomyopathy who did not drink excessively (as defined above), 8 patients with
ischaemic heart disease and congestive heart failure who did not drink excessively and
8 patients with alcoholic liver disease who were currently drinking without clinically
overt cardiac disease. In addition, sera were collected from eleven healthy laboratory
personnel who did not drink to excess (less than 21 units/week in males and less than
14 units/week in females).
Tissue samples from patients undergoing transplantation who did not have
alcoholic cardiomyopathy were obtained from the Transplant Unit at Papworth
Hospital, Cambridge. Human ventricular tissue was obtained from the explanted heart
of two different patients with ischaemic heart disease. Normal human heart was
obtained from an unused donor heart. All tissues were stored at -7(Pc until required.
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Table 18. Subjects Studied by Western Blotting
The table lists all those patients included in the present study. The diagnostic group is given along
with the patients age and weekly alcohol consumption at the lime the scrum sample was taken. Please
note that patient 3(C), though consuming less than SOg alcohol per day at the time of his biopsy, had
ingested a lifetime total ofalcohol >250kg. Subjects / to 4 in the alcoholic cardiomyopathy group are





1 (A) 46 70
2 (B) (female) 44 84





























































4 (female) 57 56





Table 19. Further Data on Subjects with Alcoholic Cardiomyopathy
This table lists data for the subjects with alcoholic cardiomyopathy including their age, alcohol
consumption, the degree offunctional impairment of activity as assessed by the New York Heart
Association(NYHA) criteria, the left ventricular end diastolic pressure (LVEDP), the effect of alcohol
on the mean corpuscular volume (MCV) and the serum gamma glutamyl transferase level (G-GT).
Subject AGE Units/Wk NYHA LVEDP MCV G-GT
1 (A) 46 70 II 8 105 115
2 (B) 44 84 IV 14 100 92
3 (C) 49 21 III 12 97.3 71
4 (D) 45 120 IV 36 - 180
5 28 60 IV 26 103.4 143
6 60 70 IV 7 89.8 126
7 48 200 IV 24 96.2 -
8 46 90+ II 16 96.9 147
9 49 50+ II 8 89.9 52
10 23 100 I 8 96.8 -
1 1 63 100 I 1 0 91.7 68
1 2 54 105 II 23 88.5 26
1 3 37 140 IV 1 6 83.9 70
1 4 35 100 II 8 89 118
7.2 Materials and Methods
















Ventricular tissue, 6-10g, was trimmed of fat, weighed and chopped into
fragments with a scalpel. These were diluted roughly 1:10 with ice cold
homogenisation buffer. Fragments were mechanically homogenised using several 10
second bursts in a Polytron homogeniser. The crude mixture thus produced was spun
in a fixed 45° angle rotor (Sorvall SS-34) at l(),00()g (9,000rpm) in a Sorvall RC5B
centrifuge for 20 minutes. The pellet (nuclei) was discarded. The resulting supernatant
was centrifuged at 100,000g (28,000rpm) in a swing-out rotor (SW41Ti) in a Sorvall
ultracentrifuge for 1.5 hours. All centrifugation steps took place at 4^C. The resulting
supernatant, the cytosolic fraction, was decanted into a single 50ml Falcon tube. The
remaining pellet, the microsomal fraction, was resuspended in lml microsome buffer,
placed in an eppendorf tube and the protein concentration of an aliquot was measured.
The microsomal fraction was then stored at -7(rC until use.
The cytosolic fraction was concentrated. This was performed using a 'Speed-
Vac' device to evaporate water from the fraction. Samples were normally concentrated
from about 60mls to around 20mls. The protein concentration was then measured using
the BioRad protein assay according to the manufacturers instructions. The cytosolic
fraction was stored in lml aliquots at -7(Pc in 10% glycerol.
7.2.2.Preparation of Adducts
Materials:
Phosphate buffered saline (PBS)
Acetaldehyde 12.5mM: 66pl of stock (22.7M solution) injected into
lOOmls distilled water with gas tight syringe.
Sodium Cyanoborohydride 600mM: 3.77g dissolved in lOOmls water




50mM Tris/HCl pH 7.5
0.5% bromophenol blue
25mM dithiothreitol
(Made up in lOOmls and stored in 10ml aliquots at -2()^C until required)
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Methods:
Microsomal and cytosolic fractions were thawed and then incubated in the
presence or absence of acetaldehyde or sodium cyanoborohydride or both, as shown in
table 20 below.
Eppendorf tubes were labelled 1 to 4 and equal volumes (200-800|il) of
cytosolic or microsomal fraction were placed in each one. The sample in tube 1 was
treated with phosphate buffered saline (PBS), in tube 2 with acetaldehyde 2.5mM, in
tube 3 with sodium cyanoborohydride lOOmM and in tube 4 with acetaldehyde and
cyanoborohydride. The tubes were all tightly capped and were incubated at 37^C for
four hours. The time period 4 hours was shown to be optimum in previous studies
where adducts of human liver cytosol were prepared (Koskinas, 1992). Each sample
was then diluted 1:1 with 2X SDS-PAGE sample buffer and boiled for 5min at lOO^C.
Samples were then aliquoted and stored at -70^C until required.
Table 20. Proportions of Reactants for Adduct Production.
The table lists typical proportions of the given substances used to produce adducts and control
solutions. The amount of the given fraction used is given in microlitres followed by the amount of
phosphate buffered saline (PBS), acetaldehyde and/or sodium cyanoborohydride added. Thefractions are
numbered, in the order in which these protein solutions were run on each gel.
Tube Fraction PBS Acetaldehyde Cyan. Total
(111) (111) 12.5mM (|al) 600mM (pi) m
1 800 400 - - 1200
2 800 200 200 - 1200
3 800 200 - 200 1200
4 800 - 200 200 1200
7.2.3. SDS-Polyacrylamide Gel Electrophoresis
Materials:
SDS-PAGE Sample Buffer: See above
Acrylamide Stock Solution: 30% Acrylamide (150grams/500mls)
0.3% Bis-acrylamide (1.5g/500mls)
Buffer B 1.5M Tris/HCl, pH 8.8 (18.18g/lOOmls)
Buffer D 0.5M Tris/HCl, pH 6.8 (6.06g/lOOmls)
10% SDS lOg sodium dodecyl sulphate per 1 OOmls water
10% APS lg ammonium persulphate per lOmls water - made fresh
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SDS-PAGE Running Buffer (for 2.51): 15g Tris
72g Glycine
2.5g SDS
SDS-PAGE Gel Stain (11): lg Coomassie Brilliant Blue R250
0.51 Methanol (Analar)
0.11 Glacial Acetic Acid (AR)
Stirred for 30 minutes at 60^C.
SDS-PAGE Gel De-Stain (11): 0.51 Methanol (AR)
0.11 Glacial Acetic Acid (AR)
SDS-PAGE Gel Silver Stain
Gel incubated overnight on orbital mixer in 50% methanol
Incubated 30 min in water
Made up staining solution: 21 mis 0.36% NaOH
1.4ml NH4OH
0.8g AgN03 in 4mls water
Made up to lOOmls with water - vortexing dropwise in fume cupboard.
Stain added for 15 min and mixed on orbital shaker.
Developed in 2.5ml 10% citric acid, 0.25ml Formaldehyde in water.
Rinsed in 10% methanol, 10% acetic acid.
Methods:
Polyacrylamide gel electrophoresis (PAGE) was carried out under reducing
conditions in the presence of sodium dodecyl sulphate (SDS) according to the method
of Laemmli (Laemmli, 1970). Either 6% or 10% polyacrylamide gels were prepared
and run using BioRad's Protean Ilxi casting stand and vertical slab gel electrophoresis
device. Gels were 16cm in length and 16cm in width. Gels were normally cast in pairs
from a single mixture made according to the table. The buffer constituents are listed
below in table 21.
Gels were prepared approximately 3 hours prior to electrophoresis to allow
adequate polymerisation to occur. For each preparation, 50|ig protein was loaded per
lane 011 the gel (this would correspond to 35-5()|al of adduct). For molecular weight
marker lanes, 1 Ogll of a 1:20 stock of BioRad Broad range molecular weight markers
was used.
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Human ventricular protein samples were run on two gels, each allowing three
sets of the four different samples to be run along with a single molecular weight marker
(Mr) lane per gel.
Gels were cast as described and were assembled onto the Protean Ilxi device as
per manufacturers instructions. Buffer was placed in upper and lower tanks to cover
each end of the gel(s). Electrophoresis took place overnight (approximately 16 hours) at
a constant 28 volts. The following morning the voltage was increased (to 100 to 150V)
until the dye front had travelled the appropriate distance into the resolving gel,
approximately 8cm. Electrophoresis was then discontinued.
Table 21. Buffer Constituents for SDS-PAGE Gels
This table shows the volumes of the stock solutions used to make up SDS-PAGE gels. Two different
concentrations ofgel were prepared and each is shown. The slacking gel was the same in each case. The






Buffer B 12.5mls 15mls
Water 25.6mls 23.7mls
10% SDS 200(ll 600(tl




Acrylamide 4m Is 4mls
Buffer D 5mls 5mis
Water 10.6mls 10.6mls
10% SDS 200(0 200(0








Made up to ll with water. Stored at 4^C until required. Not re-used.
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Blotting Membrane: Immobilon P, polyvinylidene difluoride, Millipore,
Watford, Herts
Blotting Device: Standard horizontally arranged graphite electrodes.
(Constructed by Mr Adrian Boreham,
Clinical School Workshops, Addenbrookes Hospital).
Filter Paper: Whatman 3MM chromatography paper.
Dialysis Membrane: Visking dialysis tubing, Medicell International, Liverpool.
Methods:
Dialysis membrane (15 x 15cm) was cut to size and was also equilibrated in
blotting buffer for 15 minutes in a sandwich box on a reciprocal mixer.
After electrophoresis the gels were trimmed with a metal blade. Each set of four
(or five where the Mr lane was present) lanes were clearly marked on the glass plates
with a permanent marker. The gels were cut into individual pieces, three per main gel,
and the six gels thus produced were all equilibrated in blotting buffer for 15 minutes in
a sandwich box on a reciprocal mixer. In addition, pieces of blotting membrane were
cut to the sizes of the six gels and were also equilibrated in blotting buffer for 15
minutes.
Once the gels, blotting membrane and dialysis membranes had equilibrated they
were arranged in a sandwich for electroblotting as shown in the diagram.
In order to accommodate six gels on a blotter with a 15 x 15 cm electrode
arrangement it was necessary to blot the gels in two layers of three gels in a stack as
shown in figure 13 below.
The sandwich was begun by applying two sheets of filter paper soaked in
blotting buffer to the bottom electrode (anode), after first wetting the electrode with
some buffer. The immobilon P membrane was then applied to the filter paper layer. Air
bubbles were removed from these, and all other layers, by rolling a 10ml glass pipet
over them. On top of the immobilon was placed the gel and on top of this another two
pieces of filter paper. The dialysis membrane was placed on top of this sandwich and
then an identical sandwich was placed directly over the first. Gels were arranged in sets
of three in each layer. The two gels with the Mr lanes were of identical size and so they
overlay one another. The other four gels were of similar size.
Once the double sandwich was complete and all air bubbles had been expelled
the top electrode (cathode) was wet with blotting buffer and sealed down onto the
sandwich with the aid of the threaded nuts provided for this purpose. The electrodes
were connected to a BioRad 2.0/200 power supply and blotting proceeded for 45
minutes at 25 volts (300 to 1000mA).
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Figure 13. Semi-Dry Electroblotting Arrangement
This figure illustrates the layers of the sandwich formed in performing semi-dry electroblotting. The
position of each layer is important in producing adequate blotting results. Every blot was performed in
this fashion. The blot arrangement is shown from a front elevation and also in an aerial view, to show

















Once the blotting was complete the current was switched off and the device
dismantled. The gels were placed into coomassie stain. Blots were placed into blotting
buffer temporarily. The remaining constituents of the sandwich were discarded. The
two gels with an Mr lane were placed on a clean surface (usually the top of a sandwich
box) and the Mr lane identified (since protein bands are opaque on immobilon P and
can be seen when the blot is held up to the light). These were then sliced off with a
scalpel and also placed in coomassie stain. For some gels the entire gel along with its
Mr lane was placed in the coomassie stain. Gels and blots or Mr lanes only were
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stained in coomassie for approximately 1 hour. The blots or Mr lanes were then de-
stained by washing in several successive changes of de-stain solution. Finally they
were rinsed in water and left to dry in air in a dark cupboard. Dried blots/Mr lanes were
placed in envelopes and stored in folders. Gels were de-stained for longer and were left
in de-stain until photographed or discarded.
Meanwhile the blots were examined to ensure proteins had transferred (visible
as described above). They were then placed in a folded sheet of filter paper soaked in
blotting buffer, sealed in cling film and stored in a sandwich box at 4^C until use
(usually within one week).
7.2.5.Protein Assay
Materials:
BioRad Protein Assay Kit
Bovine serum albumin (BSA, SIGMA): lmg/ml in distilled water
Methods:
All protein assays referred to were performed using a BioRad protein assay kit -
based on the method of Bradford (Bradford, 1976). The microassay test was
performed according to manufacturers instructions. Bovine serum albumin stock
solution (lmg/ml) was used as standard in all experiments.
Briefly: dilutions of BSA stock were prepared in the range l-25|i.g/ml. In a 96
well plate, 80|il test solution (BSA or unknown) plus 20p.l BioRad protein assay
concentrate solution was placed in each well as required. The plate was incubated for 1
hour at 37°C. Optical density at 620nM (OD620)was read on a Flow Titertek Multiplate
Washer (ICN-Flow). Values were corrected for those obtained from control wells
containing water and protein assay concentrate only. Standard curves were produced by
plotting corrected OD520 against concentration of BSA. The concentration of the test









Dissolved in 400mls water by stirring overnight at room temperature. Adjusted
to pH 7.6 with addition of 5M NaOH. Made up to 500mls with water and then stored at
4^C until use.




Dissolved in 3.51 distilled water by stirring overnight at room temperature.
Adjusted to pH 7.6 with dropwise addition of c.HCl. Made up to 41 with distilled water
and stored at 4^C until use.
Detergent Buffer: Washing buffer 200mIs
Triton X-100 (SIGMA) 1ml
10% SDS 2mls
Prepared fresh immediately before use.
Tris-buffered saline: Sodium chloride 23.38g
Tris/HCl 12.1 lg
Dissolved in 1.81 water and adjusted to pH 7.4 with c.HCl.
Made up to 21 with distilled water and stored at 4^C until use.
Peroxidase Buffer 4-Chloro-l-napthol 72mg
Methanol 24mls
TBS 120m Is
Hydrogen peroxide (30%) 192pl
Peroxidase conjugated Rabbit anti-human Ig: IgG, IgA and IgM (Dako)
Methods:
1. Blots were removed from storage and each one was placed in a 50ml Falcon tube
with lOmls of blocking buffer per tube. Blots were then blocked for 18 hours at room
temperature by mixing on a spiral mixer (12 blots fitted on this device at a time).
2. The blocking buffer was discarded and the appropriate sera were added to each
tube. Sera were diluted 1:25 in washing buffer (400|il in 10 mis). The blots were then
incubated at 4^C for 18 hours on the spiral mixer.
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3. The serum solution was discarded, or sometimes poured into a sterile universal
container and stored at -20^C for re-use. The blots were then washed with washing
buffer (lOmls per tube) for 5 minutes and then with detergent buffer also for 5 minutes.
After two further ten minute washes in washing buffer the secondary antibody
(peroxidase conjugated rabbit anti-human IgG, IgA or IgM as appropriate) was added
at 1:250 (40|il per lOmls). The blots were then incubated at 4^C for 18 hours on the
spiral mixer.
4. The secondary antibody solution was discarded. Blots were washed four times for
ten minutes each in washing buffer and then four times for ten minutes each in tris-
buffered saline (TBS). The blots were then incubated in peroxidase buffer for 5 to 30
minutes (until bands appeared). They were then washed in water thoroughly and left to
dry in air in a dark cupboard.
5. After drying overnight blots were placed in individually labelled envelopes.
7.3. Estimation of Relative Molecular Mass of Positive Bands
The migration of proteins in a denaturing gel is related to the logarithm of their
relative molecular mass (Mr) (Hames, 1981). By calculating the distance migrated by a
known protein (molecular weight marker) divided by the distance migrated by the dye
front the relative mobility (Rf) is obtained. A graph of logMr against Rf produces a
straight line and this allows the determination of the molecular size of an unknown
protein.
Materials:
BioRad SDS-PAGE Molecular Weight Standards, Broad Range.
BioRad, Hemel Hempstead, England.
Methods:
The molecular weight standards (MrS) were diluted 1:2() in SDS-PAGE sample
buffer and stored in working aliquots at -20()C until use. Prior to electrophoresis they
were boiled at 100()C for 5 minutes. For each lane, 10pl of stock MrS was used.
When blots were dry, measurements were made with a ruler and plotted as
described above. A sample graph is shown below (fig. 14). Where bands were large, a
measurement was made at the top and bottom of the band and a range of Mr was
calculated.
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Figure 14. Graph of Relative Mobility vs. Log Mr.
This graph shows a plot of ihc logarithm of the molecular size of a given molecular weight marker
against its relative mobility in a polyaery lamide gel. Broad Range Mr Standards were resolved on 10%
SDS-PAGE gel and blotted onto immobilon P. The blots were stained with coomassie blue. The blot
was identical to that used for immunostaining in order to make comparison with any positive bands
obtained. A typical plot from the actual experiments reported is shown. Log MW = logarithm of
molecular weight, Rf = relative mobility.
7.4. Densitometry
Where bands were not clearly discernible as either positive or negative
densitometry was performed to measure accurately the colour reaction of particular
bands of interest. The principle used was that a specific band would show a colour
reaction at least two times greater than that of a suitable control, a principle widely used
in other enzyme immunoassay procedures such as ELISA.
Materials:
Personal Densitometer. Software: ImageQuant Version 3.2
Molecular Dynamics Ltd., Kemsing, Sevenoaks, Kent.
Methods:
The device used was a densitometer which measures reflectance from a surface
and displays the resulting image on a screen, allowing manipulation of the display for
optimum clarity of viewing. The software does not allow manipulation of the raw data,
only the image, so that measurements were always made on the data as they were
acquired and not on the altered image.
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Blots were soaked in methanol for 5 seconds and then immersed in water until
use (within 15 minutes).
Blots were placed on the imaging plate after the machine had performed internal
calibration. The blot was scanned and the resulting image displayed on a colour screen.
Once the data for any given blot were stored, the blot was left to dry in air and returned
to storage in an envelope.
Bands of interest were selected. A measuring box was placed closely around
these bands using the system software and the "integrated pixel volume" (IPV)
calculated within this box. The same box was used to calculate the background from an
area of the blot remote from the band of interest but lying within the lane being
examined. Comparison with bands in adjacent lanes was made in an identical fashion.
All results were corrected for background. A positive result was one where the IPV for
the band of interest was more than twice the IPV of the control band.
7.5. Statistics used




n2 = n [ (ad-bc) - 1/2n ]2
(a+b)(c+d)(a+c)(b+d)
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8. Results: Alcoholic Cardiomyopathy
Sera from 59 subjects in five groups (see table in methods section) were
examined by Western blotting. Four different preparations of human cardiac cytosolic
protein fraction were resolved together on SDS-PAGE and then blotted onto a
membrane. This was probed with the sera. The resulting immunoblots consist of four
lanes of protein representing the four different fractions. The first lane in every blot is
the native or untreated protein. This was incubated with saline only. The second lane
contains protein that was incubated with acetaldehyde only, included as a control. The
unstable nature of acetaldehyde adducts is such that this lane might be expected to be
similar to lane one. Lane three represents protein treated with cyanoborohydride, a
reducing agent intended to stabilise adducts produced by acetaldehyde, another control
lane. Lane four is the lane where a specific positive result is expected. Here both
acetaldehyde, to produce adducts, and sodium cyanoborohydride, to stabilise them,
were used.
This layout was used for every experiment. The results are therefore similar in
format regardless of the subjects. The key feature is that native protein is present in lane
one and the altered proteins of interest in lane four. It may be observed that some
positive bands are present in all lanes. This indicates antibody activity against native
proteins and is not an unexpected finding. Koskinas et al described similar bands in
their experiments on acetaldehyde adducts in the liver and other workers using Western
blotting with heart tissue also find these non-specific bands (Koskinas, 1992).
Thus the blots resulting from immunostaining have four lanes represented
pictorially, from left to right, as:
LANE: 1 2 3 4




FUNCTION: | Native tissue : Control Control | Result I
Only bands present in lane 4 were considered positive. It was not uncommon to
see bands in all four lanes in any of the groups of subjects studied.
Where bands are present in two lanes only this is usually lanes 3 and 4. Where
they are of equal intensity they are counted as negative. Where measurement of band
intensity by densitometry shows that the band in lane 4 is more than twice the intensity
of another band it is counted as positive.
The following figures are set out according to this format, though each has a
legend describing it in detail. The immunoblots are in order, starting with subjects from
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the alcoholic cardiomyopathy group, followed by those of healthy volunteers, dilated
cardiomyopathy, ischaemic heart disease and alcoholic liver disease. A table follows the
last blot giving the overall results and then a table of the estimated molecular size of the
positive bands.
Four of fourteen (28%) patients with ACM had detectable antibodies against
acetaldehyde-modified cytosolic protein (figures 15-19 below), detected only against
samples treated with acetaldehyde and cyanoborohydride, compared with none of 28
patients with cardiac failure of non-alcoholic aetiology (p<0.05, Chi-Square).
Antibodies were of IgG class in 3 patients and two of these also had an IgA antibody.
An IgM antibody was detected in the fourth patient. The proteins identified had
molecular weights ranging from 63 to 82 kDa. No antibodies were detected in sera
from any other subject. Patients with IgG antibodies also had antibodies of the same
isotype against microsomal proteins of different size to the cytosolic target (figure 20).
Antibodies against untreated heart were noted among all groups (figures 21-24).
8.1. Alcoholic Cardiomyopathy
The fourteen patients with alcoholic heart muscle disease were tested for IgA,
IgG and IgM antibodies against normal human left ventricular cytosolic fractions treated
with or without acetaldehyde in the presence or absence of sodium cyanoborohydride.
Sera from patients with positive antibodies against cytosolic fractions were tested
against microsomal fractions, again with IgA, IgG and IgM (where the amount of
serum allowed). The resulting blots are illustrated below.
The series of blots illustrated serves to show the type of result obtained in
performing Western immunoblotting with sera from these subjects. Many more blots
were performed and blots were often repeated to confirm initial findings. The series is
intended to show the important positive results in detail and then some illustrative
negative results from control subjects.
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Figure 15: Photograph of Western Immunoblot - Patient A tested
against Human Cytosolic Protein.
The photograph shows a blot produced after development with chloro-naplhol. The four lanes represent
four fractions of human left ventricular cytosolic tissue treated with 1 jnolhing, 2)acetaldehyde alone,
3)sodium cyarioborohydride and 4)acetaldehyde and sodium cyanoborohydride. The blot was probed with
serum from patient /\, a subject with ACM. The secondary antibody was peroxidase conjugated anti-
human IgC. The "X" marks a large band centred on 63kDa, which is present only in lane 4. This
represents a positive result. 'The patient's serum reacts only with this antigen, produced by acetaldehyde
and stabilised by sodium c.yunoborohydridcflanc 4), and not with the native protein (lane 1) or with
either of the controls (lanes 2 and 3). Also seen arc bands present in lanes 1-4 at approximately 20, 44
and 100 kDa. 'These bands are non-specific and are often observed in serum from control subjects.






Figure 16: A Second Patient with ACM tested against Human
Cytosolic Protein.
I his blot is shown alongside one stained with Coornassie Blue R-250 for protein, for comparison.
Subject D has ACM and the serum has reacted with a protein at approximately 69kDa, again present
only in lane 4, marked "X". In this case the positive band is narrower than that in the previous figure.
The secondary antibody was IgG. Once more, non-specific bands, present in lanes 1-4, can be seen. The
coomassie-stained blot was an identical blot to that used for treatment with the patient's serum and was
produced in the same experiment. 'The large number of protein bands on the blot is striking when
compared with the small number with which the subjects serum has reacted.






Figure 17: Western Immunoblot. Patient A tested for IgG, IgA
and IgM against Human Cytosolic Protein.
Three blots reacted with serum from subject A are shown alongside another stained with coomassiefor
protein as above. The blots were developed with a secondary antibody to IgG, IgA and IgM
respectively. Bands are present in lane 4 on the IgG (63kDa) and IgA (two bands - 74 and 82kDa) blots
marked "X" and "Y" respectively. No specific IgM bands were detected for this subject. Bands are
present which are seen in lanes three and four only.








Figure 18: Western Immunoblot. Patient B tested for IgG, IgA
and IgM against Human Cytosolic Protein.
Scrum from subject B reacted with three blots of human left ventricular cytosol and compared with a
protein stained, blot as in the figure above. An IgG antibody is present at 63kDa in the lane marked
"X". Faint IgA bands are present at 74 and 67kDa.






Figure 19: Western Immunoblot. Patient C tested for igG, IgA
and IgM against Human Cytosolic Protein.
This photograph shows blots produced when serum from subject C was reacted with three blots of
human left ventricular cylosol. These are compared with a protein stained blot Positive bands are
present only for IgM. 'I he main one is at 77kDa in the lane marked with an "X" but a band at a lower
Mr is also visible, i'hcre are no specific IgG or IgA bands.








Figure 20: Patients A, B and C tested for IgG and IgM against
Human Cardiac Microsomal Protein.
This photograph shows the results of an experiment where human cardiac microsomal fraction was
treated in exactly the same way as the cylosolic fraction used in the experiments illustrated by the
above blots. Lanes 3 and 4 ofmicrosomal fraction blots are shown against lanes 3 and 4 stained with
coomassie blue. Sera from subjects A, B and C have been reacted with the blots and secondary antibody
was IgG, IgG arid IgM respectively. For patient A bands are present as a doublet at about 70kDa,for
patient B at approximately 66kDa (with a much weaker band in lane three which is more than three
times less strong a reaction according to densitometry). Patient C's serum reacted with a protein at
about 70kDa and also, less strongly, with a band at about 60kDa. Multiple other bands are present in
lane four with patient C, particularly at higher molecular size. This experiment, conducted
simultaneously with identical blots allows comparisons to be made directly between the bands reacting
with each individual subjects scrum.








Sera from eleven healthy individuals (age range 24 to 56 years, one female)
who drank from 0 to 16 units of alcohol per week, were examined. None of these sera
contained antibodies to proteins present in lane four only, as illustrated below in figure
21. Blots developed with IgG are shown but all three antibody isotypes were tested and
found to be negative.
Figure 21: Western Immunoblots. Healthy Volunteers tested for
IgG against Human Cytosolic Protein.
This figure illustrates the results produced when sera from non-alcoholic volunteer subjects with no
heart or liver disease were reacted with blots of human left ventricular cytosol. The secondary antibody
was directed against human IgG. Many non-specific bands are present in the central blot. These results
are similar to those produced with IgA and IgM except that there were fewer bands with IgA. When
healthy volunteers' sera (not all were tested due to shortage ofmicrosomal fraction) were reacted with
microsomal blots similar results were obtained.
IMMUNOBLOTS - HUMAN LEFT VENTRICULAR CYTOSOL
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8.3. Idiopathic Dilated Cardiomyopathy
Patients with idiopathic dilated cardiomyopathy also had serum samples tested
for antibodies to acetaldehyde adducts of human cardiac cytosolic tissue. Twenty of
these subjects were studied (age range 20 to 65 years). None of these patients
consumed more than 21 units of alcohol weekly.
Again only blots reacted with IgG are shown (fig. 22) but all isotypes were
tested. No positive results were obtained, as no bands present in lane four only were
observed.
Figure 22: Serum from subjects with Idiopathic Dilated
Cardiomyopathy tested for IgG against blots of
Human Cytosolic Protein.
Blots of human lc.fl ventricular cytosol reacted with serum from three different patients with dilated
cardiomyopathy and shown alongside a blot stainedfor protein. Many bands are present but none solely
in lane 4. These bands are non-specific auto-reactive antibodies often seen in such experiments. No
IgA or IgM antibody activity was detected either (not shown).
IMMUNOBLOTS - HUMAN LEFT VENTRICULAR CYTOSOL





8.4. Ischaemic Heart Disease
Sera from eight patients with ischaemic heart disease (age range 49 to 86 years)
and impaired left ventricular function were also studied. These patients were all
consuming less than 21 units of alcohol weekly. Their sera were reacted with blots in
the fashion described above. The secondary antibody used in the blots shown (fig.23)
was IgG, but IgA and IgM were also examined. No positive results were observed (as
defined above).
Figure 23: Subjects with Ischaemic Heart Disease tested for IgG
against blots of Human Cytosolic Protein.
Blots of human cardiac cylosolic protein treated as described above reacted with sera from patients with
IHD. A coomassie stained blot is shown for comparison. As above non-specific bands only are
observed, frequently at 66kDa. No IgA or IgM antibody activity was detected (not shown).
IMMUNOBLOTS - HUMAN LEFT VENTRICULAR CYTOSOL








8.5. Alcoholic Liver Disease
Eight patients with alcoholic liver disease were studied (aged 31 to 68 years,
two female) who were consuming 42 to 84 units of alcohol weekly. Sera were tested
with IgG, IgA and IgM secondary antibodies. Only the IgG blots are illustrated (fig.
24) as the results were all broadly similar. No positive results were observed (as
defined above).
Figure 24: Subjects with Alcoholic Liver Disease tested for IgG
against blots of Human Cytosolic Protein
Blots of human left ventricular cytosol reacted with serum from three different patients with alcoholic
liver disease and shown alongside a blot stained for protein. Again, multiple non-specific bands are
present in each lane, in this case rather more than seen with subjects suffering from ischaemic heart
disease.
IMMUNOBLOTS - HUMAN LEFT VENTRICULAR CYTOSOL
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8.6. Relative Molecular Mass of Positive Bands
The various estimated molecular masses of the positive reactions on the blots
illustrated above are listed in table 22 below. It can be seen that no single molecular
sized protein is common to all the patients, though the positive bands do seem to cluster
between 60 and 80 kDa.
Table 22: Relative Molecular Mass of Positive Bands.
This lable shows the relative molecular masses of bands judged as positive for each subject. The
method used is described above in the methods section. These figures are estimates and, particularly for
higher molecular masses, arc not necessarily entirely accurate. There may be discrepancies between
observed bands on individual blots and the figures listed in the table. There appear to be antigens at
around 63 and 77 kDa which are detected by more than one subject's sera. LVC=left ventricular
cytosolic fraction and LVM=left ventricular microsomal fraction. Subjects A to D, whose
immunoblots are illustrated above, are identified in the table by their respective letters.
Molecular Weight Estimations of Positive Bands
Su bject Tissue Antibody
Isotype
Band Size
A LVC igG 58 - 68
LVC igA 82
LVM igG 77
B LVC igG 63
LVC igA 62, 120
LVM igG 69
C LVC IgM 77
LVM IgM 60, 87, 110
D LVC igG 70
LVM igG 72
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9. Alcoholic Cardiomyopathy - Discussion
9.1 Main Findings
The major findings of this study are that a proportion of patients with alcoholic
cardiomyopathy have circulating antibodies that recognise acetaldehyde-modified
normal human cardiac protein. The antibodies identified were predominantly of IgG
isotype, but IgA and IgM antibodies were also detected. The antigens recognised by
these antibodies were in the range 58-120 kDa and were identified in both cytosolic and
microsomal fractions. All the appropriate control populations, including those with
heart disease not due to alcohol and those with alcohol-related illness not involving the
heart, were always negative for antibody to acetaldehyde-modified cardiac protein.
In this study, the antibody was detected only in the presence of sodium
cyanoborohydride, the reducing agent used to stabilise the acetaldehyde adducts.
Acetaldehyde is a highly reactive species that yields stable and unstable adducts after
binding to protein; the unstable adducts are probably Schiff bases formed with the
epsilon amino group of lysine residues (Tuma, 1987). Because the antigen was detected
in the presence only of both acetaldehyde and cyanoborohydride, it would appear that
the generation of the antigen in-vivo involves the formation of stable adducts.
Alternatively, unstable adducts might be continuously produced.
The results indicate that acetaldehyde modifies cardiac protein in some
individuals consuming alcohol to excess and renders them immunogenic. No subjects
from any of the four control groups were found to have specific antibodies of this
nature. However, it is uncertain whether the generation of the antigen and the immune
response to this antigen is the primary event in alcoholic cardiomyopathy or whether
this is a non-specific response, but the presence of such antibody, exclusively in
patients with alcoholic cardiomyopathy, suggests that this approach is worthy of further
attention.
Experiments using immunofluorescence on sections of myocardium from
patients with alcoholic cardiomyopathy might identify the cellular location of the
antigens. In initial experiments, conducted by Dr N Cary and his assistants in the
immunofluorescence laboratory at Papworth hospital, it was not possible to achieve
low enough background staining to identify specific staining. Sufficient tissue for
extensive experimentation was not available for this study. Future experiments may
centre on the use of otherwise normal heart which has been treated in a similar way to
the protein fractions used in western blotting experiments. The immunofluorescence
techniques may then be refined until meaningful results are achieved.
It is not known what concentrations of acetaldehyde are achieved in cardiac
tissues in man following alcohol consumption but it is known that the concentration in
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rat ventricle exceeds that in plasma (Espinet, 1984). Neither the nature nor the location
of the acetaldehyde-modified antigens in ventricular tissue are known, but the fact that
these antigens have induced immune responses suggests that they are accessible to the
immune system.
9.2. Sensitivity of Assay
In total, four of fourteen patients with alcoholic cardiomyopathy (sensitivity =
28%) possessed antibodies to acetaldehyde adducts of human left ventricle. One
possible reason why the number of patients who were positive for antibody to
acetaldehyde-modified cardiac protein was small is the nature of the assay seeking
antibodies. Western blotting involves conformational changes and it may be that using
an assay that does not involve such changes would give a higher yield of the relevant
antibody. The small numbers may also relate to timing of the original blood sample.
Patients labelled as having alcoholic cardiomyopathy may already have stopped
drinking by the time of tertiary referral to a major centre (the source of the majority of
these sera). A further explanation may be that the patients without the antibody
response may have a true 'dilated cardiomyopathy1 not related to alcohol consumption.
Not all patients with alcoholic cardiomyopathy will recover if they stop drinking and
these may represent cases of dilated cardiomyopathy. Alternatively it may be that more
than one mechanism of myocardial damage is at work. The acetaldehyde adduct
explanation fits the available evidence but many workers who have studied dilated
cardiomyopathy specifically excluded subjects with alcoholic cardiomyopathy. This
means that there is a paucity of literature on these patients. It is precisely because there
is no diagnostic test and empirical diagnosis is required that it has been difficult to make
more progress in studying the condition. It may be that the antibody response to
acetaldehyde adducts is a way to identify patients with a true alcoholic cardiomyopathy.
9.3. Specificity of Assay
Antibodies were identified in the serum of subjects from each group studied to
proteins not incubated with acetaldehyde. These antibodies are represented by the
presence of bands in each lane, one to four, on the blots shown in the results section.
These were clearly not specific to patients with alcoholic cardiomyopathy but this is not
an unexpected finding. Two bodies of work suggest that this could have been
predicted. Koskinas et al (Koskinas, 1992) also found that their subjects with alcoholic
liver disease, non-alcoholic liver disease or healthy volunteers had antibodies to native
proteins, in this case of liver origin. Some of these proteins will not be tissue specific
and might be present in other organs, such as the heart. In studies using Western
blotting of cardiac tissue and sera from subjects with dilated cardiomyopathy, acute
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myocarditis and normal subjects, the presence of antibodies to native protein was
observed (Neumann, 1990). Thus, non-specific antibody responses are not unusual
and have been observed previously. Therefore, the only bands to which close attention
has been paid were those present in lane four only - where stabilised acetaldehyde
adducts were present.
In terms of the ability of the assay to detect patients with alcoholic
cardiomyopathy in these studies the specificity was 100% since none of the control
subjects had any antibodies to acetaldehyde modified human cardiac cytosolic proteins.
The predictive value of a positive test is also 100% according to these figures.
9.4. Immunological Responses to the Heart
This thesis has demonstrated the presence of antibodies to acetaldehyde-adducts
using experiments not previously performed for human cardiac proteins. However,
there have been many previous studies looking for immunological responses directed
against the heart. Only a few of these have involved patients with alcoholic
cardiomyopathy. Early studies using direct immunofluorescence showed evidence of
immunoglobulin binding to the heart in patients with cardiomyopathy (Sanders, 1965;
Das, 1971; Das, 1972). Maisch et al used indirect immunofluorescence and found 'anti-
interfibrillary antibodies' in 67% (of 30) patients with alcoholic cardiomyopathy versus
41% (of 79) with primary cardiomyopathy and 3% (of 200) in healthy controls
(Maisch, 1983). In the current studies IgG, IgA and IgM antibody isotypes were
present. Maisch found IgG in 77% and IgM in 19% of alcoholic cardiomyopathy
subjects.
Another group used direct and indirect immunofluorescence to study 118
patients with 'congestive cardiomyopathy', of whom 38 were labelled as "definitely
alcoholic" and 34 as "presumably alcoholic". They found antiheart antibodies were
present in 25% of the "definitely alcoholic" group and 37% in the "presumably
alcoholic" group (Hogye, 1989). It is noteworthy that the finding of positive
immunofluorescence in 25% of the "definitely alcoholic" group compares with the
figure of 28% of alcoholic cardiomyopathy subjects producing positive results in this
thesis. It is unclear why there should be a higher proportion of positive results in the
less well defined "presumably alcoholic" group.
The bands detected for healthy volunteers in this thesis may represent non-
organ specific antibodies. These would be antibodies raised against substances present
in many organs or tissues and would not represent a specific response against cardiac
proteins. Whether or not these non-organ specific antibodies have significance is not
known. This antibody activity recognises proteins regardless of whether or not they
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have been treated with acetaldehyde or cyanoborohydride since the bands are present in
all four lanes.
Caforio et al found that 17 of 65 (26%) patients with idiopathic dilated
cardiomyopathy had organ-specific cardiac antibodies compared with only 7 of 200
(3.5%) normal subjects, using immunofluorescence (Caforio, 1990b). They found a
relatively low incidence of anti-heart antibodies, whereas in the present study almost all
subjects with heart disease had antibody activity against human cardiac proteins (the
"non-specific bands" illustrated in figures 20 and 21). It may be that the antigens
recognised as non-specific bands on these blots are not heart specific, but immunoblots
using various other tissues were not used. Alternatively it may be that the different
methods, that is immunofluorescence versus Western blotting, give very different
results.
Neumann et al used Western blotting to detect IgG antibodies against an extract
of normal human heart (Neumann, 1990). They studied 71 patients with idiopathic
dilated cardiomyopathy, 17 patients with acute myocarditis and 15 healthy volunteers.
There was no difference in the mean number of antigens recognized by serum from
each group, which would fit with my results. However, in the same study, using
indirect immunofluorescence, they showed high litre IgG antibodies to heart in 59% of
patients with myocarditis, 20% with idiopathic cardiomyopathy and none in controls.
The latter results are more akin to those of Caforio et al and the former are similar to
my findings for non-specific antibodies. This is further evidence that the different
methods produce different results. Since Neumann et al did not exclude (or did not state
either way) alcoholics some of these results may relate to patients consuming excess
alcohol.
Thus, other workers have detected antibodies directed against the heart in
patients with alcoholic cardiomyopathy. They may not be organ specific and are
detected differently with Western blotting and indirect immunofluorescence. The
question of organ specificity of these antibodies was not addressed in this thesis.
However, the presence of antibodies to other tissue preparations would merely show
that this mechanism could function in these other tissues. This might be predicted from
a knowledge of the wide range of tissues damaged in chronic alcohol abuse. These
other studies support the finding of antibodies against native heart among control
subjects. They also suggest additional antibody activity against the heart in these
patients since no other studies were performed using acetaldehyde adducts. Although
this might also indicate the presence of a stable acetaldehyde adduct in the tissues
studied, or a protein sufficiently similar to an unstable adduct to allow cross-reactive
antibody binding to occur.
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9.5. Relationship to Antibodies in Alcoholic Hepatitis
A previous study has suggested that an IgA antibody circulating against a
200kDa protein is associated closely with alcoholic hepatitis. It is interesting in this
context to note that none of the patients with alcoholic liver disease in this study were
positive for antibody to the modified cardiac protein. Similarly, patients with alcoholic
cardiomyopathy do not have IgA antibody to the 200kDa acetaldehyde-modified liver
protein identified in alcoholic hepatitis. Other workers have shown that antibodies to
acetaldehyde haptens are present in animals and humans exposed to ethanol long term
in vivo. These investigations have used a variety of stable protein acetaldehyde adducts,
often with the test antigen being produced in-vitro, for example with albumin or
haemoglobin. These results are important in that they show that the antibody response
to acetaldehyde-modified epitopes is not restricted necessarily to those with alcoholic
liver disease and has been identified in several situations previously in heavy drinkers
who do not have evidence of alcoholic liver damage (Hoerner, 1986; Niemela, 1987).
Patients with alcoholic liver disease, known to have an antibody to a 200 kilo-
Dalton liver cytosolic protein, did not have an antibody to a similar sized protein in
human heart (figure 22). This suggests that these proteins are organ specific, or at least
have differential expression in these organs. This may explain the clinical impression
that these two conditions do not co-exist - despite sufficient alcohol consumption for
either to occur. It may be that the patients genetic constitution determines a
susceptibility to the action of alcohol. This may be on the basis of production of a
protein which has important cellular functions and which may react with acetaldehyde.
This study did not examine alcoholic patients with neuropathy, pancreatitis,
thrombocytopenia or other complications of chronic alcohol abuse for anti-acetaldhyde-
adduct antibodies but it may be speculated that these different tissues may all be affected
by this mechanism to a greater or lesser extent.
9.6. Pathogenesis and Identity of Antigens
The reason for the presence of specific antibodies to proteins in lane four has
been discussed. Briefly, alcoholic subjects ingest ethanol which is metabolised in the
liver to acetaldehyde. Circulating acetaldehyde is taken up by the heart where it reacts
with various proteins, rendering them antigenic. When such subjects go on an alcoholic
binge the direct toxic effects of the ethanol on the heart cause sufficient cellular damage
to expose the altered proteins. These then raise an antibody response. The result of this
antibody response then depends on the protein in question. It may be an enzyme
important for energy use in the heart, for example ornithine decarboxylase (Behrens,
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1988), or perhaps a structural protein, such as myosin, involved in myocardial
contraction.
Evidence that this postulated mechanism can function in-vivo comes from a
study by Yokoyama et al(Yokoyama, 1993). In these experiments hepatitis was
produced in Guinea Pigs that were immunised with synthetic acetaldehyde adducts of
human haemoglobin and bovine serum albumin. They were then fed on ethanol. The
animals were divided into groups according to whether or not they were immunised and
whether or not they went on to be fed with alcohol. The study showed that animals
immunised with the adducts and then fed with alcohol developed hepatic necrosis with
elevated serum liver enzyme levels, a condition analogous to alcoholic hepatitis in
humans. Animals immunised with unmodified haemoglobin, fed on alcohol showed
fatty change only. Animals immunised only had minimal inflammatory changes in the
liver. This study is of great importance in showing that the mechanism proposed
functions as postulated. It does not of course prove that the antibody response has a
pathological function but it is highly suggestive.
The antibody response in the patients studied in this thesis may of course be
secondary to any damage occurring in their hearts. It may simply signify the degree of
myocardial damage caused by acetaldehyde which, incidentally, also leads to the raising
of an antibody response. These antibodies may therefore be a marker of myocardial
damage resulting from acetaldehyde production. As such they may offer a useful
diagnostic tool. On the other hand they may contribute to myocardial dysfunction by
interfering with the function of proteins against which they are raised. The clinical
features of alcoholic cardiomyopathy suggest that whatever process is deranging
myocardial contractility it is reversible, as a recent study has confirmed (Teragaki,
1993). However it does not reverse overnight. It takes weeks, or even months, to
recover fully from this condition. It is necessary therefore to postulate a mechanism of
reversible myocardial impairment which takes some time to diminish after the root
cause is removed. An antibody response might fit this profile.
Determination of the identity of the antigen(s) modified by acetaldehyde could
be critical in pinpointing the role of acetaldehyde-modified proteins in ACM. There is
considerable evidence that acetaldehyde may alter the function of a large number of
proteins and that protein synthesis is reduced in the presence of acetaldehyde
(Schreiber, 1972; Schreiber, 1982; Schreiber, 1974; Siddiq, 1993). However,
acetaldehyde can have positive inotropic and chronotropic effects due to secondary
release of catecholamines (James, 1967; Gallis, 1971). Unlike ethanol (Gould, 1971)
acetaldehyde has no demonstrable direct toxic effect on the myocardium and is therefore
unlikely to be causing alcoholic cardiomyopathy directly. However, the generation of
antibodies to unstable acetaldehyde adducts may explain the reversible nature of
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alcoholic cardiomyopathy since persistence of the antigens would be dependent on
chronic acetaldehyde generation. Abstinence from alcohol would be expected to result
in disappearance of the antigen and its immune stimulus.
Whilst acetaldehyde may not play a role as a direct toxin in alcoholic
cardiomyopathy, immune recognition of acetaldehyde-modified protein may be a
secondary and irrelevant effect, leaving some as yet unknown mechanism responsible
for the disorder. Alternatively, immune recognition of modified cardiac protein could be
a primary event; however there is little evidence to indicate complement activation in
alcoholic cardiomyopathy, nor do the histological findings support a role for immune
insult. However, there is a paucity of reliable data in this field and an important role for
immune involvement cannot be excluded on the published literature to date.
One intriguing possibility is that of cross-reactivity between the neo-antigens
produced by acetaldehyde binding to cellular proteins and native proteins in the
myocardium. In particular the concept of cross-reactivity between antibodies to
acetaldehyde adducts and proteins expressed at a high level in the context of cellular
injury is attractive. Sequence homology between hsp60, a ubiquitous heat shock
protein, and several autoantigens has been demonstrated (Jones, 1993). Thus a theory
might be proposed in which the heart is exposed to acute damage by excess alcohol.
This induces hsp60 production and also the formation of acetaldehyde adducts. Further
damage leads to antibody production which may then be targeted against both the
adducts and the heat shock protein. It may be that tissues which have either adducts or
heat shock protein expressed at high levels are not affected by the antibody response
but that the combination is in some way synergistic. The genetic ability to form these
two proteins may therefore determine susceptibility to disease.
This theory has interesting parallels in work examining anti-myosin responses
in mice with acute myocarditis induced by coxsackievirus infection. Susceptible mice
can be induced to develop acute myocarditis by immunising them with myosin (Neu,
1987). Furthermore, there is cross-reactivity between antibodies to certain
coxsackievirus epitopes and cardiac myosin (Alvarez, 1987; Beisel , 1990). Thus, the
evidence from carefully controlled animal studies suggests that the development of an




Having shown in this work that some patients with alcoholic cardiomyopathy
possess circulating antibodies to acetaldehyde adducts of human heart proteins it will
now be necessary to demonstrate that these antigens are actually present in the subject's
tissues. The pathogenetic relevance of having a positive antibody response will have to
be determined in long term prospective studies. In particular it will be necessary to
follow patients who stop drinking to see if the antibody response disappears, and
perhaps if it reappears if patients begin drinking again. It remains to be seen whether
possessing circulating antibodies to acetaldehyde modified human cardiac protein
adducts is associated with a poorer outcome or not.
Experiments may also be conducted to demonstrate a pathological function for
these antibodies, for example with myocardial cells in tissue culture, as previously
(Gery, 1961). In addition it may be that a similar series of experiments to those of
Yokoyama et al will be required to confirm the validity of the acetaldehyde hypothesis
(Yokoyama, 1993).
The identification of the antigens recognised by the circulating antibodies will
allow the development of an ELISA test. This would allow the rapid screening of large
numbers of samples, allowing a study of all hospital admissions with heart failure to be
performed for example. Whilst the rate of antibody detection in patients with alcoholic
cardiomyopathy was low in this study, at around 30%, it is a highly specific test and as
such may serve as a marker for detection of alcoholic cardiomyopathy in a population
of patients with idiopathic dilated cardiomyopathy.
In addition to these experiments the T cell responses against the antigens
recognised by these antibodies could be studied. It has been shown by two-dimensional
electrophoresis that there are detectable abnormalities in cardiac proteins in patients with
cardiomyopathy (Kovalyov, 1990). Two-dimensional electrophoresis has been used in
association with electroelution to provide protein fractions for experiments of T cell
responses to mycobacterial antigens (Guile, 1990). Hence fractionation of human
myocardium could be performed and peripheral blood lymphocytes from patients with
and without alcoholic cardiomyopathy could be tested for proliferative responses
against different fractions. Initial experiments were performed in healthy control
subjects but consistent responses were not obtained and further experiments are
planned. This approach may also be useful in cardiac transplant recipients, as discussed
earlier. Thus a reliable method for obtaining fractions of human myocardium in solution








10. Isolation and Identification of Unknown Myocardial Proteins
10.1. The Problem
In the studies on lymphocyte culture from EMB it was observed that when
attempts were made to sub-culture positive cultures they died if the biopsy was not
present. Therefore the antigenic stimulus of the EMB itself was felt to be necessary. If
the specific proteins responsible for this antigenic stimulation could be isolated, further
experiments could be conducted to attempt to establish the cellular components most
effective at promoting proliferation of cells cultured from EMB. In addition, in studies
on patients with alcoholic cardiomyopathy, the T cell responses against the antigens
recognised by circulating anti-acetaldehyde adduct antibodies could be studied if a
similar technique for isolating the relevant proteins were available.
Human myocardium could be fractionated and the fractions tested for
differential effects on growth of T cells. It would be possible to narrow down the
identity of the molecules against which the T cell response is directed in these two
groups of patients. As previously discussed, a similar approach has been used by
Paque et al in their study of murine coxsackievirus myocarditis (Paque, 1979) and by
Guile et al in their study of T cell responses to mycobacteria (Guile, 1990).
A given band on an immunoblot may represent a single protein or a number of
proteins of similar molecular size. When antibody activity against a protein band is
observed on a blot it may thus be directed against one or more proteins. It is very
helpful to be able to isolate or purify the protein band in order that the protein identified
by antibody binding may be further characterized. If experiments, such as those
looking for circulating antibodies to acetaldehyde adducts of human heart, repeatedly
identify a protein band of a specific molecular size, or if it is thought that a protein band
is particularly significant, then it may be felt appropriate to attempt to identify the
protein represented by the band. This may be because the band is recognised by many
patient's sera, or because it is common to all blotting results in patients with particular
clinical features. Furthermore isolated proteins may be important in looking for antigen
specific T cell reactivity as considered in section 1, both to define specificity but also to
provide a source of antigen for specific T cell expansion.
The identification of the protein recognised by the patient's antibodies would
then be a necessary step in elucidating the nature of the disease process under study. In
the case of alcoholic cardiomyopathy the cellular target for antibodies raised against
acetaldehyde adducts would be of particular interest. A structural protein or a
myocardial enzyme as a target for such antibody activity would be an intriguing result.
Therefore the ability to isolate and identify positive bands observed on immunoblots
would be extremely useful.
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The subsequent isolation of proteins producing a positive band on Western
immunoblots is a large technical problem. Identification of the protein may be achieved
by N-terminal amino acid sequencing of the band in the solid phase using Edman
degradation in automatic peptide sequencers (Choli, 1990). Two main difficulties may
arise. As mentioned above, there may be other proteins co-migrating in the region of
the positive band, or the N-terminus may be "blocked" by sugar moieties which prevent
Edman degradation, the reaction central to microsequencing.
One solution to these problems is to perform limited proteolysis (Cleveland,
1977) producing peptide fragments which are not blocked (since their n-termini are
freshly formed). These are then run on a two-dimensional gel, separated by charge and
molecular size. The gel is blotted on to a membrane and probed with the relevant
serum. A positive spot on this membrane, if produced, is highly likely to be a non-
blocked specific peptide whose sequence might be successfully determined. Mass
spectroscopy using fast atom bombardment would be an even better, though more
expensive, approach for identification of these peptide residues.
Alternatively, if there is an available monoclonal antibody then high
performance liquid chromatography (HPLC) may be the answer, using a column to
which the antibody has been bound to extract the protein from solution in relatively
pure form. This may produce manageable quantities of protein in microgram amounts
but requires very large amounts of starting material (Kozuka, 1991). However,
sometimes chromatographic separation may not be achievable (Cooperman, 1986;
Kamp, 1988).
Therefore, where a positive band is found on a Western blot, there are a number
of strategies for attempting to identify the protein producing the reaction. In doing this,
a combination of the various approaches outlined above may be most fruitful, rather
than adherence solely to one method. In the current investigations, examination of
humoral and cellular responses to myocardial proteins was desired. The T-cell response
to a range of myocardial protein fractions would be of special interest, in the area of
rejection of cardiac transplants and in terms of responses to native myocardial protein in
alcoholic cardiomyopathy. Bands detected in immunoblotting experiments may
represent proteins whose amino-acid sequences may be capable of stimulating T cell
responses as well as antigen production by B cells. In order to identify these proteins
and to obtain them in manageable quantities for further experiments a method was
required which would allow the isolation of soluble protein fractions containing protein
that has been detected by antibody on Western blots.
One strategy would be to study EMB from patients with the relevant myocardial
disease (for example acute rejection of cardiac transplants). The aim being to culture T
cells from the biopsy and to detect humoral responses against blotted myocardial
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protein using serum. Once this was achieved fractions of myocardium would be tested
for ability to induce proliferation of T cells (both cultured and PBLs from the subject).
This would identify which components of the myocardium were stimulating T cell
responses. In parallel, the identification of positive bands detected on Western blotting
would be performed by n-terminal amino-acid sequencing.
In order to facilitate this process an electroelution device was designed which
would allow the isolation in soluble form of proteins that had been resolved by SDS-
PAGE. The method required that the resolution of electrophoresis be largely preserved
and that the protein fractions be in manageable quantities. A similar device has been
reported by Guile and co-workers who examined T-cell responses to mycobacterial
proteins eluted from two-dimensional electrophoresis gels (Guile, 1990). To test a
device designed for one-dimensional gels, and to confirm the feasibility of the overall
strategy, experiments were performed to isolate and partially purify a protein already
known to be present in human myocardium, the Endothelin receptor (Davenport,
1991).
10.2. Electroelution Device
The device which will be described was designed for use with sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), but it could be used with
almost any form of electrophoresis gel. SDS-PAGE is a very widely used method of
separating proteins by size. The quantitative recovery of proteins from such gels is an
important analytical and preparative technique.
A number of elution devices and methods have been described for recovering
protein from gels. These include electroelution into membrane traps from gel slices
(Jacobs, 1986), continuous electroelution during the running of gels (Ofverstedt,
1983), and diffusion out of homogenised gel slices (Bernabeu, 1977). However there
are important limits to the usefulness of these methods. Continuous electroelution
yields large recovery volumes which may then have to be concentrated, diffusion
methods apply to smaller proteins (less than 60kDa), and membrane trap devices are
often time consuming and require gels to be sliced into pieces. Unless the size of the
protein of interest is known, it is difficult to envisage using such devices to purify a
number of proteins from a gel for screening purposes.
Guile et al designed a device, mentioned above, which appears to overcome
these problems. This device was reported to electroelute proteins simultaneously and
rapidly from two-dimensional gels (Guile, 1990). It consists of a plate with a square
matrix of 480, 4mm diameter wells, which fits between the electrodes of a standard
semi-dry blotter. For the experiments in this thesis a variant of this device was designed
for one-dimensional gels by myself and Dr A.Persidis (Persidis, 1992).
129
The device consists of a plate with wells arranged in columns which correspond
to the lanes of protein bands on a one dimensional gel which has been run on a BioRad
IlXi 16cm gel apparatus. This plate is placed on to the positive electrode of a semi-dry
blotter and the wells are filled with buffer. The plate is screwed down on to a
polyacrylamide gel block lying on the electrode, which effectively seals the wells. The
gel of interest is placed on top of the plate such that the protein lanes lie along the
columns of wells. When the top negative electrode is placed on top of the gel to
complete assembly of the device, the applied current is normal to the gel surface and
forces the proteins to simultaneously migrate out of the gel and into the underlying
wells. A multichannel pipette can be used to harvest the well contents. Two tips fit into
each well across the columns and tips fit into alternate wells down the columns.
The recovery volume using this device is small (200jal per well), which
facilitates subsequent handling of the protein solutions. Elution time is minimal because
the proteins have only to migrate across the width of the gel (typically less than
1.5mm), instead of along a gel slice, before they are eluted.
In testing this device l4C labelled molecular weight markers were used to
demonstrate elution time course and recovery from an SDS-polyacrylamide gel. In
addition (3-galactosidase was run on a non-denaturing non-reducing gel and then eluted
using the device. The recovered solution was tested for enzymatic activity following
elution, to demonstrate that a biologically active enzyme could be obtained using this
method.
10.3. Endothelin Receptor Isolation
The requirement to isolate myocardial proteins has been discussed above. Such
proteins may be the antigens against which autoantibodies are raised in alcoholic
cardiomyopathy, for example. Alternatively they may be proteins which stimulate T cell
proliferation in acute rejection of cardiac transplants. The ability to isolate these proteins
for further studies would be highly advantageous.
Once the device described above had been built and tested it was used to
demonstrate that a protein whose location on a gel was initially unknown, in this case
the endothelin receptor, could be isolated. The endothelin receptor was chosen because
it is known to be present in human myocardium and because its ligands were easily
available in radiolabelled form. In order to isolate the endothelin receptor, a peptide-
protein "mobility shift assay" was developed using native polyacrylamide gel
electrophoresis. This enabled the isolation of non-denatured receptor proteins from
small amounts of human cardiac tissue. This work has been published (Persidis,
1993).
130
The endothelins are a related group of peptides which includes endothelin-1
(ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3). The snake venom sarafotoxin
S6b is structurally related. All three ET-isoforms bind to cardiac tissue (Davenport,
1991) and have been found to increase cardiac contractility and cause vasoconstriction
(Davenport, 1989). Indeed ET-1 is the most potent vasoconstrictor known. However,
the nature of the cardiac endothelin(ET) receptor(s) is largely unknown. The study of
the human ET receptor would therefore be greatly facilitated by a simple method for
receptor isolation from small quantities (milligrams) of cardiac tissue.
Conventional biochemical methods require large amounts (grams) of starting
material (Kozuka, 1991), whilst expression of cloned receptors in cell lines requires
knowledge of the receptor sequence and produces receptors which have not undergone
the same post-translational modifications as native receptors. Other techniques such as
ligand blotting used in studies on the acetylcholine receptor(Gershoni, 1983) and on
lipoprotein-binding proteins (Graham, 1987) do not permit recovery of solublised
receptor in non-denatured form. Al-Hakim and Linhardt (Al-Hakim, 1990) reported the
isolation of individual oligosaccharides following transfer from polyacrylamide gels
onto a nylon membrane. However this method was not tested on proteins and required
an additional step, namely the semi-dry transfer, before recovery could be effected by
elution.
10.4. Aim
The aim of these experiments was therefore:
1 . To design and test an efficient electroelution device.
2 . To use this method to isolate and purify a known myocardial protein in a
functional form. To illustrate this a protein known to be present in
myocardium (the endothelin receptor) was selected.
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11. Endothelin Receptor Isolation: Methods
11.1. Elution Device
The device used in these experiments was designed around a semi-dry blotter
with a central plate screwed down onto the bottom or positive electrode of the blotter.
The central plate was 6mm thick and had a grid of wells arranged in eight columns of
thirty-two wells per column. Each well was shaped as a flattened ellipse which
measured 4 x 15mm. There was a gap between the columns vertically of 0.5mm. The
gap between the wells in each column horizontally was 0.2mm. The blotter electrodes
measured 150 x 150mm. The rows were numbered, 1 to 32 and the columns
designated with a letter, A to H, in order to facilitate identification of individual eluted
fractions.
To assemble the device (fig.25) the bottom electrode was smeared with 20mm
Tris pH 8.0 (elution buffer). Two pieces of Whatman 3MM filter paper (Whatman
LabSales Ltd, Dorset,UK), wet in elution buffer and cut to the size of the electrode
were placed on it.
An identical sized 1mm thick polyacrylamide gel block (10%, in elution buffer
with no SDS), was placed on the filter paper. An identical sized piece of dialysis
membrane (Visking Dialysis tubing, Medicell International, Liverpool), equilibrated in
elution buffer, was placed on top of the gel block. The central plate was then screwed
down onto the membrane by means of threaded nuts on each side of the grid of wells.
The wells were then filled with approximately 2()()pl per well elution buffer, filled by
pouring from a beaker and then wiping off the excess. The gel of interest, previously
equilibrated for lOmin in elution buffer, was placed on top of the grid. The gel was
placed such that each track, identified by the loading well ears, lay above a column of
underlying wells. The dimensions of the grid of wells were chosen such that a whole
gel prepared using a standard comb with one centimetre wide wells would fit almost
perfectly aligned with the underlying wells.
On top of the gel were placed another two sheets of Whatman filter paper
soaked in elution buffer. The top electrode was then sealed down onto this sandwich.
The device was leak free since the underlying dialysis membrane and gel block
effectively prevented cross-contamination between wells. Five to fifteen volts were
applied across the electrodes, corresponding to approximately 50-400mA, depending
on the area, thickness and density of the gel. After elution the top electrode and gel
were removed and the contents of the wells aspirated using a multi-channel pipette
(Flow Laboratories, Bucks, UK). The grid of wells was designed so that the tips of
this pipette fit into alternate wells when sampled down the column and two tips into
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each well when sampled across the columns. The contents of the wells were transferred
to microtitre wells prior to scintillation counting.
Figure 25. Electroelution - Arrangement of Gel on Device
This figure is a diagrammatical representation of the assembly of the elution device. It shows the
important elements and the order in which they are placed on the device. Each element is labelled on the
left hand side and the text explains their function.
Top Electrode (-ve)
Filter Paper x 2
Gel - - i -■
Central Plate
Dialysis Membrane ~~~ *~™ __
and dummy gel
Filter Paper x 2
Bottom Electrode (+ve)
11.2. Native PAGE
(3-galactosidase (Grade VI, from Escherichia Coli; Sigma Chemical Company
Ltd, Dorset, UK) was prepared as a stock solution in 20mM Tris/HCl pH 7.3.
Amounts ranging from 1 to 30|ig were diluted in equal volumes of double strength
native sample buffer (20% glycerol, 0.01% bromophenol blue, 0.1M Tris/HCl pH
7.3). Non-denaturing non-reducing PAGE was performed using 10% resolving gels.
These were eluted for 30 minutes at 5V. A track containing 3()|ig of the enzyme was
sliced prior to elution of the remaining gel, fixed and stained (50% methanol, 10%
acetic acid, 0.1% Coomassie brilliant blue) and then destained (10%methanol, 10%
acetic acid) to locate the protein band so that the appropriate well contents could be
assayed. The enzyme substrate (o-nitrophenyl-p-galactopyranoside, Sigma) was
prepared at 4mg/ml in sodium phosphate buffer, pH 7.0 containing lOmmKCl,
ImMMgSO/t, 5()mM 2-mercaptoethanol (assay buffer); lOOpl of the substrate was
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added to 2()0|ll of the eluted enzyme and incubated at 37°C for 1 hour prior to
measurement of the absorbance at 414nm. Controls included the same enzyme amounts
prepared in native sample buffer without dye.
11.3. SDS-PAGE
One-dimensional SDS-PAGE was performed as previously described
(Laemmli, 1970), with 5% stacking gels and 10% resolving gels. 14C-methylated
molecular weight markers (Amersham, Bucks, UK) ranging from 200 to 14.3kDa,
were loaded at lOnCi per track. The tracks were sliced and eluted at 5-15V for different
time periods after which they were fixed in 50% methanol, 10% acetic acid, amplified
(Amplify, Amersham), dried and exposed against Fuji X-Ray film for periods up to 3
days. The marker bands on the autoradiographs were quantified as described
(Davenport, 1988), using a Cambridge Instruments Quantimet 970 Image Analyser.
11.4. Extract Production
Human atria (from the explanted hearts of cardiac transplant recipients, stored at
-70°C) were homogenised in ice cold buffer (50mM Tris/HCl, 5mM MgCl, 5mM
EDTA, ImM EGTA pH 7.5 supplemented with 250|ll/100mls aprotinin). After
filtering, washing and centrifugation at 30,000g, extract pellets were suspended in
Hepes buffer (50mM Hepes, 5mM MgCl, pH 8.0) and stored at -70()C. Thawed extract
was solublised (150 |ig per gel lane) with CHAPS in the presence of lmg/ml BSA as
described before (Nakajo, 1989) at 4()C for thirty minutes. After centrifugation the
pellet was discarded, the supernatant being the partially purified extract.
11.5. Electrophoresis
The ET and S6b peptides were labelled with 125iodine (specific activity 2,200
Ci/mmol; Amersham International pic, Amersham, Bucks, UK). Radiolabelled peptides
(4xlO"10M final concentration) and a structurally unrelated unlabelled 18-amino-acid
peptide (100pg/ml final, kind gift from Dr S. Graham) were incubated with partially
purified extract at room temperature for 30 minutes, in the presence or absence of the
relevant unlabelled ET or S6b peptides (10 to lOOOnM; Novabiochem, Nottingham,
UK). The unrelated 18 amino-acid peptide was present to reduce non-specific
interactions. The range of concentrations of unlabelled ET/S6b peptides was chosen to
include up to a 1000-fold excess over the Kd, sufficient to block the receptor. In
control samples extract was excluded from the incubation mixture. The solutions were
run on native electrophoresis gels (5% polyacrylamide in TBE buffer: 0.09 M Tris,
0.09 M Boric acid, 10 mM EDTA, pH 8.0) for 4 hours at 25mA. Gels were fixed
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(10% methanol, 10% acetic acid), dried and exposed to Fuji RX X-ray film (Genetic
Research Instrumentation Ltd., Dunmow, Essex, UK) at -70°C for periods ranging
from 16 hours to 7 days.
11.6. Antibody Production
A polyclonal antibody was raised in rabbits against a peptide derived from the
predicted C-terminal sequence of the cloned human ETb receptor (Sakamoto, 1991)
(kind gift of Dr A.P.Davenport, Clinical Pharmacology Unit, Addenbrookes Hospital,
Cambridge). The sequence chosen does not show sequence similarity with any other
known peptide sequence on the Swiss-Prot database. An ELISA test (performed in the
Clinical Pharmacology Unit, Addenbrookes Hospital, Cambridge, by Dr C.Plumpton)
using the peptide antigen to which the antibody was raised showed the ETb antibody to
be sensitive and specific.
11.7. Electroelution
For electroelution of putative l25I-ET/receptor complexes from native gels the
method described above was used. The method has also been published previously
(Persidis, 1992). The elution buffer (20 mM Tris/HCl, pH 8.0) used also contained
0.4% CHAPS. To dissociate the ET-l/receptor complex it was incubated in high salt
(0.5M NaCl) for 30 minutes.
After dissociation the solution was sub jected to four cycles of ultrafiltration by
centrifugation through Centricon-10 ultrafiltration devices (Amicon Ltd., Stonehouse,
Glos., UK) according to the manufacturer's instructions. These devices are small
containers which contain a filter or membrane with a known molecular weight cut-off.
They are designed for use in a centrifuge. On spinning the tubes, solutions placed in
them can be filtered. The resulting solution, which has not passed through the filter is
called the retentate. The solution which does pass through is the filtrate. It depends on
the nature of the experiment whether the retentate or the filtrate or both are of interest.
In these experiments the membrane cut-off was lOkDa and hence it was the
retentate, which did not pass through the membrane, which contained the putative
endothelin receptors. This was designated receptor eluate (RE). No radioactivity was
detected in this retentate, demonstrating that effective dissociation had occurred, the
radiolabelled ET-1 having passed through the Centricon-10 membrane. Control eluate
(CE) was obtained by elution from an irrelevant portion of the gel, producing a solution
of concentration 32.8p.g/ml. Estimations of protein concentration of atrial membrane
preparation, enriched receptor preparation and control eluate were performed using the
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BioRad protein assay kit according to the manufacturers instructions (BioRad UK,
Hemel Hemspstead, Herts, UK).
11.8. Immunobinding
The retentates from the RE and CE preparations were applied to nitrocellulose
filters (Schleiser and Schuell, Anderman & Co. Ltd, Kingston, Surrey), along with
elution buffer (EB), which were then blocked with 5% dried milk (Marvel) in Tris
buffered saline (TBS: 50 mM Tris/HCl, pH 7.4, 200 rnM NaCl). Antisera (1:100)
were added in blocking buffer with 0.1% Tween-20, the secondary antibody (1:500)
was alkaline phosphatase conjugated goat anti-rabbit immunoglobulins (DAKO, High
Wycombe, Bucks, UK) with BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitro
blue tetrazolium, SIGMA) as substrate.
11.9. Saturation Analysis
Fixed quantities of atrial extract (75jig) were solublised and incubated with
I I-labelled ET-l in concentrations ranging from 0.1 to 3nM as described above.
Extracts were run on native gels and autoradiography was carried out as described
above, with the addition of a calibrated radioactive scale to the cassette. Densitometry
was performed using a Quantimet 970 image analyser (Cambridge Instruments,
Cambridge, UK). Details relating to quantitative autoradiography have been described
previously (Davenport, 1988). The specific band was measured using a sample box
placed around each band. Values obtained fell within the linear range for quantitative
radiography and the film was not saturated at the highest concentration of ET-l. Curves
of optical density against final concentration were plotted and the equilibrium constant
for ET-l binding to the endothelin receptor in this system was determined using an
iterative curve fitting program (Munson, 1980).
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12. Results: Endothelin Receptor Isolation
12.1. Electroelution
The device described was used to demonstrate that a range of cardiac proteins
could be electro-eluted. Various experiments were performed in testing the device. Only
a few of the resulting gels are shown.
Figure 26. Human Right Ventricle - Before and After Elution
This figure shows the result of an experiment where human right ventricle was homogenised
mechanically in SDS-PAGE sample buffer and then run on 10% SDS-PAGE. The gel was sliced at the
left hand side. The right hand portion of the gel was eluted using the device and the left hand portion
was not. After elution was finished both the portions of gel were stained with Coomassie blue. The
lanes of the central plate from the device can be seen where protein has not been eluted. Some protein
has remained on the gel in the middle of a lane. 'This is ascribed to air bubbles, an early problem with
these experiments before their influence was abolished by more careful preparation.
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Figure 27. Eluted Human Right Ventricular Microsomal Fraction.
This figure shows two identical gels of human right ventricular microsomal fraction, prepared in an
identical fashion to human left ventricular microsomal fraction as detailed in chapter 7. The fractions
were treated with nothing, acelaldehyde alone, cyunoborohydride alone or both acetaldehyde and
cyanoborohydride, producing samples 1 to 4, as detailed before. 'The preparations were run in two sets
offour lanes on a 6% SDS-PAGE gel and then elulcd using the device. The non-eluted gel, on the left,
was prepared with a set ofmolecular weight standardsfor comparison (lane at far left). It can be seen
that cleaner elation results have now been obtained than with the early elution in fig.26. Also note that
the 200kDa band is eluted to a lesser degree than the other proteins on the gel. This is discussed in
more detail later.
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Figure 28. Silver Stain of Selected Eluted Fractions.
1 his is a photograph of a silver stained 10% SDS-PAGE gel. The gel was produced by taking different
fractions eluted from the gel in fig. 27 and running them on another 10% SDS-PAGE gel. The
concentration of protein in the individual wells does not allow Coomassie staining to be effective,
suggesting that sub-microgram amounts are present. It can be seen that preferential elution of different
fractions has been achieved. However, also visible are bands of some proteins which have cross
contaminated the wells. The fractions selected were from wells numbered 1, 5, 10, 15 and 20.




12.2. Elution of Radiolabeled Proteins
In order to gain some insight into the performance of the device with regard to
the length of time different proteins would take to be eluted, radiolabeled proteins were
resolved on lnini thick gels and eluted for various time periods as shown below (fig.
29).
Figure 29. Elution Time Course - Radiolabeled Markers.
This is a photograph of an autoradiogram of elated and non-eluted ^C-labelled molecular weight
marker proteins. The electrophoresis is described in the methods section. The applied voltage for
elution was 5V, current 40mA. The molecular size in IcDa is given at the left hand edge of the picture.
The lanes are numbered 1 to 4 representing lime of elulion: 0,15, 30 and 60 minutes respectively. At
the end of each lime point, an aliquot from each of the wells underlying a gel strip was measured for
radioactivity, while the corresponding gel strip was removed from the device and processed for
autoradiography. It can be seen that within I5min the intensity of some bands has diminished and by
30min extensive elulion has occurred.
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The time course of elution is illustrated in more detail (table 23), which shows
the results of densitometric measurements made on serial autoradiograms of the six
marker bands, at different time points. The table shows additional data to those
represented in the photograph in figure 29.
Table 23. Elution Time Course of Radiolabelled Proteins
This table shows the measurements of optical density made on autoradiograms of the gel strips
produced in the time course experiment using radiolabelled markers. The first column shows the actual
optical density measurement but the other columns show a percentage of the measurement at lime zero.
It can be seen that after 15min the 97.4kDa protein was eluted by about 40% whereas none of the other
proteins were eluted to any significant degree. By 30min elulion was complete for the 30kDa protein
and by 90% or better for the 46. 69 and 97.4 kDa proteins. The 200kDa protein took 120min to be
eluted by 80%, this was reduced to 60min when elulion was carried out at 15V. Increasing the voltage
also caused the other proteins to be eluted by 90% or better within 15min.
Non-eluted Eluted markers
0 Dabs (%ODabs remaining on
14C Markers (kDa) autoradiogram)
0 min 15 min 30 min 60 min
(Gel Lane:) (1) (2) (3) (4)
Myosin
(200)
0.655 100 95 93
Phosphorylase b
(97.4)
0.7 l l 62 11 10
Bovine serum albumin
(69)
0.787 95 14 8
Ovalbumin
(46)
0.818 0 6 0
Carbonic Anhydrase
(30)
0.847 86 0 0
Lysozyme
(14.3)
0.81 1 100 59 5
To confirm that the proteins had indeed been collected in the wells, lOpl
aliquots were taken and the amount of radioactivity in each well was plotted against
well number for the different time periods of elution. This is shown as an area graph in
fig.30.
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Figure 30. Area Graph of Protein Recovery after Elution
An aliquot was taken from each well (numbered 1 to 18) under each gel strip following elution for the
time periods shown. Radioactivity for each well number, measured by liquid scintillation counting, is
plottedfor each of three time periods. The. peaks correspond to protein bands elutedfrom the gel and are
labelled accordingly (14.3 to 200 kDa, see fig.y). There are two peaks for the 14.3 kDa band at the
60min time period because the gel may have changed size due to absorbance of buffer solution.




The autoradiograph of the non-eluted proteins (lane 1 fig.29) shows bands that
directly correlate with the well numbers showing high counts, as shown in fig.30.
Peaks are clearly identifiable, demonstrating the resolution of the wells. The peaks
usually straddle one or more wells and the background count is also significant.
However, examination of lane 1 in fig.29 shows that there are more bands than the six
proteins of the cocktail, this being due to impurities and protein breakdown upon
boiling in sample buffer. However, all bands are simultaneously eluted giving rise to a
high background of radioactivity in all wells and reducing the sharpness of the peaks
corresponding to the actual marker proteins. No radioactivity was detected on the
dialysis membrane after elution and aspiration of the well contents, indicating that










12.3. Elution of Active Enzyme
As additional evidence of the existence in the well eluate of the protein run on
the gel, (3-galactosidase was run on a native non-denaturing non-reducing gel (details in
methods) and was subsequently eluted at 5V (40mA) for 45 min. The enzymatic
activity of an aliquot of the eluate from the corresponding well was compared to that of
an appropriate non-eluted standard. The standard (3()pig) gave an OD414 of 0.482 and
the eluate (30|4g loaded on to the gel) OD414 was 0.505, indicating that active enzyme
was obtained after elution.
In another experiment, ().8mcg of (3-galactosidase was run on a non-denaturing
non-reducing gel and samples taken from around the row where the band was to
determine the scatter of protein which had diffused sideways (table 24). Wells from
further away from the target well did have detectable (3-galactosidase according to the
OD414 values but this did not usually extend beyond three wells from the target well.
Table 24. OD414 of Samples from Wells Around the Target Well
of Eluted [3-galactosidase
[i-galactosidase was run on a non-denaturing gel in a concentration of O.Smcg. The well directly
overlying the hand was tested for enzymatic activity as were the wells on either side. The results are
shown both as the obtained OD value and as a percentage of the value obtained in the target well. From
the table it can be seen that perhaps half or more of the electrophoresed protein diffuses into adjacent
wells.
Well OD414 OD414 as % of
Target Well OD
Above 0.247 47
Target Well 0.521 100
Below 0.251 48
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12.4. Mobility Shift Assays of Endothelin Receptor and Peptides
These experiments involved running extracts of human atrium on SDS-PAGE
after incubation with radiolabeled ligands for endothelin receptors. The gels were dried
down and autoradiograms produced after exposure of the gels to X-Ray film for
various time periods. The autoradiograms produced usually consisted of lanes where
no extract was added as a control to show what pattern the radiolabeled ligand
produced simply running in the gel alone. There were also various lanes where un-
labelled (or "cold") ligand, corresponding to the radiolabelled-ligand in use, was added
in increasing amounts to compete out the binding of the radiolabelled-ligand to the
endothelin receptor. This competition by cold ligand is suggestive of a specific
interaction.
This pattern of lanes is followed for most of the autoradiograms shown below.
Figures 31a to 3Id show mobility shift assays with ET-1,-2,-3 and S6b. The
autoradiograms show that radiolabelled ET-1, ET-2 and S6b all migrated to similar
positions on different gels, but ET-3 was less mobile. Addition of membrane extract
caused a retardation of the mobility of each radiolabelled peptide, suggesting a peptide-
receptor interaction (Fig.31 a-d,arrows). The addition of increasing quantities of the
corresponding unlabelled peptide resulted in a reduction in intensity of this band and its
eventual abolition (Fig.31 a-d).
Membrane extract was incubated with l-^l-labelled ET-1, ET-2, ET-3 and S6b
in the presence or absence of lOOOnM unlabelled peptide and run on the same non-
denaturing gel for comparison. ET-1 and ET-2 behaved in a similar manner, with the
ET-receptor complex band appearing in the same position on the gel for each. The
complex band appeared in a similar position with S6b, although the interaction was
weaker and to visualise this band gels required to be exposed to X-ray film for longer.
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Figure 31a. Mobility Shift Assay with ET1
The autoradiog rain was produced in a mobility shift assay using human atrial extract and Ell, both
radiolabeled and unlabelled. The lanes represent the different substances added to the incubation mix, as
listed below. The origin of the gel is at the top of the figure. Insoluble material which complexes with
the radiolabeled ligand is seen at the top of the gel. In this case, this supposedly non-specific
interaction is reduced by addition of cold competitor. Radiolabeled E'T-1 is retarded in the presence of
extract to a position representing the E'l'-l/receptor complex (arrow). Competition with unlabeled ET-
1 eventually abolishes this specific band. The regions between the dashed and dotted lines were
selectively elcctroeluted to provide receptor and control material respectively (see Fig. 35). The presence
or absence of extract is indicated by the plus or minus signs (respectively) in the first row under the
photograph. 'The concentration of cold E'Tl in the incubation mixture is given in nanomoles (nM) in
the second row. The effect of addition of a reducing agent (2-mercapto-ethanol, right half offigure) is
shown and the presence or absence of this substance is indicated in the third row with a plus or minus
sign. 'The reducing agent alters the migration of the ligand alone such that it extends from the origin
into the gel as well as occupying its' previous position in the gel. 'There appear to be bands in the area
of the specific complex band but these are little affected by increasing amounts of cold E'Tl and are not
inlerprelable.
Extract - + + + + - + + + +
ET-1 (nM) o o 10 iooiooo o o io 100 1000
BME _____ + + + + +
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Figure 31b. Mobility Shift Assay with ET2
In this photograph the autoradiogram was produced by mobility shift experiments using El-2 as the
radiolabelled ligand. All oilier aspects of the experiment were the same as for fig.3 la. Again insoluble
material marks the origin of the gel at the top of the picture. The arrow indicates the position of a
specific complex band, which is eventually abolished with increasing unlabelled ET2. The addition of
the reducing agent produces non-specific bands which are uninlerpretable.
Extract - + + + + - + + + +
ET-2 (nM) o o 10 too iooo o o to ioo 1000
BME ---- - + + + + +
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Figure 31c. Mobility Shift Assay with ET3
In this figure an auloradiogram produced by mobility shift assay with E'l'3 is shown. The experiment
was identical in all important respects to that represented in fig.31 a.The E'T3 ligand does riot migrate so
far into the gel. Insoluble material in association with radiolabeled ligand is seen at the origin. The
arrow indicates the position of the specific complex band, which is eventually abolished with
increasing respective untabelled E'l'3. Note that the insoluble materials' interaction with labelled ET3 is














Figure 31d. Mobility Shift Assay with S6b
In this figure an autoradiogram produced by mobility shift assay with S6b is shown. The experiment
was identical in all important respects to that represented in fig. 31a. The arrow indicates the position
of the specific complex band, which is much fainter in this autoradiogram. The autoradiogram was
exposed for four days in order to show the band at all, illustrating the weaker interaction that S6b has
with the endothelin receptor, l'lic specific band is quickly abolished by the addition of unlabelled S6b.
The addition of the reducing agent makes interpretation difficult, as before.
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The above figures represent the results of individual experiments using the 125I-
lablelled ET-1, 2 and 3 and S6b ligands. In order to demonstrate the relationship
between these ligands and to show the interactions together for comparison, an
experiment using all four ligands together on the same gel was performed (fig. 32,
below).
Figure 32. Mobility shift of ET-1, ET-2, ET-3 and S6b
The auloradiogram shows all four peptides incubated in the presence or absence of extract and in the
presence or absence of IGOOnM unlabellcd peptide run on the same gel. Lanes 1,4,7 and 10 are labelled
ET-1 ,-2,-3 and S6b alone respectively; lanes 2,5,8 and 11 are the respective labelled peptides with
partially purified extract and lanes 3,6,9 and. 12 are the relevant labelled peptides with extract and the
corresponding unlabelled peptide in excess. The appearances of the other peptides on this gel are
different from those shown in fig.31 because the gel here was exposed for much longer with the X-Ray
film in order to try to show the. complex bandfor S6b.
ET-1 ET-2 ET-3 S6b
Extract — + + — + + — + + — + +
Competitor(nM) o o 1000 o o iooo o o 1000 o o iooo
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12.5. Saturation Analysis
To determine the binding characteristics of the putative receptor, increasing
amounts of labelled ET-1 were incubated with a fixed quantity of extract in mobility
shift assays (fig.33). Specific binding was saturable with an equilibrium dissociation
constant (Kq) of 2nM calculated by an iterative curve fitting program (Munson, 1980).
Since the protein concentration in individual bands was not known, Bmax could not be
calculated.
Figure 33. Saturation Binding of 125I-ET1 to Human Atrium
This experiment was conducted in a similar fashion to that illustrated in fig.3 la. The autoradiogram
shown in the photograph has six lanes which are each the equivalent of lane 2 infig3la (and fig.32)
except that increasing concentrations of labelled ETI were added to the incubation mixture. A serial
increase in density and eventual saturation of the specific complex band occurs. Human atrial extract
(75/J.g/lane) was incubated with increasing concentrations of ET-1 from 0.1 to 3nWl (lanes 1-6) prior to
electrophoresis as for fig.31 a. Optical density of the. complex band was measured, using a Cambridge
Instruments Ouantimet 970 image analyser on autoradiograms exposed for periods from three to ten
days. Radioactive standards were exposed simultaneously for calibration purposes.
a
125l-ET1(nm) 0.1 0.2 0.5 12 3
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Figure 34. Graph of Saturation Binding
This graph is a plot of absolute optical density (OD) of the specific complex band, shown in fig.33,
j n c
against concentration of 1-labelled Ei'-l. Data shown are single measurements from an experiment
typical of the results obtained. A rectangular hyperbola is produced suggesting a one-to-one receptor-
ligand correspondence. The equilibrium dissociation constant (Kd) was calculated as 2 nM using an
iterative curve fitting program. Note that the calculated value is markedly different to that which would
be ascertained from direct observation of the curve. This reflects the well recognised difficulties of
obtaining these figures using graphical methods.
nM ET-1
12.6. Receptor Elution
Receptor-enriched material was prepared by electrocution of the complex band.
The components of the complexes were dissociated and the receptor fraction separated
and concentrated. The radiolabeled peptide, being of low molecular weight, passes
through the membrane chosen whereas the larger receptor protein is retained. Antibody
raised against the ETb receptor was used to identify the eluted, dissociated and
concentrated receptor preparation. Dot blots of the concentrated receptor eluate probed
with the antibody revealed the presence of immunoreactive protein (fig.35). The initial
amount of starting material was 3mg and from this approximately 30|ig of receptor-
enriched eluate was obtained.
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Figure 35. Dot-immunobinding of electroeluted ET receptor
This photograph shows blots produced after dot-immunobinding analysis of eleclroeluted and
dissociated ET receptor with anti-El's receptor antibody. Receptor eluale (RE) was obtained from
between the dashed lines and control eluale (CE) from between the dotted lines on the gel in Fig.31a by
eleclroelulion as described under methods. Both immune and pre-immune sera were tested as shown,
with RE, CE and also elution buffer (EB). Only immune sera gave a positive result with RE material
but not with CE or EB. The three RE preparations shown were each made in separate experiments.
RE RE CE RE EB




13. Endothelin Receptor Isolation - Discussion
These studies demonstrated that efficient electroelution of a range of proteins
was possible. Experiments confirmed that the use of non-reducing gels would allow the
recovery of enzymes which retained their function. In addition a specific functional
myocardial protein was eluted and shown to be present in the eluate by dot
immunobinding assays.
13.1. Electroelution
The device described is effective at eluting a range of proteins initially resolved
by SDS-PAGE. Most proteins can be eluted rapidly from a gel, but higher molecular
weight proteins take longer. This might be predicted from first principles and is also the
case in Western blotting. The time course experiment demonstrated that there is
differential elution of proteins but that recovery of proteins from the gel is quantitative.
Therefore the ability of the device to function as planned was confirmed.
This device is not confined to use with proteins alone however and the range of
substances that could be eluted is large. Among the other macromolecules that can be
electroeluted are nucleic acids(Symons, 1988) and oligosaccharides(Al-Hakim, 1990).
Importantly, biologically active protein can be recovered, as demonstrated for p-
galactosidase.
One of the potential problems encountered with electroelution following SDS-
PAGE is the presence of SDS and denatured protein in the eluate. It is possible to
remove SDS efficiently, together with low protein losses, by ice-cold acetone
precipitation (Hager, 1990). During renaturation the presence of detergents can improve
yields of active proteins (Tandon, 1986; Tandon, 1988) although renaturation must be
adapted to each protein in question (Schultes, 1990). In these experiments this was not
addressed.
13.2. Endothelin Receptor Isolation
In the experiments described above, radiolabelled endothelin-1 and related
peptides were used to identify and isolate endothelin receptors from partially purified
membrane extracts of human atrial tissue. Binding analysis using radiolabelled
endothelin-1 gave a Kt-j of 2nM, similar to results from binding experiments conducted
directly on tissue. Peptide-receptor complexes were electroeluted from native gels and
dissociated. Receptor material was characterised by dot-immunobinding analysis of
eluates using an antibody raised against a predicted human endothelin receptor
sequence. This method therefore allows simple isolation of peptide receptors from
small quantities of human material. The technique could be applied to receptors which
have not been cloned. It could be applied to any protein for which a suitable ligand,
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including an antibody, is available. All that is required is a means of locating the protein
on the gel and it can be eluted on a preparative scale, limited only by the loading
characteristics of the SDS PAGE gel used. In the experiments described it was possible
to obtain milligram quantities of total eluate from 20 wells of crude extract.
The figures show that the use of native gels leads to more diffuse banding
patterns on the autoradiograms than are usually seen on gels run under denaturing
conditions, but specific bands are clearly identifiable. In these experiments, labelled
peptide was retarded in the presence of extract, suggesting the formation of a
peptide/receptor complex, for each of the four peptides studied. These experiments
were repeated with partially purified extract from several patients to be sure that the
findings were not peculiar to any one subject.
Differences in primary structure among the ET peptides were reflected in their
different electrophoretic mobilities when compared on the same gel (Fig.32). In
particular ET-3 was less mobile than the other peptides in these gels. This was not
unexpected since the amino-acid sequence for ET-3 is significantly different from the
other ET peptides (Inoue, 1989). However, variations in mobility might also result
from the labelling of each peptide with '-•''Iodine.
Saturation binding experiments suggested the presence of a specific ET-receptor
in the position of the band arrowed in Figures 1 and 2. The of 2nM obtained in
these experiments compares favourably with a Kd of 0.787nM calculated by Dr AP
Davenport and Dr P Molenaar (Clinical Pharmacology Unit, Addenbrookes Hospital,
Cambridge) from conventional saturation binding experiments using 125I-labelled ET-1
and adult human right atrium. It also compares with 0.64 nM, the concentration of
unlabelled ET-1 required to reduce the binding of labelled ET-1 by 50%, obtained from
radioligand competition binding studies on human fetal right atrium (Wharton, 1991).
In another study, the concentration required to produce 50% of the maximal positive
inotropic action of ET-1 on human right atrium was 2 nM (Davenport, 1989).
Equilibrium data obtained in this study are therefore comparable with data obtained by
saturation and competition studies and are closely similar to those estimated from
physiological responses.
Immunoblotting also confirmed the presence of ET receptors in the complex
band. Therefore this technique provides a simple and quick way of isolating receptors.
The quantities of receptor isolated would enable the raising of antibodies, the partial
sequencing of the protein and potentially X-ray crystallography. However, since the
receptors are not present in pure form, further purification procedures may be required
prior to other studies.
These studies demonstrate that gel electrophoresis followed by electroelution
can be used to obtain target proteins from human myocardium. These may be receptors
or functional enzymes. Where more information is available, for example the relative
molecular mass, such experiments would be more straightforward. Therefore, where a
particular myocardial protein is targeted for study in the future, this approach could aid
in its isolation and identification. When dealing with a band on an immunoblot for
example, it would not be difficult to elute the equivalent protein from a preparative gel
in order to facilitate further studies.
One potential problem involves the diffusion of target proteins into adjacent
wells on the elutor. This may not be a problem where only a few proteins, well
separated by SDS-PAGE, are present on the gel. However, in human myocardium
there is a large number of proteins which all lie very closely. A number of solutions to
this problem are possible. A larger gel could be run, allowing the dye front to migrate
further and producing better resolution. A gradient gel could be employed or
alternatively two-dimensional electrophoresis, again to better separate individual
proteins. A technical solution to the problem would be to produce an elution plate with
a bonded membrane rather than a free dialysis membrane cut to size. This would have
the advantage of being watertight and would allow no leakage of the contents of the
wells and less cross-over from one well to another. Presumably this would not
completely eliminate diffusion since some of the sideways movement may be taking
place within the gel itself if the electric field is not uniformly applied.
13.3. Protein Isolation, Alcoholic Cardiomyopathy and Acute
Rejection of Cardiac Transplants
The relationship between the above studies and those concerning acute rejection
of human cardiac transplants and the presence of circulating antibodies against
acetaldehdye adducts in alcoholic cardiomyopathy lies in the ability to separate
manageable quantities of protein. In order to identify the components of human
myocardium against which T cell responses are directed in rejection it is necessary to
have some means of isolating the relative proteins. Similarly B cell responses, in the
form of circulating antibodies in patients with alcoholic cardiomyopathy, are directed
against proteins whose isolation is of crucial importance in defining the role of antibody
responses in this disease. Separation by molecular size is an obvious choice for initial
resolution and the use of electroelution could readily provide protein fractions for
testing with subjects T cells, whether they be cultured from EMB or from peripheral
blood.
The use of electroelution could therefore be applied to either situation. The
study of patients with alcoholic cardiomyopathy would be greatly aided by the ability to
rapidly isolate proteins recognised by antibodies in patients sera. It is not known what
components of the myocardium are dysfunctional in this condition and the ability to
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identify proteins targeted by antibody responses would be a significant advance. It is
assumed that since systolic dysfunction is a key clinical feature of this condition that
structural proteins involved in myocardial contractility are damaged by alcohol, or its
metabolites. However, it may be possible to show, using these methods, that a
myocardial cytosolic enzyme or other protein, is the main target of the damage caused
by alcohol, and that this damage occurs indirectly.
Hence, in either area of study, the ability to isolate proteins, known or
unknown, from protein mixtures resolved on SDS-PAGE, would be of great assistance
in further studies.
156
14. Final Conclusions and The Future
These studies demonstrated efficient culture of T lymphocytes from EMB from
cardiac transplant recipients. The ability to culture lymphocytes relates to clinically
significant rejection when medium with IL-2 alone, or lL-2 supplemented with PHA,
was used, but not medium supplemented with anti-CD3. It was not possible to predict
subsequent rejection. More cultures were obtained in the presence of 2 HLA DR mis¬
matches compared with one or no mis-matches. Positive cultures would most easily be
obtained from EMB with acute rejection where 2 HLA DR mis-matches between donor
and recipient were present. Biopsies should be cultured in Il-2 alone. PHA supplements
could be used to produce larger cell numbers due to its polyclonal activating effect,
whilst retaining a correlation with rejection. The ability to culture T cells from EMB
more efficiently might be enhanced if specific myocardial proteins involved in
stimulating proliferation could be isolated. The electroelution studies demonstrated that
efficient electroelution of a range of proteins was possible. The recovery of functionally
intact enzymes was shown and the ETgR was successfully eluted. This suggests that
this approach may be feasible and there are previous studies which have employed
similar methods.
The study of patients with alcoholic cardiomyopathy demonstrated circulating
antibodies that recognise acetaldehyde-modified normal human cardiac protein in 4 of
14 (28%) patients. Antibodies were mainly IgG, but IgA and IgM antibodies were also
found. The antigens recognised by these antibodies were in the range 58-120 kDa. All
the appropriate control populations were negative for these antibodies and thus this is
not a sensitive but a highly specific test for alcoholic cardiomyopathy. The mechanism
by which the myocardium might be damaged in this disorder is not clear but
possibilities include antibody mediated damage or soluble factors secreted by activated
T cells. The antigens against which the immune response is directed are not known.
Identification of these using fractionated human myocardium may be possible in a
similar way to that proposed for the study of lymphocyte culture from EMB.
The use of electroelution could therefore be applied to either situation. The
study of patients with alcoholic cardiomyopathy would be greatly aided by the ability to
rapidly isolate proteins recognised by antibodies in patients sera. It is not known what
components of the myocardium are dysfunctional in this condition and the ability to
identify proteins targeted by antibody responses would be a significant advance. It is
assumed that since systolic dysfunction is a key clinical feature of this condition that
structural proteins involved in myocardial contractility are damaged by alcohol, or its
metabolites. However, it may be possible to show, using these methods, that a
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myocardial cytosolic enzyme or other protein, is the main target of the damage caused
by alcohol, and that this damage occurs indirectly.
Hence, in either area of study, the ability to isolate proteins, known or
unknown, from protein mixtures resolved on SDS-PAGE, would be of great
assistance in further studies.
14.1. Endomyocardial Biopsy
The initial experiments re-iterated previous findings, namely that it is possible to
obtain proliferating lymphocytes from small biopsy fragments of the transplanted heart.
It was not found that the ability to grow lymphocytes correlates very closely with
cellular rejection in contrast with previous studies. This technique therefore has more to
offer in terms of providing cells with which to perform functional studies than for
diagnostic purposes. In the future such a technique will prove highly useful in the study
of inflammatory conditions of the heart such as acute myocarditis. In addition cultured
lymphocytes obtained in this way could be tested for their proliferative response when a
target protein for cellular rejection is identified, which may help to predict patients at
high risk of developing rejection.
14.2. Alcoholic Cardiomyopathy
These studies are the first reported which are able to propose a mechanism
whereby alcoholic cardiomyopathy may be produced. They are based on similar studies
of alcoholic liver disease but produced different findings. In alcoholic cardiomyopathy
there is no single protein antigen detected but a pattern peculiar to each patient. This will
make it harder to elucidate the nature of the processes involved.
In the future these studies will be extended to include a prospective study,
which is in fact now in progress.
The identification of the antigens involved is crucial and this will be done using
two-dimensional electrophoresis and n-terminal amino-acid sequencing, with the help
of staff at the Microchemical Facility, AFRC Institute for Animal Physiology,
Babraham, Cambridge. These studies are also in progress.
Part of the study now underway is directed at identifying the presence of the
putative antigens in the tissues of subjects with alcoholic cardiomyopathy. This is
possible using endomyocardial biopsy tissue from the subjects which is then treated in
a similar fashion to the stock heart used in the above experiments. It is then blotted and
the blots reacted with both the subjects serum and a polyclonal antibody to acetaldehyde
adducts, provided by Dr ,IG Kenna, St Mary's Hospital, London. The polyclonal
antibody is more sensitive than the patients serum and so far we have been able to
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clearly demonstrate the presence of acetaldehyde adducts in the tissues of patients with
both alcoholic liver disease and alcoholic cardiomyopathy.
The prospect of being able to explain the mechanism by which this particular
non-ischaemic heart disease is produced is very enticing. However, it is important to
state that so far all that has been shown is the presence of a circulating antibody. In only
a few conditions, such as myasthenia gravis for example, are the antibodies truly
functional. Many previous studies have demonstrated such antibodies which are then
shown to have no pathological function.
These studies raise the prospect of an adjunctive treatment for use in these
patients, particularly where they prove unable to give up alcohol. There are agents
which can reduce the levels of circulating acetaldehyde which might reduce the
production of tissue adducts and therefore abrogate the immune response. For example,
human blood acetaldehyde concentrations can be lowered in vitro by doses of
pantethine (Watanabe, 1985). Furthermore, a study in rats showed protection against
lethal doses of acetaldehyde by combinations of thiamin, L-cysteine and L-2-
methylthiazolidine-4-carboxylic acid (Sprince, 1974). These studies suggest that if the
acetaldehyde adduct theory is correct there may well be clinical benefits to be gained by
appropriate treatment.
14.3. Protein Isolation
This study showed that it is possible to isolate and partially purify a target
protein from the myocardium without knowledge of its molecular size, provided a
known ligand is available. The technique would be even more useful where this critical
information was available. Hence, when a particular band on immunoblotting is to be
identified this will be greatly aided by the ability to selectively elute relatively large
quantities. In the study of antibody responses to acetaldehyde adducts this will be of
great value in helping to isolate the protein targets involved.
In the experiments shown the endothelin type B receptor was obtained. This
work has been published and may allow partially purified receptor preparations to be
obtained in a simple series of experiments.
14.4. Summary
This thesis has shown that polyclonal stimulation offers little in the study of
lymphocyte culture from EMB, that prediction of subsequent rejection is not feasible
and that ELI are related to acute rejection. In addition the first assay of peripheral blood
which is able to distinguish alcoholic cardiomyopathy from idiopathic cardiomyopathy
has been developed, though its sensitivity is low it is very specific. Both these areas of
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study may be furthered through the use of fractionated myocardial proteins and a
technique to allow this has been developed.
The ability to detect, isolate and purify proteins of interest will be of great
assistance in the further studies which are planned. It has therefore provided the
opportunity to develop appropriate technical skills and knowledge to investigate cardiac
disease in the future. As such it represents the work necessary to begin to answer
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Addendum
Alcoholic Cardiomyopathy: Diagnostic Criteria
The diagnosis of alcoholic cardiomyopathy (or alcoholic heart muscle disease)
is one of exclusion. Therefore, for accurate research studies and precise interpretation
of data, certain conditions must be satisfied before the diagnosis can be accepted. The
features of a dilated cardiomyopathy must be present and patients must have been
drinking a defined amount of alcohol for a sufficient length of time. The period of time
taken as sufficient to accept a diagnosis of alcoholic cardiomyopathy has varied.
Teragaki et al selected ten years (Teragaki, 1993), but most other authors have used
five years (for example: Levi, 1977 and Cerqueira, 1991). To confirm the diagnosis,
cardiac catheter studies must rule out significant coronary artery disease and
endomyocardial biopsy is necessary to exclude other forms of heart muscle disease.
In this study, patients described as having alcoholic cardiomyopathy all had
impaired left ventricular function, as defined by moderate or severely impaired left
ventricular function on left ventricular angiography, 2D-echocardiography and/or on
nuclear imaging (MUGA). At least two imaging modalities were used in each patient.
Consumption of alcohol in these patients exceeded 80g per day (as in Richardson,
1986) for a five year period (or >250kg lifetime intake). All patients with alcoholic
cardiomyopathy underwent coronary angiography and no significant coronary artery
disease was detected (that is, no lesions causing greater than 50% reduction in luminal
diameter in an epicardial artery). In addition, no regional wall motion abnormalities
consistent with previous myocardial infarction were observed. All fourteen patients also
underwent endomyocardial biopsy, with at least three biopsy fragments being obtained
for histological examination.
Alcohol consumption, detailed in the methods section, was typical of that
exhibited by patients at the time of hospital admission. However, information was not
available on precisely when (or if) consumption ceased in these patients. From the
records that were available, it appears that patients were drinking alcohol to within two
weeks of invasive studies, including biopsy, being performed. The features observed at
histology were non-specific, being those consistent with dilated cardiomyopathy.
Typical findings were of myocyte hypertrophy, some fibrosis and occasional
inflammatory cells.
The patients in this study were therefore well characterised according to
accepted criteria. Other forms of heart disease were excluded by endomyocardial biopsy
and ischaemic heart disease was ruled out. The specificity of the findings is therefore
not in doubt.
